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Abstract
Radiotherapy benefits half of all cancer patients in the management of their disease.
Several studies have shown dose escalation and hypofractionation leads to better
tumour control for lung and prostate cancers. The large dose encountered in these
treatments has the potential to increase toxicity to surrounding organs, especially for
lung and prostate patients, due to tumour motion during treatment. The limiting
factor for expanding the use of techniques such as stereotactic ablative radiotherapy
(SABR) is toxicity.
Real-time adaptive radiotherapy re-configures the radiation beam during treatment
in response to the moving patient anatomy. This allows treatment margins to be re-
duced and the resulting dose distribution is highly conformal to the moving tumour.
Depending on the patient motion of the day, the delivered dose may not match the
planned dose. Careful quality assurance processes are required to quantify the dose
to the target as well as organs at risk during real-time adaptive radiotherapy.
Modern radiotherapy techniques such as SABR or stereotactic radiosurgery (SRS)
utilise very small radiation fields. The dosimetry of small radiation fields is complex
due to factors such as loss of charged particle equilibrium and partial volume aver-
aging. Dosimeters that have long been the gold standard in radiation dosimetry are
not always suitable for use in small fields.
The Centre for Medical Radiation Physics at University of Wollongong (Australia)
has developed a high spatial and temporal resolution dosimetry system for use in
adaptive radiotherapy. The system consists of two silicon diode array detectors
(MP512 and DUO) of various geometry, custom designed read-out circuitry and an
end user software interface. The detectors have been extensively characterised for
dosimetric performance in static small field conditions.
This thesis presents the application of these detectors for real-time dose measure-
ment in adaptive radiotherapy quality assurance. The accuracy of the system in
reconstructing the dose delivered during MLC tracking is investigated. The tempo-
ral performance of the read-out system in reconstructing the dose delivered pulse-
vii
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by-pulse is determined. A discussion on the effect of phantom material density on
tracking performance is presented. The system was also used for quality assurance of
a two arc VMAT treatment with MLC tracking. The reconstructed dose is compared
to EBT3 film and the treatment planning system.
Another novel radiotherapy technique undergoing significant development is mi-
crobeam radiation therapy (MRT). Potential uses will be delivering curative doses
to otherwise incurable brain cancers such as glioblastomas. High intensity x-rays
generated from a synchrotron are spatially fractionated into microbeams of width 50
µm which are spaced 400 µm apart. Dosimetry during MRT is difficult due to the
small field size, extremely high dose rate and several orders of magnitude difference
between the high and low dose regions. A detector system called X-treme has been
developed previously at Centre for Medical Radiation Physics, University of Wollon-
gong (Australia) for use in MRT. It consists of a single silicon strip detector (SSSD)
and a custom designed read-out system. Much work has been done to characterise
the performance of the system in MRT.
Intra-fraction motion can also affect MRT due to the cardio-synchronous motion
of the brain, which generates a lateral displacement of the same order of magni-
tude as the microbeam width and spacing. This thesis presents the first experi-
mental measurement of the effect of this motion on the resulting dose distribution.
Microbeams reconstructed from the SSSD are compared to film and Monte-Carlo
simulations.
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Radiotherapy has the potential to benefit approximately 50% of all cancer patients
in the management of their disease [1]. Modern radiotherapy aims to deliver a suffi-
ciently high dose of ionising radiation to tumours while at the same time minimising
potential damage to surrounding healthy tissue. Techniques such as 3D Conformal
Radiotherapy shape the treatment beam to match the outline of the tumour volume
and Intensity Modulated Radiation Therapy extends this by varying the intensity
and size of the beam at various angles to achieve greater dose conformity and spare
organs at risk.
The advantages of these techniques are compromised by tumour movement both
during and in-between treatment fractions. Lung tumours have been reported to
move up to 25-30 mm [2] which implies that treatment volumes need to be en-
larged to encompass the full movement of tumours which can potentially increase
the dose to healthy tissue. There is a constant trade-off in radiotherapy to achieve
the required dose to the tumour while sparing healthy tissue and critical organs.
An enlargement of the treatment volume is often undesirable especially when the
tumour is in the vicinity of vital organs.
Adaptive radiotherapy uses patient specific anatomical changes during the course of
treatment to to re-optimise the radiation delivery in order to spare healthy tissue
and maximise tumour coverage. Several approaches exist, all with advantages and
disadvantages. As treatment delivery gets more complex, so do the performance
specifications required from detectors for accurate radiation dosimetry.
Another novel radiotherapy technique is Microbeam Radiation Therapy (MRT).
This involves spatially fractionating a low energy synchrotron x-ray beam into beam-
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lets with width 10s of microns. The spatial fractionation has excellent radiobiolog-
ical results in terms of tumour control and healthy tissue sparing. Dosimetry is a
challenge in MRT due to the small beams and high dose gradients.
This thesis investigates the application of novel high resolution silicon detectors for
dosimetry during adaptive radiotherapy and MRT.
1.2 Thesis Structure
This thesis comprises 7 chapters which detail several applications of silicon detec-
tors to complex radiotherapy treatment deliveries. This introductory chapter is
designed to give the reader a brief background and context for the concepts that are
presented.
Chapter 2 is a literature and theory review. It covers current implementations of
adaptive radiotherapy and the subsequent requirements for dosimetry systems. The
challenges of small field dosimetry is discussed and MRT is introduced.
Chapter 3 covers the materials used in all the experimental work. It largely com-
prises technical details of the detector systems. Three detectors are presented:
MagicPlate-512 (MP512), DUO and a silicon single strip detector (SSSD). Their
geometry, readout systems and characterisation is discussed.
Chapter 4 contains three distinct experiments. The first was a preliminary test of
MP512 under MLC tracking conditions. The second experiment tests the timing
resolution of the detector readout system. The final experiment compares dose
profiles delivered using various MLC tracking methods. The effect of tissue density
heterogeneity is also discussed.
Chapter 5 is based on a published research article [3] that describes the application of
MP512 for QA of a VMAT treatment when MLC tracking is applied. Measurements
with MP512 are compared to EBT3 radiographic film and the dose distribution
extracted from the treatment planning system.
Chapter 6 is based on a published research article [4] that presents the first ex-
perimental measurement of the effect of brain motion during MRT. Measurements
are made with the SSSD and compared to radiographic film and a Monte Carlo
simulation.




The goal of radiotherapy is to deliver a sufficient dose of radiation to tumour volumes
while sparing surrounding healthy tissue. In the ideal case 100% of the delivered
dose would be deposited within the tumour and 0% of the delivered dose would be
deposited in healthy tissue, however in reality this is not possible to achieve. Radio-
therapy treatment plans can be designed so that radiation beams tightly conform
to the tumour shape, 3D conformal radiotherapy achieves this by using a multileaf
collimator (MLC) to shape the treatment beam. The MLC is made up of many
tungsten metal leaves that slide next to one another to form complex treatment
fields, as seen in Figure 2.1.
Intensity modulated radiotherapy (IMRT) is another form of highly conformal ra-
diotherapy that delivers many sub beams from various angles around the patient.
These sub beams are heavily modulated by the MLC and are not necessarily shaped
to the tumour volume, however the addition of all of these sub beams from all an-
gles results in a conformal coverage of the tumour. Volumetric arc therapy (VMAT)
extends this concept further by constantly producing modulated sub beams as the
gantry rotates around the patient, this increases the conformity of the treatment
even further.
As treatments get more and more conformal, it becomes increasingly important to
ensure that the radiation dose is being deposited in the intended location, the tumour
volume. To achieve proper dose coverage, a set of tumour and target volumes are
defined within a patients treatment plan. The first and most fundamental volume
is the location and extent of the gross tumour which is contoured on the CT data
set by a radiation oncologist. This volume is called the gross tumour volume or
3
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Figure 2.1: A multileaf collimator used to shape a radiotherapy treatment beam.
Courtesy Ron Witherspoon Inc. Campbell, CA, USA.
GTV and represents the part of the tumour that can be palpated or imaged . An
additional margin known as the clinical target volume (CTV) is added to account
for uncertainty in tumour size and disease spread. From here there is an expansion
of the CTV to account for uncertainties in treatment delivery and planning, such
as patient alignment, and this margin is called the planning target volume (PTV),
the PTV is then used to define the beam shape and size within a patient treatment
plan [5].
A patients radiotherapy treatment is split up into many ’fractions’ which generally
occur daily over a period of a few weeks. This allows healthy tissue to regenerate
sufficiently while still achieving tumour shrinkage and killing. The tumour can move
between fractions (inter-fraction motion) and can even move during a treatment
fraction (intra-fraction motion). Intra-fraction motion is especially noticeable in
lung tumours as the patient breathes during treatment. When highly conformal
and high dose radiotherapy modalities are employed such as Stereotactic Ablative
Radiotherapy (SABR) intra-fraction motion becomes a serious concern due to the
potential to deposit high dose in healthy tissue.
Lung tumours can move as much as 25-30 mm [6] during treatment, to compensate
for this motion an extra margin is added to the treatment plan called the internal
target volume (ITV). The ITV encompasses the entire volume occupied by the mov-
ing tumour throughout several breathing cycles, meaning that the tumour should
always be within the treatment beam. The PTV is then added as an expansion of
the ITV. An inevitable downside to this approach is an increase in the amount of
healthy tissue that can fall within the bounds of the PTV.
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Prostate motion can occur between fractions as well as during treatment. Move-
ments of up to 18 mm are common [7], the likelihood of a large displacement in-
creases with treatment time. Prostate motion is also difficult to predict from CT
scans, for example initial rectal volume and cross-sectional area are poor predictors
of prostate motion [8]. It has also been shown that the delivered dose to the rectum
can be significantly higher than the planned dose due to prostate motion [9].
To help minimise the amount of healthy tissue being irradiated, a treatment regime
known as ’adaptive radiotherapy’ (ART) has been introduced. ART uses patient
specific anatomical changes during the course of treatment to re-optimise the radi-
ation delivery in order to spare healthy tissue and maximise tumour coverage [10],
ART strategies can be divided into two distinct groups:
1. Strategies to compensate for inter-fraction motion (offline adaptation)
2. Strategies to compensate for intra-fraction motion (online adaptation)
An example of offline ART for inter-fractional motion is also known as adaptive re-
planning, this is when a patients treatment planning process is repeated (sometimes
several times during their course of radiotherapy) in response to anatomical changes
in the target volume or nearby critical structures. Online or real-time adaptive ra-
diotherapy refers to methods of beam modulation that occur during a treatment in
response to intra-fraction motion, examples include gating or patient motion track-
ing, which are discussed in detail below.
2.1.1 Intra-fraction adaptive radiotherapy
The focus from here will be on real-time adaptive radiotherapy (RTAT) methods,
which modify the beam according to patient movement during a single fraction.
There are several strategies currently employed clinically, all follow the same basic
principles:
1. Measure tumour motion in real time (or an appropriate surrogate)
2. Interpret motion information and compare with applicable thresholds
3. Modify or gate the beam if needed
These steps are repeated continuously throughout the entire treatment. Some ex-
amples of common RTAT strategies employing these steps are discussed in further
detail below.
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Figure 2.2: Schematic illustrating respiratory gating. The beam is only on
during a specified window of the patient breathing cycle, this ensure that the
tumour in always within the PTV. Image courtesy of KoreaMed.
2.1.1.1 Gating
Respiratory gating involves continuous monitoring of the patients breathing and
triggering of the linac during a specific phase of the breathing cycle [11]. A common
implementation of respiratory gating is through the use of the RPM System (Re-
altime Position Monitoring) from Varian Medical Systems (Palo Alto, CA, USA).
RPM is a non-invasive video based motion management system which uses an in-
frared tracking camera and reflective marker [2]. Motion of an external marker has
been proven to be highly correlated with true internal superior-inferior diaphragm
motion [12] and RPM can reconstruct respiratory motion in three dimensions. When
the tumour is within a pre-defined tolerance window the beam is on, then the beam
is held when the tumour moves out of the window. This effectively synchronises the
patient’s breathing with the treatment, as shown in figure 2.2.
Another implementation of gating is the Brainlab Exactrac Adaptive Gating system
[13, 14]. This system combines infrared tracking (similar to that of RPM) with an
in-room stereoscopic x-ray system. The x-rays are triggered based on the patients
breathing measured by the infrared cameras. Implanted fiducial markers are used
to monitor the position of the tumour during treatment. The beam is then gated
based on the position of the tumour and a predefined window. This implementation
relies on the fiducial markers being a reliable surrogate of the tumour volume, which
is not always the case [15, 16].
Respiratory gating has the disadvantage of significantly increasing treatment time
(up to three times longer) [17] and placing additional mechanical stress on the gantry
when treatments are interrupted.
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2.1.1.2 Kilovoltage Intrafraction Monitoring (KIM)
Kilovoltage Intrafraction Monitoring (KIM) is an online adaptive radiotherapy modal-
ity currently in use for prostate VMAT [18]. It uses the gantry mounted on-board
imager (OBI) to localise the position of the prostate during treatment, if the prostate
moves outside a predefined tolerance window the treatment is paused and the patient
is repositioned (using the couch) before treatment is resumed.
A pre-treatment kV arc is acquired so the markers can be segmented from various
angles. The marker positions are used to build a probability density function (PDF)
[19] which aids in converting the 2D marker positions to a 3D position prediction.
The PDF is updated so that it is built using the latest 500 projections and every
three images are averaged to improve performance.
The workflow for KIM is shown in figure 2.3 [20] and summarised below:
1. Patient is aligned on treatment couch with kV/kV match
2. KIM software is activated
3. Acquire a single kV image to compare current marker positions with planned
marker positions
4. Acquire a pre-treatment arc of 120 degrees in order to segment the markers
and build a probability density function (PDF)
5. Begin MV treatment
6. Acquire kV images at 5-10Hz
7. Segment markers and determine 2D marker positions. Convert 2D positions
to 3D positions using the PDF
8. Compare 3D marker positions to threshold values
9. If positions exceed threshold then pause treatment and realign patient. If
positions are within tolerance then repeat steps 5-8
2.1.1.3 EM Guided MLC Tracking
A third type of online adaptive radiotherapy is electromagnetic target tracking com-
bined with dynamic MLC tracking. The Calypso 4D localisation system is a commer-
cial product by Varian Medical Systems (Palo Alto, CA, USA) for electromagnetic
target tracking. The system consists of three major components:
• Dipole beacons that are implanted in or near the tumour volume
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Figure 2.3: Overview of the KIM Workflow. Reproduced from [20].
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• RF coil array to excite the beacons and localise their position
• Infrared camera system to localise the RF coil array in the treatment room
Figure 2.4 shows an overview of the layout of the Calypso system in the treatment
room as well as the dipole beacons. The beacons are 8 mm in length and 2 mm in
diameter. They consist of an electromagnetic resonant circuit embedded in a glass
structure. The RF coil array placed above the patient transmits an AC signal at
various frequencies which correspond to the individual, distinct resonant frequency
of each beacon. The beacons re-emit a lower intensity signal of the same frequency
which is detected by the coil arrays in the panel above the patient. In this way the
system is able to localise the position of each of the individual beacons. The panel
consists of 4 transmitting coils and 32 receiving coils. Infrared cameras mounted
on the roof of the treatment room act to localise the position of the RF panel.
The position of the beacons can then be related to the treatment room coordinate
system. The position of the target is then reconstructed in three dimensions and is
available to the operator at the linac console. The software is able to flag when the
target exceeds a pre-defined threshold in any direction.
This information can also be fed into the MLC controller which enables real time
tracking of the target during treatment [21, 22]. This is discussed further in section
4.2.1.
(a) The Calypso system in the treatment
room
(b) Implanted dipole beacons
Figure 2.4: (a) The components of the Calypso system within the treatmenet
room. (b) Dipole beacons are implanted in or near the tumour [23].
Several studies have shown the accuracy of the system in localising a target in a
phantom is better than 1 mm [24–28]. The advantage of the Calypso system is
that no additional radiation is delivered to the patient to facilitate tracking. The
trade-off is the surgical procedure required to insert the beacons.
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2.1.2 Clinical Impact
The following section discusses the clinical use of real-time motion tracking for
prostate and lung tumours and the effect of intra-fractional motion on patient out-
comes.
2.1.2.1 Prostate
Clinical outcome is improved for prostate cancer radiotherapy treatments using dose
escalation and/or hypo-fractionation. At M. D. Anderson Cancer Centre, a research
group compared outcomes for patients treated to 78 Gy vs 70 Gy [29]. They found
that twice as many patients treated to 70 Gy either did not survive, or are alive with
cancer, compared to patients treated to 78 Gy. 78% of patients who received 78 Gy
were free from biochemical failure (recurrence) compared to 59% who received 70
Gy. Patients with higher prostate specific antigen (PSA - a measure of progression
of prostate cancer) had a larger benefit from the increased dose; 78% free from
biochemical failure compared to 39%. However patients treated to 78 Gy presented
with gastrointestinal toxicity twice as often as those treated to 70 Gy. They found
the complication rate could be decreased significantly by irradiating a lower volume
of rectum.
An Australian study compared two fractionation regimes for prostate carcinoma [30].
One group of patients received hypo-fractionation of 55 Gy in 20 fractions (4 weeks),
the second group received a conventional fractionation of 64 Gy in 32 fractions (6.5
weeks). The first group of patients received a higher dose per fraction and less
fractions; there is a greater chance that prostate motion will effect the treatment
outcomes for these patients. 217 patients participated in the study and were followed
up 90 months after treatment. 85 in total had a biochemical failure (recurrence);
36 received hypo-fractionation and 49 received conventional fractionation. Hypo-
fractionation resulted in 53% of patients being biochemical failure free at 90 months
compared to 34% with conventional fractionation.
There is compelling evidence that dose escalation and hypo-fractionation results in
better clinical outcomes for patients undergoing prostate radiotherapy. However
these treatment regimes can lead to longer treatment times per fraction which, as
mentioned earlier, can increase the chance of a large intra-fraction prostate move-
ment [7].
To overcome this potential issue many groups have used and recommend real-time
tumour tracking [7, 22, 31–34]. Calypso tracking has been used in several studies, one
in particular highlights the benefit of real time tracking. 20 patients who underwent
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prostate bed radiotherapy were monitored during treatment with Calypso [31]. A
tracking threshold of 5 mm was defined. The threshold was exceeded for 32% of all
delivered fractions. In addition, 15% of treatments had to be interrupted for the
patient to be repositioned. Overall 70% of patients had to be repositioned at least
once throughout their treatment.
Real-time tracking has also been implemented with prostate SBRT [32]. 37 Gy
was delivered in 7 fractions to 60 patients. 68% of patients had Calypso tracking
and the remainder used ExacTrac. Median follow up was 27 months. No patients
presented with gastrointestinal or genitourinary toxicity higher than grade 2 (mod-
erate). There was one case of grade 3 (severe) gastrointestinal toxicity. Overall they
reported that SBRT was tolerated well with minimal impact on quality of life.
MLC tracking has been implemented clinically for real-time tracking during prostate
VMAT [22]. Dose reconstruction was performed to determine the dose delivered with
tracking and the dose that would have been received if MLC tracking was not used.
This was calculated using a combination of the motion measured by Calypso and
the MLC log files. It was found that with MLC tracking the dose to 95% of the
PTV (D95) was the same as the treatment plan. With no MLC tracking D95 was
only 1% less than planned. However the volume of rectum tissue receiving >60 Gy
(V60) was 30% higher than planned with no tracking, compared to 4% with tracking.
V60 is correlated with the risk of high grade (>2) rectal toxicity.
Another study came to a similar conclusion [35]. They studied the effect of intra-
fractional motion on treatment outcomes for 71 patients who received prostate tu-
mour tracking with CyberKnife (Accuray Inc. Sunnyvale, USA). They found no
significant correlation between intra-fraction prostate motion and tumour control.
However the number of patients suffering grade 2 or worse rectum or bladder toxicity
was directly correlated with intra-fraction motion.
For prostate treatments, there is clear benefit when using real-time tumour tracking
and a potential to reduce toxicity in surrounding tissues. This leads to better disease
free survival and quality of life for patients. A clinical trial is currently underway
in Australia, the SPARK trial: Stereotactic prostate adaptive radiotherapy utilising
kilovoltage intrafraction monitoring (KIM) [34]. The trial will quantify the dose
distribution with KIM and compare to the estimate dose without KIM. The trial
also aims to reduce the number of treatment fractions from 40 to just 5.
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2.1.2.2 Lung
Stereotactic ablative radiotherapy (SABR) for non-small cell lung cancer (NSCLC)
has shown excellent local control rates and can increase overall survival [36–38]. A
group in the Netherlands treated 177 NSCLC patients with 60 Gy in 3-8 fractions
[38]. They found a three year survival rate of 85% and local control rate at three
years was 93%. In addition, the 30 day mortality rate post SABR was 0%, compared
to the predicted 30 day mortality post lobectomy of 2.6%.
The ablative dose used during SABR treatments has the potential to produce severe
toxicity in organs at risk, especially if the tumour is central (eg heart, oesophagus
or spinal cord) [36]. In general, wider adoption of SABR is limited by toxicity [39].
Patient alignment and intra-fraction motion are critical considerations for treating
NSCLC with SABR. Real-time tumour tracking has been implemented for such
treatments. CyberKnife combined with radio-opaque markers has shown excellent
local control with no severe toxicity [40].
Real-time MLC tracking has the potential to match the reduction in treatment
volume and favourable treatment outcomes obtained from using CyberKnife tracking
[41]. MLC tracking with Calypso has been used as part of a clinical trial: The Lung
Intensity Guided Hypofractionated Tumour tracking SABR (LIGHT SABR) trial
[42]. Twenty patients are to be treated with 48 Gy in 4 fractions with Calpyso
guided MLC tracking. The first patient has been treated and DVH metrics were
compared between MLC tracking and no MLC tracking [42]. Compared to standard
ITV based planning, MLC tracking reduced the PTV size by 40% and the mean
lung dose by 30%.
2.2 Small Field Dosimetry
Modern radiotherapy modalities such as IMRT or SBRT use single or multiple nar-
row radiation fields. Target coverage is achieved by the superposition of several of
these small ’beamlets’. Typical beams are less than 4×4 cm2 in size and irregularly
shaped. The following section gives a brief overview of the characteristics of small
fields followed by a more detailed discussion.
2.2.1 Overview
A photon beam can be considered small if lateral charged particle equilibrium (CPE)
cannot be established in the irradiated medium. This occurs when the range of
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secondary electrons is larger than the lateral field length. Electrons can escape the
portion of irradiated medium and are not compensated by electrons scattered back
into the central axis. For a 6 MV photon beam, a 3×3 cm2 field is considered small,
according to the equation reported in IAEA TRS-483 [43]:
rLCPE = 8.369× TPR20,10 − 4.382 (2.1)
Where rLCPE is the minimum radius to maintain lateral CPE, in cm and TPR20,10
is the beam quality specifier for the particular beam. Typical values of TPR20,10 for
6 MV range from 0.6 to 0.7.
The collimation system of linacs can produce a partial occlusion of the primary
photon source at small field size settings, which can effect the penumbra width. In
addition, there is a reduction of output at small field sizes which leads to a discrep-
ancy in defining the field size by the full-width at half maximum, when compared
to the collimator setting. Partial source occlusion can also change the energy spec-
trum of the beam which may effect detector response. The extent of partial source
occlusion depends on the electron beam spot size on the target.
Detector size with respect to the beam is also of importance; particularly if the
beam is smaller than the detector as this can result in partial volume averaging
effects. The density of the materials used in the detector construction also has a
more pronounced effect on the detector response in small fields [44, 45].
2.2.2 Small Field Characteristics
2.2.2.1 Lateral Charged Particle Equilibrium
Figure 2.5a shows the variation with depth of the absorbed dose and electronic
kerma from a large photon beam. There is a build up of absorbed dose until the
point where absorbed dose equals electronic kerma. These would remain equal
and constant with depth if there was no photon attenuation. In reality there is a
decrease in absorbed dose and electronic kerma with depth, due to attenuation, and
electronic kerma remains larger than absorbed dose. This gives rise to a region of
partial electronic equilibrium (PCPE). The displacement of the absorbed dose from
the electronic kerma is denoted by x¯ and represents the average distance travelled
by secondary electrons before depositing dose.
PCPE also exists in the lateral direction for broad photon beams. Secondary charged
particles generated within the irradiated medium, away from the central axis, are
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scattered towards the centre of the beam (’in-scatter’). This compensates for elec-
trons that are scattered out of the central region (’out-scatter’). When the beam
becomes small the amount of ’in-scatter’ reduces such that it no longer balances the
amount of ’out-scatter’ and CPE no longer exists on the central axis. This affects
the relationship between electronic kerma and absorbed dose, as shown in figure 2.5b
for a beam of 5 mm radius. The absorbed dose is now less than the electronic kerma
due to the imbalance of the scatter components and the breakdown of CPE.
(a) Broad beam conditions (b) Small field conditions
Figure 2.5: Comparison of the relationship between electronic kerma and ab-
sorbed dose for (a) broad beam conditions and (b) small field conditions. D is
dose, K total kerma and Kel is electronic kerma [46].
The size at which a field can be considered ’small’ then depends on the range of
secondary charged particles that scatter in or out of the centre of the beam. This
implies that the definition of a small photon beam is energy dependent. Figure
2.6 shows the point of breakdown of CPE for beams of various energies. This
occurs when the ratio of the absorbed dose to electronic kerma is no longer unity, i.e
Dw/Kel,w 6= 1. As beam energy is increased the radius at which a beam is considered
small also increases.
2.2.2.2 Partial Source Occlusion
In a medical linac, the size of the electron beam as it strikes the target (spot size)
depends on the tuning of the steering coils and bending magnet. When tuned cor-
rectly the electron beam spot size will be small, however the primary photon source
exiting the target will be wider due to scatter. Further broadening then occurs from
additional scattering in the flattening filter. For small field sizes, the collimation of
the beam can obscure the direct view of the primary photon source from the point
of measurement, this is called ’partial source occlusion’ and is illustrated in figure
2.7. This also occurs when the measurement point is moved off axis towards the
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Figure 2.6: Ratio of absorbed dose to electronic kerma, in water, for various
beam radii and energies [46].
beam edge. Partial source occlusion therefore effects measurements in the penumbra
region of a beam of any size.
As field width decreases and approaches the range of secondary electrons, the penum-
bra from opposite sides of the beam begin to overlap. This results in a decrease in
output on the central axis and a discrepancy between the field FWHM and the
beam collimation setting [47]. This phenomenon is shown in figure 2.8. There is an
apparent widening of the beam FWHM for small field sizes compared to the true
collimation setting.
2.2.2.3 Spectral Changes
The photon spectrum incident on a medium depends on the collimation. Small fields
can have a photon spectrum that differs significantly from a broad beam of the same
energy. Figure 2.9 shows the mean photon energy of the fluence in air and water,
as a function of field size. The contribution to the total fluence is split into primary
photons and scattered photons.
The fluence in air is strongly dependant on scattering from the collimator. The
primary photon spectrum in air is influenced by the flattening filter and the photon
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Figure 2.7: The field size setting determines how much of the primary photon
source is visible. (a) The entire primary photon source is visible from the mea-
surement plane for a broad beam. (b) The source is only partially visible from
the measurement plane for a small field. This also has the effect of overlapping
the penumbrae. [46]
emission lobe from the target. The flattening filter is designed to make the beam
flat at 10 cm depth in water. In air the emission lobe still has a strongly forward
peaked high energy component on the central axis. As field size decreases, more
of the low energy photons on the periphery of the emission lobe are cut off, this
increases the proportion of high energy photons (centre of the lobe) to low energy
photons (periphery of lobe). Scatter from the collimation system may slightly offset
this effect at small field sizes.
In addition to the above effects, as the aperture gets larger the mean energy of
the primary photons decreases since more off-axis (lower energy) photons can pass
through the collimator without scattering. This is seen in figure 2.9a. The mean
energy of the total fluence slowly increases with field size due to less photons scatter-
ing from the collimator assembly. The mean energy of the scattered photon fluence
in air is essentially constant with field size.
In phantom, as beam size decreases the mean photon energy increases. This beam
hardening effect is due to phantom scatter (in towards the central axis) contribut-
ing less to the absorbed dose on the central axis in small beams compared to in
broad beams. The average energy on the central axis is higher as primary photons
dominate the fluence spectrum.
This results in a reduction of the low energy photon component as field size decreases,
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Figure 2.8: Effect of partial source occlusion and lack of CPE on the FWHM of
dose profiles. (a) Broad beam where CPE is well estabished and the source is fully
visible. FWHM is equal to the field size setting. (b) Field width is of the same
order as secondary electron range. The penumbra from opposite fields overlap
slightly causing a small discrepancy in FWHM. (c) Field width is smaller than
the range of secondary electrons. CPE no longer exists. Penumbra from opposing
fields overlap significantly and the FWHM of the beam is largely overestimated
compared to the field size setting [47].
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as shown in figure 2.10.
Figure 2.9: Mean photon energy depends on the field size. (a) In air (b) In
water on the central axis at the depth of maximum dose [46].
The spectral change off-axis is a lot more unpredictable compared to on the central
axis. There are competing effects such as:
• Lack of high energy secondary electrons due to break down of CPE - softer
spectrum off axis
• Higher average energy of secondary electrons due to harder photon spectrum
on central axis - harder spectrum off axis
It is difficult to predict the exact contribution of each of these effects on the final
spectrum. Monte-carlo simulations have been performed to determine the off-axis
spectrum [48]. They found that the spectral changes off-axis depend heavily on the
beam collimation and simulations require extremely accurate modelling of collima-
tor dimensions and material composition. This implies that measurement of beam
profiles and depth dose for small fields is extremely important in order to correctly
model the energy spectrum in the TPS.
Figure 2.11 shows photon and electron spectra for a 6 MV photon beam with various
field sizes. A large difference is observed for the 2 × 2 cm2 beam between spectra
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Figure 2.10: The low energy component of the photon spectrum reduces with
decreasing field size. Data at 10 cm depth in a 6 MV beam [46].
on-axis and off-axis.
2.2.2.4 Stopping Power Ratios
A key step in radiation dosimetry is converting the absorbed dose in the sensitive
volume of the dosimeter into absorbed dose in the surrounding medium in the ab-
sence of the dosimeter. For a field of MV photons, dose is deposited by secondary
electrons generated in the medium. Electron stopping power ratios are used to












Where Φmed and Φdose is the electron fluence in the medium and dosimeter, respec-
tively, and S¯col/ρ is the mass collision stopping power ratio for the medium and
dosimeter.
Figure 2.12 [49] shows calculated water to air stopping power ratios as a function
of depth for various field sizes. In general the stopping power ratio decreases with
depth. This is attributed primarily to the beam hardening effect, which is less
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Figure 2.11: Photon and electron spectra for a 6 MV beam with various field
sizes: (a),(d) 10× 10 cm2. (b),(e) 2× 2 cm2 on central axis. (c),(f) 2× 2 cm2 8
cm off axis [48].
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pronounced for larger field sizes due to increased scatter contribution to the central
axis. There is very little field size dependence of the stopping power ratio, less
than 1% from 10 × 10 cm2 to 0.3 × 0.3 cm2. Other studies have found similar
results [48, 50]. The relative constancy of the stopping power ratio with field size is
advantageous for small field dosimetry.
Figure 2.12: Stopping power ratios as a function of depth for various field sizes
[49].
2.3 Challenges in dosimetry
2.3.1 Considerations for small field dosimetry
Air filled ionisation chambers are considered the gold standard for radiotherapy
dosimetry. However as discussed above, for small fields, CPE cannot be established.
This means that Bragg-Gray cavity theory can no longer be applied for absolute dose
determination. In addition, air filled ionisation chambers are limited to a minimum
size in order to maintain a sufficient signal to noise ratio and uniform electric field
within the sensitive volume. The latter point is important as a distorted electric field
leads to non-uniform collection of secondary electrons and invalidates the chamber
calibration factor. The limiting size is around 0.01 cm3, but chambers of this volume
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experience stem and cable induced signal of similar magnitude as signal measured
from the sensitive volume.
The characteristics that would make a dosimeter more suitable than an air-filled
ionisation chamber for small field dosimetry are:
• Radiation interaction and absorption characteristics equivalent to that of water
• Density of sensitive volume close to the density of water
• Size of the sensitive volume small compared to the beam size
There are three classes of detector currently available that approximate the desired
characteristics above: calorimeters constructed from water equivalent materials, de-
tectors that are based on ionisation in water equivalent solids or liquids and liquid
chemical dosimeters.
The most water equivalent detector is the water calorimeter which shows no energy
or dose rate dependence. However large amounts of time are required to generate
sufficient signal due to the heat diffusion properties of water. Graphite calorimetry
addresses this issue to an extent however the physical setup and read-out remains
somewhat cumbersome, their use is generally limited to primary standards dosimetry
laboratories [51, 52].
Solid state detectors maintain sufficient sensitivity even at small sizes. Silicon diodes
are widely used in radiotherapy dosimetry but their mass energy absorption coeffi-
cient and atomic number are higher than water. This causes them them over respond
to low energy photons. In broad beams, the over response is corrected by using a
shielded diode. A thin layer of high-Z material is placed above the sensitive volume
to absorb low energy scattered photons. Shielded diodes are unsuitable for small
field dosimetry due to perturbation effects from the shield at small field sizes [53].
Unshielded diodes are unsuitable for use in broad beams due to the aforementioned
over response. However due to the spectral changes in small fields, the low-energy
photon component is reduced for smaller field sizes (figure 2.10), so the over-response
of unshielded diodes is is sufficiently reduced.
The energy dependence of diamond is less of an issue compared to silicon, however
recombination effects are large in diamond detectors [54]. This leads to appre-
ciable dose rate dependence of the diamond response. Other solid state detectors
such as thermoluminescent dosimeters (TLD) and optically stimulated luminescence
dosimeters (OSLD) are useful for in-vivo dosimetry but require a detailed and care-
ful readout and analysis. In addition the uncertainty in their response can be as
high as 10%.
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Plastic scintillator dosimetry systems have excellent spatial resolution, each element
can be manufactured of the order of 1-2 mm3, whilst retaining high sensitivity.
In addition the material can be chosen to be water equivalent over a large energy
range (0.2 - 25 MeV), linear in dose and dose rate and energy independent [55–57].
The disadvantage of creating an array of plastic scintillators is the amount of fibres
needed for readout. Depending on the resolution of the array, this can become
cumbersome.
Liquid filled ionisation chambers can be made much smaller than air filled chambers.
The liquid can be chosen to have a density and radiological properties close to that
of water. However recombination is much higher than air filled chambers and there
is non-negligible temperature dependence.
Liquid chemical dosimeters can be made to be water equivalent and are very precise.
This precision requires detailed handling procedures and facilities to prepare and
readout the chemical mixture. They also suffer relatively low sensitivity.
All detectors have advantages and disadvantages for small field and also broad beam
dosimetry in general, detector choice should be performed on a case-by-case ba-
sis.
2.3.2 Considerations for real-time adaptive radiotherapy
Infra-fraction tracking or motion management requires real-time modification of the
dose delivered, potentially leading a to a different dose distribution to that planned
originally by the TPS. This implies that some form of pre-treatment, patient specific
QA would be beneficial. A ’fraction zero’ consisting of measuring the dose delivered
from each radiation field, before the patient starts treatment, is a common pre-
treatment check for more complicated treatment plans, i.e SABR, VMAT or MLC
tracking. Usually this form of QA involves comparing the delivered integral dose
distribution with the planned integral dose distribution. This kind of measurement
is sensitive to gross delivery errors, but small errors are likely to go unnoticed as
they will be averaged out over the duration of treatment. These small errors can
be potentially harmful if they result in dose being deposited in organs at risk, es-
pecially if the treatment plan already brings the dose to these organs close to their
tolerance.
As previously discussed, IMRT and VMAT are made up of many small beamlets
or segments. Depending on the amount of modulation, a portion of these segments
will fulfil the conditions to be considered a small field. In addition, when RTAT
is combined with an IMRT/VMAT delivery, the proportion of small field beamlets
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contributing the final dose distribution can increase. For this reason, the detectors
used for QA of RTAT should be suitable for small field dosimetry.
A real time dosimetry system with sufficient temporal resolution would be able to
detect all dose errors, even small ones, that occurred throughout the entire treat-
ment delivery. Potential QA of adaptive radiotherapy could involve comparing the
expected dose distribution (2D or 3D map) for each treatment control point with
the measured distribution. Typical patient specific motion can be used to drive the
adaptive radiotherapy delivery if a 4DCT was taken for treatment planning.
In addition, real time MLC tracking can adopt one of several different algorithms
to drive the treatment aperture position and shape. As will be discussed further in
section 4.2.1, passive or predictive algorithms can be used to calculate the required
MLC positions to follow the target. The predictive algorithm has several parameters
that can be adjusted to change the tracking behaviour. A real time, high temporal
resolution dosimeter would allow these parameters to be optimised for a specific
patients’ motion.
Adaptive radiotherapy modalities that monitor the patient motion in real time will
usually generate an additional electromagnetic radiation field that is incident on
the patient. E.g the kV imaging used for KIM, RF field from the Calypso array
or infrared light from RPM. It is important that a dosimeter used for QA during
these deliveries is not influenced by these additional signals. The dosimeter response
should be from the treatment beam only. An effective method to reduce the influence
of the RF field of Calypso is discussed in section 5.3.2.
Ideally suited dosimeters should also have high spatial resolution due to the possible
creation of very steep dose gradients when the beam is following target motion. This
would vary depending on the motion experienced and location of the target.
The applicability of currently available commercial devices for adaptive radiotherapy
is discussed further in the next section 2.3.3.
2.3.3 Currently available detector systems
This section reviews commercial detector systems in the context of small field
dosimetry and RTAT. Comparisons are made between devices specifications/per-
formance and ideal detector properties (as discussed in the previous sections).
Several commercial detector systems exist for pre-treatment quality assurance. They
are generally a 2D or quasi-2D array of detector elements that measure the integral
dose delivered by patient treatment beams. This spatial dose map is then compared
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back to the planned dose.
The Delta4 by ScandiDos (Upsalla, Sweeden) is a cylindrical PMMA phantom with
inbuilt silicon diodes. 1069 diodes are spread across two orthogonal planes. The
cylindrical diodes have an active area of 0.78 mm2 and height of 0.05 mm [58]. De-
tector spacing is closer in the centre of the phantom compared to the periphery. In
the central 6 cm × 6 cm region the detectors are spaced 5 mm apart. The remaining
detectors are spaced 10 mm apart. The patient treatment plan is copied onto an ar-
tificial CT dataset of the Delta4 phantom and dose is calculated. The CT dataset is
higher density than water, this can cause uncertainties in dose calculations for some
planning systems [59]. The phantom comes with an inclinometer to independently
monitor gantry angle in order to apply angular corrections to the diode array. Soft-
ware automatically compares the planned vs measured dose and generates gamma
pass rates. Additionally profiles in two directions can be visualised for both the
planned and delivered dose.
The ArcCheck by Sun Nuclear is a cylindrical PMMA phantom housing a helical
array of silicon diodes around the periphery. The central region of the phantom
is an empty cavity. This section can be utilised for various point dose or film
measurements by using appropriate inserts. 1386 diodes are spaced 1 cm apart
over an active area of 12 × 12cm2. Each diode has a sensitive volume of 0.8 x 0.8
mm3. 3.3 cm of phantom material surrounds the diodes above and below. The
diodes are arranged such that they are always directly facing the beam and the
detector geometry relative to the beams eye view remains constant for all gantry
angles. This negates the need for angular correction. The phantom geometry also
allows simultaneous measurement of both the entrance and exit dose. There have
been reports that the array has some field size dependence with pass rates showing
correlation with jaw size [60]. Software compares the reconstructed dose distribution
from the ring of detectors. Both the entrance and exit dose is compared to the
planned dose.
The Octavius 4D phantom is a system from PTW (Freiburg, Germany). It consists
of a rotatable cylindrical phantom that houses a planar detector array. The phantom
rotates during beam delivery such that the detector array is always orthogonal to the
beam central axis, removing the need for angular correction. Two detector arrays
are available, the first consists of 1405 vented plane parallel ionisation chambers (4.4
mm x 4.4 mm x 3 mm, 0.06 cm3) spaced 7.1 mm apart. The total active area is 27
cm2. The second array consists of 997 liquid filled ionisation chambers of size 2.3
mm x 2.3 mm x 0.5 mm, 0.0003 cm3. Detector spacing is 2.5 mm in the central
5.5 cm x 5.5 cm of the array and 5 mm in the outer area. The maximum sensitive
area is 11 cm2. Software analysis calculates 3D gamma pass rates based on the
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reconstructed dose from each gantry angle.
Electronic portal image detector (EPID) dosimetry is widely adopted for pre-treatment
fluence checks of IMRT and VMAT deliveries [61]. Nearly all modern linacs come
with an EPID installed and measurements are easily performed in air with no phan-
tom to setup. The detector panel is large to accommodate many treatment types
and spatial resolution is of the order of 0.3 mm. Measurements can be made in real
time and the silicon panels are linear in dose. However there is also a significant
amount of high-Z material in the detector construction that means the response is
not water-equivalent. In addition, the out of field or off-axis response is often over
estimated due to an increase in photoelectric interactions of low energy photons in
silicon.
Correction factors have been proposed to address many of the issues above, such as
algorithms to predict the EPID response or convert it to a water equivalent dose
plane [62]. The variation between each pixel element also needs to be taken into
account, along with the off-axis response variation [63]. The mechanical arm used to
position the EPID panel also exhibits sag/flex throughout gantry rotation [64].
Although very convenient, there are many corrections and assumptions that have
to be made to obtain truly accurate dose information from the EPID panel. An
alternate approach in utilising the EPID for pre-treatment VMAT QA is MLC posi-
tional accuracy verification [65]. This novel technique acquires images continuously
throughout treatment and uses edge detection algorithms to compare the real (pro-
jected) MLC positions with the planned positions in the machine log file. This
approach largely avoids the above downfalls of direct EPID dosimetry.
In addition to 2D arrays there are detectors available specifically for measuring dose
at a point in small radiation fields. These detectors have the inherent disadvantage
of providing no spatial dose distribution however can be more accurate for dose
measurement in small field sizes.
As discussed above, diamond detectors show less energy dependence than silicon
diodes. The microDiamond detector by PTW (model 60019) has a sensitive volume
of 0.004 mm3. The diamond layer is a disc of diameter 2.2 mm and thickness 1 µm.
As field size decreases the proportion of secondary electrons interacting in phantom
material to those interacting in the detector material also decreases. This implies
that the detector mass density will have a more pronounced effect on the detector
response at small fields compared to large fields [45, 66, 67], this is discussed further
in section 3.1.2.7. Diamond has a mass density of 3.5 g cm-3 which is significantly
higher than that of water. As a result, an over response of over 5% has been observed
at fields of size 5 mm [68]. The over response reduces as field size increases up to 2
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cm, then is negligible.
The mass density of the detector packaging components can also have a large in-
fluence on the overall response. This is a limiting factor on the ability to create
a pixellated detector with diamond; it is difficult to create an array of diamond
sensitive volumes and avoid using high density materials for readout. In contrast, it
is possible to minimise the amount of high density material used in a silicon diode
array detector, which is discussed in section 3.1. The manufacturing process for
silicon detectors is also significantly cheaper than that of diamond.
Small volume ionisation chambers are also available for point dose measurements in
small fields. The PinPoint chamber by PTW (model 341014) has sensitive volume
of length 5 mm and diameter 1 mm. When used ’face on’ the cross section of the
sensitive volume as seen from the beams eye view is minimised, resulting in the best
spatial resolution. However this also leads to a fairly large directional dependence
[69] which is not ideal for VMAT deliveries.
There are a range of other commercially available detectors for small field point dose
measurements such as OSL/TLD or silicon diodes. The suitability of these detectors
is discussed in section 2.3.1
Generally the commercially available devices are easy to setup and use and pro-
vide a reasonable estimate of the accuracy of the delivered dose. Many of them
have relatively coarse spatial resolution (5 mm at best) that would not be ideal for
techniques such as SRS or SABR. In addition, all the devices are comparing the
measured integral dose distribution to the planned distribution. Some devices claim
to measure every linac pulse, but are limited to 50 ms refresh rate. This is insuf-
ficient to reconstruct the dose delivered from every pulse, especially for flattening
filter free delivery.
Section 3.1 introduces a novel detector system developed at Centre for Medical
Radiation Physics at the University of Wollongong. The detectors are high spatial
and temporal resolution and aim to address some of the drawbacks of the current
commercial detector systems for small fields and adaptive radiotherapy.
2.4 Microbeam Radiation Therapy
Microbeam Radiation Therapy (MRT) is a novel, pre-clinical radiation treatment
technique that uses high dose rate x-ray beams generated from synchrotrons. The
x-ray beam is spatially fractionated using a tungsten-carbide multi-slit collimator
(MSC) to create microbeams.
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The following sections give a brief overview of the motivation for MRT and current
dosimetry methods.
2.4.1 Motivation and Purpose
Glioblastomas are malignant grade IV brain tumours characterised by rapid growth
and high radio resistance [70]. Radiation doses required for adequate tumour control
can result in unacceptable healthy tissue complications. Microbeam radiation ther-
apy (MRT) is a pre-clinical radiation oncology modality which has shown significant
improvements in treatment outcome when treating such inoperable brain tumours
compared to traditional methodologies [71]. Healthy tissue has shown a surpris-
ingly high tolerance to large entrance doses during MRT [72]. The most accredited
mechanism of tumour control is attributed to hypoxia where the blood vessels, in
immature tumour masses, are severely damaged beyond repair by the highly spa-
tially fractionated beams [73–75]. Normal tissue tolerance has been shown to be
up to 10 times higher for microbeams compared to a homogenous broad beam [76].
In order to achieve this result, MRT employs quasi-parallel beams of low energy
x-rays generated by high brilliance synchrotrons which provide the dose rate and
beam parallelism required. In contrast to conventional radiotherapy, MRT uses a
tungsten-carbide multi-slit collimator (MSC) to spatially fractionate the beam [77].
A common geometry uses rectangular beams 50 µm wide (peaks) separated by a
centre-to-centre distance of 400 µm (valleys) [78–80]. The beam height is approxi-
mately 500µm high and 2cm wide. A common field size of 2x2 cm2 is achieved by
scanning the target vertically through the beam.
The peak to valley dose ratio (PVDR) is of critical importance to the efficacy of
MRT. The underlying radiobiological advantage of MRT relies on high peak doses
and low valley doses. The extremely high dose rate (approximately 15 kGy/s) and
steep dose gradients associated with the highly collimated collinear beams and low
energy x-rays also contribute to this favourable radiobiological effect [81].
2.4.2 Dosimetry Requirements
The high dose rate and steep dose gradients in MRT make dosimetry challeng-
ing. Stringent requirements are placed on dosimeters to obtain accurate results. A
dosimeter used in MRT should meet the following specifications:
• Very high spatial resolution (of the order of 10 µm or less)
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• Minimal recombination effects over the rage of dose rates encountered (10s of
kGy/s)
• Dynamic range sufficient to resolve the dose in the peak and valleys simulta-
neously
• Minimal energy dependence at the energy range encountered (50-350 keV)
Currently in practice there are several dosimetry methods available. MOSFET
dosimetry has been investigated by several authors [82–84]. MOSFET dosimeters
can have extremely good spatial resolution, down to 1 µm which is ideal for MRT.
The practical lifetime of MOSFETs is limited by radiation damage that causes the
response to saturate after around a few thousand gray. In addition there are energy
dependency effects due to the silicon chip.
Gel dosimetry has also been proposed as a viable dosimetry method for MRT [85].
Readout is done with Magnetic Resonance Imaging so spatial resolution of the
dosimeter depends on MRI image resolution. Fluorescent nuclear track detectors
also have large dynamic range and sufficient spatial resolution [86] but are cumber-
some to read out.
The dosimetry methods proposed above all require post processing to read out the
detector response. An ideal dosimeter would allow real-time readout and recon-
struction of the microbeam profiles.
2.5 Conclusion
Real time adaptive radiotherapy has been implemented into clinical practice for
prostate and lung radiotherapy treatments. There is clinical evidence that 1) intra-
fraction motion can effect the patient outcome and quality of life and 2) hypo-
fractionation and dose escalation can lead to better tumour control. Adaptive
radiotherapy is an adopted method for addressing intra-fraction motion meaning
treatment margins are reduced significantly. The combination of higher doses, less
fractions and smaller radiation fields leaves very little room for treatment error. In
addition, dosimetry in small radiation fields is a lot more challenging than broad
beams. There are several phenomena such as the the loss of CPE, source occlusion
and spectral changes that impact on the types of detectors that can be used for
small field dosimetry.
Real-time adaptive radiotherapy changes the dose distribution during treatment.
It is important that dose measurements include a temporal component sufficient
to detect perturbations that have the potential to go un-noticed in an integral dose
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measurement. High spatial resolution detectors should be used in order to accurately
reconstruct the steep dose gradients that can occur. Currently available commercial
detectors for pre-treatment quality assurance are easy to setup and use, however
suffer from low spatial and temporal resolution in the context of real-time adaptive
radiotherapy and small field dosimetry.
Microbeam radiation therapy in a pre-clinical technique showing huge potential for
treating in-operable brain tumours. These treatments are also affected by intra-
fraction motion due to the extremely small beam size. Dosimetry is challenging in
MRT due to high dose rates and large difference between maximum and minimum
dose delivered, which impacts the dynamic range required for a detector.
The following chapter introduces some novel silicon detector systems that are de-
signed to address some of the short comings of the currently available systems for
real-time adaptive radiotherapy. The remainder of the thesis then focusses on the ap-
plication of these detectors under real-time adaptive radiotherapy conditions.
Chapter 3
Materials
This chapter contains an overview of the equipment used in each experiment. The
detector geometry, read-out system and software application are described. The
results of dosimetric characterisation of the detectors from previous studies are pre-
sented here for completeness.
The application of the detectors to real-time adaptive radiotherapy (RTAT) is then
discussed in the following chapters.
3.1 MagicPlate-512 and DUO
The Centre for Medical Radiation Physics has developed a suite of silicon diode array
detectors for dosimetry of linac radiotherapy beams. They vary in geometry to suit
a range of clinical needs. The system has high spatial and temporal resolution and
is suitable for measurements of small fields and during RTAT. Discussed here will
be the geometry of two particular detectors as well as the common data acquisition
system and software application.
3.1.1 Detector System Specifications
3.1.1.1 MP512 Detector Geometry
MagicPlate-512 or MP512 is a 2D silicon diode array. It consists of 512 individually
implanted silicon diodes on an epitaxial substrate. Each diode has an active area of
0.5 × 0.5 mm2 with 2 mm centre-to-centre spacing. The detector array is 52 × 52
mm2 and assembled on a 500 µm printed circuit board (PCB). The detector operates
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in passive mode where no bias is applied across the n+ p junction. A cross-section
of the detector geometry is shown in figure 3.3.
Figure 3.1: MP512 detector mounted to printed circuit board (a) and close up
of the 2D diode arrray (b)
Figure 3.1 shows MP512 mounted on the PCB. An adapter plugs in to the connectors
at the rear of the PCB which allows all 512 channels to be individually wired to
the read out electronics. The detector is predominantly made up of 22 rows of 22
diodes, with each side flanked by an additional 7 diodes. The small active volume
of each diode combined with 2 mm spacing allows for high spatial resolution dose
map reconstruction as well as profiling.
MP512 is encased in a PMMA phantom for structural rigidity and to provide a
suitable air gap above the sensitive volume, this is illustrated in figure 3.2. The
effect of the phantom and air-gap on dosimetry is discussed in section 3.1.2.
Figure 3.2: Rendering of MP512 encased in PMMA phantom.
CHAPTER 3. MATERIALS 33
Figure 3.3: Cross-section of the detector geometry showing the PMMA phantom
and air gap.
3.1.1.2 DUO Detector Geometry
DUO is a monolithic silicon detector used for high resolution dose profile measure-
ments. It consists of 505 individual silicon diodes in two orthogonal linear arrays,
figure 3.4 shows the layout. Each diode has an active area of 0.02× 1 mm2 with 0.2
mm centre-to-centre spacing. The total active area is 52×52 mm2. DUO operates in
passive mode with no bias applied across the n+ p junction. Each of the 505 diodes
is individually wired to the readout electronics in the same way as MP512, this
allows all the channels to be read out simultaneously. DUO is capable of resolving
beam penumbrae even in the high dose gradients generated from RTAT.
3.1.1.3 Data Acquisition System
The data acquisition system (DAS) is common for both detectors and is custom
designed at Centre for Medical Radiation Physics [87, 88]. The DAS is primarily
made up of eight analog front ends (AFE) which are commercially available chips
from Texas Instruments (Texas, USA) called AFE0064. Each AFE comprises of
64 current integrators providing a differential output which is proportional to the
charge accumulated by the input integrating amplifier. The differential signals from
each AFE are read in parallel by four analog to digital converters (ADC) with 16 bit
precision. Reset of the integrators and conversion takes approximately 70 µs which
is effectively the dead time of the system.
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(a) DUO detector mounted to printed cir-
cuit board
(b) Close up of the orthogonal linear diode
arrays
Figure 3.4: DUO consists of two orthogonal 1D arrays of individual diodes
spaced 0.2mm apart.
A field programmable gate array (FPGA) is used to synchronise the AFE and ADC
chips. It is a commercially available device from Opal Kelly (Portland, USA) called
XEM3001. It contains a Xilinx Spartan 3 FPGA module and USB 2.0 data interface.
A block diagram of the DAS is shown in figure 3.5.
The system can be self triggered using an internal clock with variable frequency up
to 5 kHz, alternatively it can be synchronised with an external trigger pulse. This
feature is extremely useful when the system is used for dosimetry in pulsed radiation
beams. Medical linacs operate in a pulsed beam configuration generally in the range
of 200 Hz to 400 Hz. The electron gun is fired for a period of approximately 3.7
µs with a few milliseconds between pulses. The DAS can be synchronised with the
electron gun trigger pulse so that the detector is only sampling when the beam is
on, this gives a better signal to noise ratio and allows full temporal reconstruction
of the measured dose.
The FPGA controls and synchronises a variety of additional sensors including an
inclinometer for an independent measurement of the position of the linac head with
respect to the detector. This feature is particularly important to compensate the
angular dependence of the detector response with respect to the angle of incidence
of the beam in full rotation delivery modalities such as IMRT or VMAT.
Several parameters of the DAS are variable and can be specified by the user. The
integration time can be set from 14 µs to hundreds of microseconds, the maximum
value being limited by the full scale range. The range is variable to provide multiple
levels of sensitivity from 0.9 pC up to 9.6 pC.
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Figure 3.5: Block diagram of the data flow within the DAS [89]
3.1.1.4 Software Application
In order to acquire and analyse data for the experiments planned in this thesis,
a graphical user interface has been designed and coded in C++ using the QT5
framework (The Qt Company, Helsinki, Finland). The author of the thesis was
heavily involved in the development and maintenance of the software application,
along with two colleagues. The application runs on a Microsoft Windows based PC
and connects to the DAS via a USB 2.0 link. The main features of the application
are:
• Upload acquisition parameters to the FPGA - e.g integration time, length of
acquisition, trigger frequency etc
• Start and stop the acquisition
• Receive data frames from the FPGA
• Save data frames to file for later processing
• Display frame-by-frame and cumulative integral detector response on screen
during an acquisition
• Automated baseline subtraction and equalisation procedure
• Post processing tools such as exporting mapped integral response or exporting
the time resolved response of a single diode
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The software is split into two main tabs; acquisition and analysis. Figure 3.6 shows
the main screen of the acquisition tab. From here the user enters their desired ac-
quisition length, range (sensitivity), integration time, buffer size (amount of data
transferred from the FPGA to PC in each communication event) and trigger fre-
quency. There is also the option to toggle the external trigger, for example to
synchronise the acquisition with the linac electron gun pulse.
Above the acquisition parameters is the real-time visualisation panel, in this case
the MP512 2D detector geometry is shown. This section displays both the instanta-
neous and cumulative integral detector response during an acquisition. The colour
scale is normalised to the maximum detector response during the acquisition. Al-
ternatively, a histogram display can be selected which shows the response of each
detector channel in a linear bar graph.
The auto-decode option will trigger the file to be decoded immediately after the
acquisition. The raw data files are saved in a binary format and contain hexadecimal
values generated by the DAS. The decode function converts the binary hex files into
text files. The resulting text file is a matrix of 512 columns (corresponding to
the number of channels in the system (8 × 64 channel AFEs)). The number of
rows depends on the acquisition frequency and length of measurement. The values
generated in the text file are proportional to the detector response and depend
on what range (sensitivity) the acquisition was performed at. For example, the
default range setting of 7 means each integrator in the AFE will accumulate 9.6pC
before registering a ’count’. The total counts for each channel in each data frame
is then expressed as a value between 0 and 65535 - i.e values have 16-bit resolution.
A value of 65535 represents a full scale reading and a value of 32766 represents
approximately a half scale reading. The range can be changed to ensure the detector
is not saturating for a given set of experimental conditions.
Data files are automatically named with the date and time of acquisition and all of
the acquisition parameters. For example a typical file name would be ”11-12-16 15-
12-13 AcqLength-70s IntTime-78us Range-7 Freq-360Hz.dat”. A logfile feature ex-
ists to relate each data file to a description of the acquisition. The user is prompted
to enter a description after initiating each measurement. The logfile is then used at
a later date for opening the data files for analysis.
The second major tab of the software application is the analysis tab, shown in
figure 3.7. From here the user can use the ’Read Log’ button to open a logfile
from an experimental session and browse all of the data files associated with that
particular session. The user can decode or load files directly from the logfile by
double clicking. A file has to be decoded first before it can be loaded for analysis.
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Figure 3.6: Main screen on the acquisition tab of the software application
Figure 3.7: Main screen on the analysis tab of the software application
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Data files can be separately decoded and loaded outside of the logfile environment
with the ’Decode File’ and ’Load File’ buttons, respectively. This is particularly
useful if a user has defined their own folder structure when saving data files or has
a paper logbook.
The metadata from each measurement is displayed front and centre for quick refer-
ence. This includes date and time of measurement, acquisition length and frequency,
integration time and range. These values are read directly from the filename of the
currently loaded datafile. Above the metadata is the visualisation panel. Similarly
to the acquisition tab, this consists of an instantaneous and cumulative integral de-
tector response. In figure 3.7 the MP512 2D detector geometry is displayed and the
resulting dose map can be seen. Controls exist below the instantaneous display to
step through the dataset as a function of time. The display then updates to show
the detector response at that particular point in time.
The pixels in the integral map are interactive, single pixels or entire rows or columns
can be selected. If a single pixel is highlighted and the users hits ’Enter’ on the
keyboard then a dialog popup displays the response of that individual pixel as a
function of time. From there this data can be saved to an additional file for offline
processing. If a row or column is selected and the user hits ’Enter’ then a dialog
popup displays a profile generated for the integral response of each of the pixels in
the row or column. This subset of data can also be saved for offline analysis.
In addition to the dose map display, the analysis tab can also display the detector
response as a 1D histogram, as shown in figure 3.8. This is useful for testing and
debugging the system.
3.1.2 Characterisation and Dosimetry
MP512 has been extensively characterised for dosimetric performance in a previous
study, seperate from the work presented in this thesis [90]. The DUO detector
has been characterised similarly [91]. Several parameters were investigated in order
to prove the basic performance of the device as dosimeter for small field photon
beams. This characterisation is instrumental to define the settings and some of the
methods adopted during the experiments and data analysis of RTAT presented in
this project.
The author was involved in general discussion surrounding experimental methodol-
ogy and advice on data analysis procedures. The author was present for some of the
experiment measurements in this section, however the data presented in this section
is acknowledged as preliminary work undertaken separately from this thesis.
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Figure 3.8: Alternate histogram display of the detector response
The detectors were characterised in terms of:
• Uniformity
• Sensitivity (radiation damage)
• Dose linearity
• Percentage depth dose
• Dose per pulse dependence
• Output factor
• Beam profiling
The methodology and results of the characterisation of each of the above parameters
is summarised in the following sections.
3.1.2.1 Geometric uncertainty
The geometric uncertainty associated with pixellated detectors depends on the pixel
spacing (pitch). The furtherest point away from the centre of a detector element is
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For the DUO detector, the detector pitch is 0.2 mm, therefore the geometric un-
certainty is ∆x = 0.1 mm. For a 2 dimensional array of detectors, the uncertainty





Combining both ∆x and ∆y gives the final uncertainty:
∆d =
√
∆x2 + ∆y2 (3.3)
For MP512, the detector pitch is 2 mm, therefore the geometric uncertainty in two
dimensions is ∆d =
√
12 + 12 = 2 mm. In one dimension (i.e a profile along a certain
direction), the uncertainty is given by half the pitch, so ∆x = 1 mm.
These estimates represent the worse case scenario of the geometric uncertainty.
3.1.2.2 Uniformity
MP512
MP512 is made up of 512 individually implanted silicon diodes. Each of these diodes
inevitably has a slightly different sensitivity. In order to get a uniform response
across the entire detector, a matrix of equalisation factors is generated which scales
the response of each individual pixel. To derive the equalisation factors the detector
has to be irradiated with a uniform field of radiation. The beam produced by a
linac operating with a flattening filter is designed to be flat (i.e uniform) in both
the cross-plane and in-plane directions a 10 cm depth in water. This design aspect
is exploited here and the detector is irradiated at 10cm depth with a 20 × 20 cm2
field of 6 MV x-rays with 100 cm source to surface distance (SSD). The equalisation





Where xi is the response of a given pixel and x is the average response of all pixels.





Where xi,eq is the equalised response of a given pixel.
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Ideally there would be zero fluctuation between the response of each pixel after the
equalisation procedure, however this very hard to achieve in practice. The variation





Where xi,centre is the response of the central pixel after equalisation and is used as
a normalisation point.
Uniformity of the entire array can be represented as a frequency histogram such as
that in figure 3.9. In this case uniformity is within 0.25% across the array, when
considering 2 standard deviations from the mean.




The response of silicon diodes decreases over time due to cumulative radiation dam-
age to the crystal structure of the p-n junction. The damage creates so called
’recombination centres’ and charge traps which reduces the number of charge car-
riers reaching the collecting volume. MP512 is pre-irradiated with 140 kGy water
equivalent dose to stabilise the response before use. This was done at the Australian
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Nuclear Science and Technology (ANSTO) using the Gamma Technology Research
Irradiator (GATRI) facility, which is a Co-60 gamma source. The detector was
irradiated in 10 kGy steps up to 140 kGy [92].
The response of the detector as a function of accumulated dose is shown in figure
3.10. The response of the detector reduces by nearly half with increasing dose. At
140 kGy the response becomes stable.
Figure 3.10: Variation in response of the pixels in MP512 as a function of
accumulated dose [92].
The resulting sensitivity is 1%/10 kGy after pre-irradiation of 140 kGy.
3.1.2.4 Linearity
MP512
Dose linearity is measured by examining the detector response when delivering suc-
cessively larger doses. 500 monitor units (MU) was delivered in 50 MU increments.
The detector response as a function of MU is shown in figure 3.11. Data points
match the linear fit with maximum deviation of 2.5%.
MP512 exhibits a linear response to dose, the straight line equation can be used to
convert from MU to charge (pC) or dose (cGy) by deriving an appropriate calibration
factor. This is discussed further in section 5.5.
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Figure 3.11: Response of the central pixel to accumulated dose. Solid line
represents the linear fit, error bars represent two standard deviations from five
repetitions.
3.1.2.5 Percentage depth dose
MP512
Energy dependence is evaluated by comparing the percentage depth dose (PDD)
from MP512 and a Markus ionisation chamber (PTW Freiburg, Germany). MP512
was placed inside a PMMA holder (as discussed in section 3.1.1.1) and placed at
various depths as defined by 30× 30 cm2 solid water slabs. Depth was varied from
1.5 cm to 30 cm depth for both detectors. 100 MU was delivered by 6 MV photons
at each depth using a 10× 10cm2 field size at 100 cm SSD.
The PDD from each detector is plotted in figure 3.12. Maximum observed variation
between the two was ±1%.
DUO
Energy dependence is characterised by comparing the percentage depth dose of
DUO with that of a Markus ionisation chamber (PTW Freiburg, Germany). Mea-
surements were taken at depths from 0 cm to 25 cm in solid water, using slabs
30 × 30 cm2 of various thickness. 10 cm of solid water was used as backscatter. 6
MV x-rays were collimated to a 10× 10 cm2 field size at 100 cm SSD. 100 MU was
delivered per depth at a rep rate of 600 MU/min. The response of DUO at depth
was corrected for dose per pulse dependence (see below) as per the procedure in
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Figure 3.12: Percentage depth dose measured with Markus ionisation chamber
(IC) and MP512.
reference [91].
Figure 3.13: Percentage depth dose measured with Markus ionisation chamber
(IC) and DUO
The PDD reported by DUO and the Markus chamber match to within 1.5%.
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3.1.2.6 Dose per pulse
MP512
Dose rate dependence was evaluated by varying the dose per pulse and comparing
the MP512 response to the response of a CC13 (IBA Dosimetry) ionisation chamber.
Dose per pulse was varied from 0.9× 10−5 Gy/pulse to 3.4× 10−5 Gy/pulse. Dose
rate was fixed at 600 MU/min (all pulses result in dose) and SSD changed from
90 cm to 350 cm. The response of MP512 is normalised to the response of CC13,
placed next to the detector. The ratio MP512/IC is then normalised to the dose per
pulse measured at dmax by the CC13 at 100 cm SSD, 2.78× 10−4 Gy/pulse.
Figure 3.14 shows the dose rate dependence of MP512. Maximum variation over the
dose range was 5%, which is comparable to the dose rate dependence of commercially
available diodes [93].
Figure 3.14: Dose per pulse dependence of MP512. The ratio MP512/IC is
normalised to the dose per pulse measured by the CC13 at dmax and 100cm SSD.
DUO
A similar methodology was followed to obtain the dose per pulse dependence of the
DUO detector; varying the SSD and comparing to the dose rate as measured by a
CC13 ionisation chamber.
Figure 3.15 shows the dose rate dependence of the DUO detector. The diode re-
sponse decreases with decreasing dose per pulse. This is consistent with findings
of other studies [94]. At lower instantaneous dose rates there are more available
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Figure 3.15: Dose per pulse dependence of DUO. The ratio DUO/IC is nor-
malised to the dose per pulse measured by the CC13 at dmax and 100cm SSD.
recombination centres in the silicon crystal structure which reduces the charge col-
lected. DUO exhibits a large dose per pulse dependence at very low dose rates, up
to 23%. At intermediate dose rates the effect is a reduction of around 5% of the
diode response. To overcome this issue a series of correction factors were derived
by using the polynomial fit shown in figure 3.15, as per the procedure in reference
[91].
The use of DUO in this work in sections 4.4 and 4.5 is at a constant depth and SSD,
so no dose per pulse corrections were applied.
3.1.2.7 Output factor
MP512
The detector response as a function of field size (output factor) was compared against
EBT3 film and a silicon metal oxide field effect transistor (MOSFET) detector called
Moskin which has water equivalent depth 70µm, similar to that of skin. Output was
measured for various jaw defined square field sizes at a depth of 10 cm and SSD of
90 cm, i.e the detectors were placed at isocentre. Response is normalised to the field
size 10× 10 cm2.
Figure 3.16 shows the measured output factors for each detector. MP512 exhibits an
over-response at small field sizes due to perturbation of the secondary electrons in
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higher density silicon and packaging materials [66, 67]. The large field response of an
individual diode is primarily due to secondary electrons scattering from surrounding
material, in this case solid water. I.e The ratio of the number of secondary electrons




small for a large field.
As the field size is reduced the relative proportion of the beam interacting with the
packaging material increases, as does the ratio
e−packaging
e−S.W
. Under these conditions the
density and atomic number of the packaging materials begins to dominate the overall
response. Reducing the size of the non-tissue equivalent detector packaging can help
to minimise this effect. This is the approach adopted by the Moskin detector and it
shows good agreement with EBT3 film.
Alternatively, the air gap above the detector can be optimised, this is achieved by
using various depth cut outs milled in the PMMA holder (see section 3.1.1.1 for a
description of the PMMA holder). A study was performed to investigate the optimal
air gap and it was found that at 6 MV a 0.5 cm air gap gives the best match (within
2%) of output factors between MP512, EBT3 film and Moskin [95].
Figure 3.16: Field size dependence of MP512. EBT3 film and a Moskin detector
are used as a reference.
DUO
Output factors measured by DUO were also compared to EBT3 and Moskin detec-
tors. The output from square jaw defined field sizes ranging from 0.5 × 0.5 cm2 to
30× 30 cm2 were measured at 10 cm depth and 100 cm SSD for all detectors.
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Figure 3.17: Field size dependence of DUO. EBT3 film and a Moskin detector
are used as a reference.
Figure 3.17 shows the measured output factors from all detectors, normalised to
the response of a 10 × 10 cm2 field. The air gap was also optimised for the DUO
detector [91] by measuring output factors with air gaps of 0.5 mm, 1 mm, 1.5 mm
and 2 mm. It was found at 6 MV that a 0.5 mm air gap gave the best agreement
with EBT3 and Moskin, within 1.8% for all field sizes. The largest discrepancy was
seen at the smallest field sizes. This is due to similar effects as discussed above for
MP512.
3.1.2.8 Beam profile measurements
MP512
Cross-plane profiles were compared between MP512 and EBT3 film. Details of the
measurement and processing procedures for EBT3 film can found in reference [90].
Profiles were measured for square field sizes in the range 0.5 × 0.5 cm2 to 10 × 10
cm2. Measured values were normalised to the response on the central axis for both
detectors. MP512 and EBT3 profiles were aligned to their left 50% response point.
The 10× 10 cm2 and 5× 5 cm2 profiles measured by MP512 had no 50% response
point due to the field size being larger than the detector active area. In this case
the profiles were aligned with the 100% response points on the central axis.
Full width half maximum (FWHM) and penumbral width was calculated for all pro-
files. MP512 matched EBT3 within 1.3% for FWHM across all field sizes. Penumbral
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width was over estimated by MP512 by approximately 0.4 mm, with the effect being
more pronounced at smaller field sizes. This is due to a combination of voluming
averaging due to the individual diode size (0.5 mm2) and the detector to detector
spacing of 2 mm which becomes large for measuring penumbral response as field size
reduces.
Beam profile measurements with MP512 is investigated further in sections 4.3 and
5.5.1.
DUO
High resolution beam profiles were compared between DUO and EBT3 film in the
cross-plane direction. The detectors were placed at isocentre (SAD = 100 cm) at
10 cm depth (SSD = 90 cm). Square fields ranging from 0.5 × 0.5 cm2 to 5 × 5
cm2 were profiled. Measured values from both DUO and EBT3 were normalised to
the maximum central axis response. FWHM and penumbral width was compared
between the data sets.
FWHM agreed between DUO and EBT3 within 1%. Again there was a discrepancy
in penumbral width of 0.44 mm.
Beam profile measurements with DUO is presented in section 4.5.
3.1.3 Conclusion
MP512 and DUO are high spatial and temporal resolution silicon detector arrays
suitable for measurements in small fields. They have been extensively characterised
under ’standard’ radiotherapy conditions and for small field static irradiations for
several dosimetric parameters. Chapter 4 discusses the benchmarking of the de-
tectors for use in RTAT quality assurance. Temporal performance and dose recon-
struction under real-time MLC tracking conditions is explored. Chapter 5 presents
a published study on the use of MP512 in reconstructing the dose delivered from a
VMAT treatment using MLC tracking.
3.2 Single Strip Detectors
Single silicon strip detectors (SSSD) have been developed at the Centre for Medi-
cal Radiation Physics for use in Microbeam Radiation Therapy (MRT) [96]. The
detector geometry, readout system and characterisation is discussed below.
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The work in this section was carried out prior to this thesis project, as such that
author was not involved in the measurements presented in this section.
3.2.1 Detector Geometry
The SSSD consists of a single silicon microstrip fabricated on a 50 µm thick epitaxial
substrate. The epitaxial layer is grown on 370 µm thick lower resistivity silicon
substrate. The width of the microstrip is 10 µm and length 900 µm. The chip die
is 1 × 1.4 mm2. Figure 3.18 shows a scanning electron microscope image of the
sensitive volume of the detector [97].
Figure 3.18: Scanning electron microscope image of the SSSD with 128x mag-
nification. The sensitie volume of the microstrip is marked. [97]
The SSSD can be used in passive mode or with applied bias voltage. An n+ guard
ring surrounds the microstrip which defines the outer bounds of the sensitive area,
as shown in figure 3.19. The effective size of the collection volume depends on the




– Microstrip at 90 degrees
• Edge on
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– Microstrip Straight
– Microstrip at 90 degrees
Figure 3.20 summarises the orientation options.
Figure 3.19: Schematic of the geometry of the SSSD sensitive volume, guard
ring and substrate [96].
Figure 3.20: Possible orientation options for the SSSD with repect to the in-
coming beam [97].
In ’edge-on’ orientation the effective spatial resolution is determined by the size
of the depletion region. It is possible to get a sensitive volume of approximately
7− 10µm when a bias of -30 V is applied.
The packaging materials and bonding of the detector has been carefully designed to
avoid an over response in silicon from low energy x-rays encountered in MRT. The
chip is readout via a flexible kapton carrier probe which is 600 µm thick, 10 mm
wide and 300 mm long. The detector is supported by a thin chemically deposited
aluminium layer and the pads are tab bonded to the carrier. Figures 3.21 and 3.22
shows the arrangement of the chip on the end of the flexible carrier.
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Figure 3.21: The silicon chip is chemically bonded to a thin aluminium layer
on a kaptop carrier [96]
3.2.2 X-tream Readout System
The detector readout system has also been custom designed at Centre for Medical
Radiation Physics and is called ’X-tream’. The system comprises two main parts;
a preamplifier and a central system unit (CSU). Figure 3.23 shows a schematic
representation of the system.
The main issue facing dosimetry systems for use in MRT is the dynamic range
required to simultaneously estimate the dose in the peak and valleys. Typical peak
to valley dose ratios (PVDRs) can be of the order of a few thousand [98]. The
response of the silicon microstrip is directly proportional to the MRT dose rate,
hence the dynamic range of the system should be of the same order of magnitude
as the dose rate expected from the PVDR.
The preamplifier module has been designed to fulfil the following requirements:
• A dynamic range of at least 104
• Linearity of response over the entire dynamic range
• Input impedance that matches the inherent capacitance of the microstrip probe
• Minimal input leakage current to reduce the amplified output offset
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Figure 3.22: Photo of the SSSD chip and flexible kapton carrier
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Figure 3.23: Schematic representation of the central system unit and preampli-
fier module [96].
A transimpedence amplifier combined with a pair of differential amplifiers was cho-
sen to fulfil the above requirements. The kapton carrier probe of the microstrip
connects directly to the preamplifier. The CSU is located outside of the treatment
room, several meters away, the preamplifier is connected to the CSU with a long
cable.
The CSU serves the following functions:
• Remote control of the acquisition of the differential signal coming from the
preamplifier
• Offset adjustment
• Analogue to digital conversion of the signal
• High voltage bias of the microstrip
• Regulate supply bias to all associated circuitry
The CSU is controlled by an FPGA which also allows data transfer over USB to
a host computer. A digital clock manager operates at 140 MHz and controls the
synchronisation of the I/O busses. This fast readout is required for the high dose
rate experienced in MRT. Further details of the FPGA and CSU architecture can
be found in reference [96].
A custom designed software application called RadPlot is used to control the ac-
quisition and visualise/analyse the measured data. The software has the following
features:
• Establish and maintain the USB communication with the CSU
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• Upload firmware to the FPGA
• Definition of bias voltage and offset
• Immediate display of the measured current
• Statistical analysis of the microbeam peaks including PVDR and FWHM
3.2.3 Dosimetric Characterisation
The energy dependence and charge collection characteristics of the SSSD have been
extensively studied [99]. The results are not reproduced here.
The performance of the SSSD under MRT conditions has been characterised at the
biomedical beamline ID17 at the European Synchrotron Radiation Facility [100].
These results are summarised below.
A multislit collimator (MSC) was used to segment the homogenous synchrotron
x-ray beam into 59 microbeams. The incoming broadbeam was 0.5 mm high and
24 mm wide. The resulting microbeams had a width of 50 µm and pitch of 400
µm. The SSSD was mounted ’edge-on’ at 2 mm depth in a PMMA phantom of
dimensions 15 × 15 × 15 cm3. No bias was applied to the detector. The phantom
was placed approximately 1 m downstream from the MSC.
The current generated by the SSSD was readout with a Keithley model 467 bench
multimeter. The SSSD was stepped through the radiation field in 10 µm incre-
ments. Measured current at each point was corrected for the synchrotron storage
ring current. Figure 3.24 shows the measured microbeam profiles. The detector can
reconstruct the expected number of microbeams within the beam width.
Figure 3.24: Lateral profile of the microbeams measured by the SSSD [100].
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The FWHM of the peak was calculated to be 70 ± 3µm which is 20 µm larger
than the nominal microbeam width of 50 µm. The measured FWHM is actually a
convolution of the intrinsic microbeam profile width and the width of the sensitive
volume of the SSSD. This shows that the effective resolution of the detector for this
experiment was 20 µm. This is less than the thickness of the sensitive epitaxial layer
(50 µm) of the SSSD (as shown in figure 3.19) and proves that the guard ring is
working to limit the size of the sensitive area. As previously mentioned the effective
resolution of the detector can be adjusted by varying the applied bias.
The PVDR was calculated for measured microbeams at various depths in the PMMA
phantom, these values were compared to the PVDR calculated by Monto Carlo sim-
ulation [101]. Figure 3.25 shows the trend of the PVDR as a function of depth.
Error bars represent the 95% confidence limit from the average PVDR of 10 repeti-
tions.
Figure 3.25: Measued and calculated PVDR values as a function of depth in
PMMA [100].
There is a clear trend seen in both the measured and calculated PVDR. However
the measured PVDR are a factor of approximately 4.5 less than the calculated
PVDR. This can be attributed to several factors [100]: charge recombination, dose
enhancement and partial volume effects.
Charge recombination can effect the PVDR due to the large difference in dose rate
between the peak and valley of the microbeams. Dose response enhancement can
occur in the valley due to the lower energy spectrum because the sensitive volume
is silicon and cross section of photoelectric effect has a large impact (up to 700%)
at the energy range of MRT pink spectrum. Partial volume effects due to the size
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of the sensitive volume can under estimate the dose in the peak due to the steep
dose gradient. The dose gradient in the valley is not as steep, so the effect would be
minimised in this region.
A second study benchmarked the performance of the SSSD in combination with the
X-treme readout system [96]. This experiment was also performed at the biomedical
beamline ID17 at the European Synchrotron Radiation Facility.
The SSSD was mounted in the ’edge-on’ orientation at 6cm depth in a 15× 15× 15
cm3 PMMA phantom. The detector was scanned laterally continuously through the
beam (there was no discreet step size) and the current was continuously sampled by
X-treme. The beam size defined by the primary slits was 50µm× 20mm.
(a) (b)
Figure 3.26: (a) Beam profile of the homogenous broadbeam defined by the
primary slits of the beamline. (b) A zoom in of the response across the top of the
profile to show beam x [96].
Figure 3.26 shows the response of the SSSD across the homogenous broadbeam. The
uniformity across the top of the profile is also shown.
The beam height was increased from 50 µm to 500 µm and the MSC was put in in
the beam (same geometry as above) to generate microbeams. The lateral scan was
repeated and the resulting microbeams are shown in figure 3.27. Again the detector
can reconstruct the expected number of microbeams within the beam width, and
the distribution of the microbeams uniform with respect to the broadbeam.
The RadPlot software application was used to automatically calculate the FWHM
and spacing of the microbeams. The average FWHM for all microbeams was 62 ±
2µm at a 99% confidence limit. For these measurements the SSSD was biased with
-30 V, based on the FWHM the effective resolution of the detector with this bias is
approximately 10 µm. The spacing of microbeams was on average 410± 3µm which
agrees well with the nominal spacing of 400 µm.
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(a) (b)
Figure 3.27: (a) Beam profile of the microbeams defined by the MSC. (b) A
zoom in of the response across the top of the microbeams to show beam uniformity
[96].
3.3 Conclusion
The SSSD combined with X-treme is a ultra-high resolution dosimetry system suit-
able for use in MRT. The system has real-time readout and high dynamic range
which enable measurements in the high dose rates encountered in MRT. Chapter
6 presents a study on the use of the SSSD to experimentally quantify the effect of




4.1 MP512 and DUO for Static Gantry Adaptive
Radiotherapy Conditions
This chapter describes three experiments performed at Northern Sydney Cancer
Centre (Royal North Shore Hospital, St Leonards NSW):
1. Measurement of delivered dose with MP512 under motion conditions to deter-
mine the ability of the detector system to reconstruct dose delivered during
MLC tracking.
2. Measurement of delivered dose with DUO with MLC tracking applied to bench-
mark the timing performance of the detector system.
3. Measurement of delivered dose with DUO in phantoms of varying density to
investigate the effect on tracking performance.
The first experiment serves as a proof-of-concept, that MP512 is suitable for accurate
reconstruction of the dose delivered to a homogenous phantom with MLC tracking.
The second experiment is designed to test to temporal performance of the system,
DUO is used here however the detector readout is the same for both detectors
(see chapter 3). The final experiment builds on the first by using a more complex
phantom of varying density. This is closer to a true clinical scenario and gives an
indication of the performance of MLC tracking in low density targets, for example
lung tissue. Small field dosimetry becomes more of an issue in lower density material,
this was also a consideration for employing a variable density phantom.
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All three experiments have a common experimental setup which is discussed in sec-
tion 4.2. The measurements, analysis procedure and discussion for each experiment




Patient motion tracking was achieved using the Calypso 4D localisation system, as
discussed in chapter 2, section 2.1.1.3. Dipole beacons were detected by a coil array
in order to reconstruct the position of the moving tumour in the MLC coordinate
system. The beacons translation was monitored in real time and this spatial infor-
mation was sent to a custom tracking software developed at University of Sydney
[102]. Beacons were placed centrally on the top surface of the phantom.
The tracking software has two components; patient motion calculation and MLC
leaf position calculation. Two different methods were used for patient motion cal-
culation, a passive algorithm and a predictive algorithm. The passive algorithm
essentially passes the tumour trajectory straight through and the MLC leaf posi-
tions are calculated based upon this information. There is a measurable delay of
approx. 230 ms [22] using this method due to computation time and finite leaf speed.
As a result the beam lags slightly behind the real tumour trajectory. The predictive
feedback algorithm uses kernel density estimation [102] and a short learning time
frame to approximate the position of the target some small time in the future, based
on the difference in the nominal and actual tumour position. Let t represent the
current time and τ be a small increment of time, if τ = 230 ms then the prediction
can calculate the tumour position at time of t+ τ and almost eliminate the system
latency [103].
In order to further investigate both tracking algorithms, several tracking modalities
were implemented:
1. No motion - detector phantom is static throughout the treatment
2. Motion with no tracking - detector phantom follows supplied motion trace and
no MLC tracking is applied
3. Motion with passive tracking - detector phantom follows supplied motion trace
and passive MLC tracking algorithm is applied
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4. Motion with predictive tracking - detector phantom follows supplied motion
trace and predictive MLC tracking algorithm is applied
A solution was needed to move the phantom during treatment delivery to mimic
patient motion. The phantom is relatively heavy and bulky, so the solution would
need to move with sufficient speed under load. The movable platform HexaMo-
tion by Scandidos (Upsalla, Sweeden) is designed as an accessory for the Delta4
dosimetry phantom. It is able to reproduce patient specific motion patterns with
sub-millimetre accuracy in 6 dimensions. A flat, solid board made of timber was
manufactured to attach to HexaMotion in place of Delta4 which provided the surface
necessary to place our detector phantom, figure 4.1. HexaMotion was used to pro-
vide simultaneous motion in each of the x (lateral) and y (sup-inf) directions. The
detector was aligned such that it’s coordinate system was aligned with HexaMotion:
x direction corresponds to lateral motion, y direction corresponds to longitudinal or
sup-inf motion.
The HexaMotion device employed in the following experiments is used clinically at
Royal North Shore Hospital, as such its positioning accuracy and reproducibly is
tested as per local quality assurance processes.
Figure 4.1: The HexaMotion platform was used to simulate patient motion
during treatment delivery.
Several motion traces were used to benchmark the performance of the system:
1. Basic sinusoidal waveform with variable frequency (breaths per minute)
2. ’Lung 1’ - Clinical lung trace with approximately 8 mm sup-inf offset (baseline
shift)
3. ’Lung 2’ - Clinical lung trace centred around zero
4. ’Prostate’ - Clinical prostate trace with a slow basline shift
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Figure 4.2 shows the motion traces as a function of time in the x (left-right) and y
(sup-inf) direction. Data was taken from traces acquired during 4DCT (lung) and
KIM (prostate), sampled every 25ms.
4.2.2 Detector Phantom
Two phantoms were used in these experiments:
1. A homogenous solid water phantom
2. A phantom mimicking the lower density in lung tissue
The solid water phantom was simply constructed by placing slabs of solid water
above and below the detector, as shown in figure 4.3.
A phantom of variable density was constructed to mimic the scattering conditions in
the lung. To accomplish this a combination of solid water and pine timber was used.
Two timber slabs were manufactured that encapsulated the detector and PCB; one
slab above and the other below. A recess was milled into the top piece so that it
would sit flat against the PCB and minimise the air gap around the detector. Pins
and holes were used for localising the detector within the timber pieces.
The timber section of the phantom was then surrounded by solid water and PMMA,
as shown in figure 4.4.
Both phantoms were encased in 2mm of aluminium shielding to reduce the interfer-
ence from RF coming from the Calypso coil array. This is discussed in further detail
in section 5.3.2.
4.2.3 Treatment Plans
A CT dataset was acquired of the detector phantom and used to generate two
treatment plans with Eclipse (Varian, Palo Alto, USA) at Northern Sydney Cancer
Centre (Royal North Shore Hospital, St Leonards NSW). A 3D conformal plan
(3DCRT) consisted of a MLC defined circular field around a 2 cm diameter GTV,
delivered from gantry angle 0. Jaws were set to 6 cm x 6 cm to allow unshielded
movement of the MLC over the entire detector face. Collimator was set to 85 degrees
as per local protocol. This also allowed the major motion axis to be closely aligned
with the direction of MLC motion. 621 MU was planned to be delivered.
A single field sliding-window intensity modulated radiotherapy (IMRT) plan was
also developed which was to deliver 962 MU from gantry 0. Machine parameters
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Figure 4.2: Motion traces corresponding to (a) Lung 1, (b) Lung 2 and (c)
Prostate. Data is reconstructed from traces acquired during 4DCT (lung) and
KIM (prostate), sampled every 25ms. X component corresponds to motion in
left-right direction and Y component corresponds to motion in sup-inf.
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Figure 4.3: Geometry of the scattering conditions for the homogenous solid
water phantom.
Figure 4.4: Geometry of the scattering conditions for the low density timber
phantom.
were the same as the 3D conformal plan and dose was optimised according to the
following:
1. 100% of prescribed dose to 100% of GTV volume
2. Max 5% of prescribed dose to a ring contour generated 5mm from the GTV
Calculated dose distributions for both treatment plans are shown in figure 4.5. Note
the MLC leakage in the 3DCRT dose map. For this plan MLC leaves are not
shielded under the jaws as it would take too long for them to move into position
when instructed by the tracking system.
All treatment deliveries for each experiment were 6 MV x-rays generated by a Varian
2100C linac.
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(a) 3DCRT Dose Map (b) IMRT Dose Map
(c) 3DCRT Depth Dose (d) IMRT Depth Dose
Figure 4.5: Calculated dose distributions for the 3DCRT and IMRT plans.
a), b) show beams eye view (coronal plane) at the detector surface (1.5 cm water
equivalent depth) and c), d) show transverse slice view in the centre of the detector
volume (again the detector is at 1.5 cm water equivalent depth). Note anatomical
direction in bottom left of c) and d).
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4.3 Experiment 1 - Dose response under motion
conditions
4.3.1 Measurements
This experiment was carried out using MP512 (see section 3.1) and the ’Lung 1’
motion trace (figure 4.2(a)). The aim was to prove the capability of the detector
system to reconstruct dose profiles under MLC tracking conditions. The detector
was placed in the solid water phantom and aligned to isocentre on the Hexamotion
platform. The 3D conformal treatment plan was delivered with three modalities:
no motion, motion with no tracking and motion with passive tracking. See section
4.2.1 for descriptions of each modality. For each modality the detector sampled the
dose throughout the entire delivery. This was then repeated for the IMRT treatment
plan.
4.3.2 Analysis Procedure
2D dose maps were reconstructed from the integral detector response throughout
the entire radiation delivery. This allowed for identification of columns and rows
of detectors that passed centrally through the target region, for the no motion
modality. The response of each pixel in a column forms a profile in the Y direction
(along the bed) and the response of each pixel in a row forms a profile along the X
direction (across the bed). The resolution of the profile is 2 mm and corresponds
to the centre-to-centre distance of adjacent pixels in a row or column. Figure 4.6
shows the pixelated dose map from MP512 and the corresponding profiles in the
X and Y directions. The black lines overlaid on the dose map show the column
and row chosen to create the profiles. The same row and column was used for each
motion modality; this gives an indication of the dose distribution experienced by a
specific anatomical structure (i.e the same place geometrically in phantom) between
each motion modality. The same plane in phantom is examined for each modality,
therefore a different region of the dose distribution can potentially be sampled.
Profiles were normalised to dose maximum measured for the no motion modality.
Full width half maximum (FWHM) and penumbral width was calculated. The pro-
files shape and metrics were compared across the motion modalities. The expected
uncertainty for measurements is ±1% [3, 90, 104]. This is represented by the size of
the marker in the profiles presented in this section.
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Figure 4.6: 2D integral dose map extracted from MP512. Each pixel can be
seen in the matrix, profiles are reconstructed from a row or column of pixels as
shown by the overlaid black lines.
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Modality FWHM (mm) Left Penumbra (mm) Right Penumbra (mm)
No Motion
3DCRT
X 15.3 6.2 7.0
Y 20.9 6.4 4.6
IMRT
X 16.1 6.6 6.1
Y 19.4 5.5 4.6
Motion
3DCRT
X 23.4 10.0 12.0
Y 20.9 6.8 7.6
IMRT
X 19.4 5.7 4.6
Y 19.2 6.5 7.3
Passive Tracking
3DCRT
X 16.9 7.6 8.0
Y 21.2 6.8 5.7
IMRT
X 17.9 7.8 8.4
Y 19.4 6.5 5.8
Table 4.1: FWHM and penumbral width for profiles reconstructed from MP512.
X corresponds to the lateral direction and Y corresponds to the sup-inf direction.
Uncertainty is ±0.3mm.
4.3.3 Results and Discussion
Profiles were reconstructed for both treatment plans and all motion modalities,
shown in figure 4.7 (full size figures are presented in appendix A.1.1). Profiles are
normalised to the dose maximum of the no motion case. Under each profile is an
error plot which shows the percentage difference of the motion and passive tracking
modalities with respect to the no motion modality. Profiles and percentage difference
are plotted as a function of distance across the detector face in millimetres.
The FWHM and penumbral width of the profiles in each direction and for each
modality were calculated and are shown in table 4.1. The percentage difference of
FWHM and penumbral width with motion and passive tracking is shown in table
4.2. This is calculated with respect to the no motion case and indicates the error
in treatment delivery when motion is present. The following results will reference
data from tables 4.1 and 4.2.
When motion was applied during the 3DCRT delivery, the measured dose across
the lateral direction appears to widen compared to the no motion case. There was
an observable increase in the FWHM from 15.3 mm to 23.4 mm or 53%. The left
and right penumbrae also increase in width (60-70%) meaning the dose is smeared
over a larger area and dose gradients are compromised. In figure 4.7a the maximum
dose can be seen to be higher for the motion case than for no motion, due to
dose displacement with motion. This can cause complications for critical structures
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(a) 3DCRT lateral direction (b) 3DCRT sup-inf direction
(c) IMRT lateral direction (d) IMRT sup-inf direction
Figure 4.7: Profiles reconstruced from MP512. Profiles are normalised to the re-
sponse of the no motion case. Uncertainty is estimated as ±1% and is represented
by the size of the markers. See appendix A.1.1 for full size figures.
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Modality FWHM (% diff) Left Penumbra (% diff) Right Penumbra (% diff)
Motion
3DCRT
X 53.1 60.1 71.7
Y -0.1 6.2 64.9
IMRT
X 20.9 -13.7 -24.5
Y -1.0 17.4 58.4
Passive Tracking
3DCRT
X 10.7 22.5 14.4
Y 1.3 6.6 23.4
IMRT
X 11.1 17.2 37.6
Y -0.1 17.2 26.5
Table 4.2: Percentage difference of FWHM and penumbral width for profiles
reconstructed from MP512. Difference is expressed with respect to the no motion
case. X corresponds to the lateral direction and Y corresponds to the sup-inf
direction. Uncertainty is ±0.3mm.
nearby the target. The error across the dose profile is up to 50% when motion is
not compensated.
With passive tracking enabled the FWHM is reduced to 16.9 mm which is 10%
wider than the no motion case (compared to 53% with no tracking). The effect on
penumbral width is also reduced by more than half, with the increase reducing from
60-70% with no tracking to 15-25% with tracking. In figure 4.7a the dose distribution
with tracking is brought closer to the no motion case with the maximum error around
20%.
In the sup-inf direction with motion applied the entire profile is offset of about
5-7 mm compared to the no motion case, see figure 4.7b. This could result in a
geographic miss of the target and irradiation of surrounding healthy tissue. The
offset creates two peak areas of error in the penumbral regions of up to ± 50%
which means these areas are being under and over dosed significantly. FWHM is
relatively unchanged with motion however the right penumbra width increased by
3 mm from 4.6 mm to 7.6 mm which corresponds to a 65% increase.
The dose profile offset is compensated when passive tracking is applied to closely
match the no motion case. The error across the dose profile reduced to maximum
15% on the right side of the profile. The right penumbral width is brought back
to 23% larger than no motion case, which is a reduction of more than half when
tracking is used.
Profiles corresponding to the IMRT treatment plan are shown in figures 4.7c and
4.7d. The effect of motion is similar to that of the 3DCRT delivery due to the same
motion trace being applied. MLC leaf positions are different in the IMRT delivery
so the resulting profiles are not exactly the same. In the lateral direction there is an
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overdose on the central axis of about 10%, however this time the dose is not spread as
widely. FWHM increased 3 mm for the IMRT plan and 8 mm for the 3DCRT plan.
This difference is due to the larger interplay effect between the moving MLC and
phantom during the IMRT delivery. This results in a ’average’ increase in FWHM
that is less than that of stationary MLC. The dose profile with motion is actually
’sharper’ than the no motion case, both the left and right penumbral widths are
less with motion applied. On the surface this may seem advantageous however this
could result in incomplete coverage of the target if the delivered field does not match
the treatment planning system.
With tracking enabled the overdose on the central axis is eliminated and the overall
error across the profile is reduced from 40% to 14%. FWHM is maintained within
10% however left side penumbral width increased by 17% which highlights some
limitations in the tracking algorithm.
In the sup-inf direction there is a large offset in the dose profile under motion
conditions. There are under and over dose regions of over ± 50%. FWHM remains
relatively unchanged however the right side penumbra increased from 4.6 mm to
7.3 mm which corresponds to nearly 60%. When tracking is activated the profile
is brought back into line with the no motion case with maximum error across the
profile of 10%. The right side penumbra is also brought down to 5.8 mm which is a
reduction of nearly half.
In general tracking is more effective in the sup-inf direction, this is due to the
geometry of the MLC. Individual leaves move along the sup-inf direction (when
collimator is at 85 degrees) meaning that motion of any magnitude can theoretically
be compensated for, the resolution of leaf position is that of the MLC motor step
size. In the lateral direction motion can only be compensated by an entire leaf
either moving out of or into position, resolution in this direction is 5 mm which is
equivalent to the thickness of a leaf. Tracking in this direction is therefore limited
by the maximum acceleration and velocity of the MLC leaves.
For both treatment plans MP512 was able to reconstruct the delivered dose when
MLC tracking is applied. The expected benefit of applying MLC tracking is quan-
tified through the measured profiles.
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4.4 Experiment 2 - Temporal Analysis
4.4.1 Measurements
Experiment 2 involved a verification of the ability of the detector system to accu-
rately resolve the temporal response of an individual pixel to the dose distribution
during treatment delivery. As discussed in section 3.1.1.3, the system can be trig-
gered by the linac electron gun pulse. This means the detector is sampling the beam
output for every pulse, with dead time falling in between pulses. Using the known
sync pulse frequency of 360 Hz (for a Varian Clinac 2100C), the entire delivery can
be reconstructed as a function of time for any pixel in the detector.
The DUO detector was used for this experiment in combination with a basic motion
trace. Three sine waves were used with breaths per minute (BPM) of 10, 15 and
20. This corresponds to frequencies of 0.17 Hz, 0.25 Hz and 0.33 Hz, respectively.
The 3DCRT treatment plan was delivered using four motion modalities: no motion,
motion with no tracking, motion with passive tracking and motion with predictive
tracking. See section 4.2.1 for descriptions of each modality. For each modality
the detector sampled the dose and was synchronised with the linac electron gun
pulse.
The same measurements were then repeated with a clinical prostate motion applied
to HexaMotion. The motion pattern is shown in figure 4.2(c).
4.4.2 Analysis Procedure
Temporal analysis is performed by inspecting the response of individual pixels as
a function of time throughout the treatment delivery. To identify the pixels that
will be affected most by motion, the derivative of a dose profile is considered, as
in figure 4.8. It is seen that the pixels around the 50% response of the profile are
located at the maxima and minima of the first derivative. This implies these pixels
will show the most interplay effect between the moving phantom and MLC leaves.
These pixels have been chosen for further analysis.
Two methods are used to determine if the detector system can successfully recon-
struct the temporal component of the treatment delivery:
1. Visual inspection of the detector response when sine wave motion is applied
to the phantom
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2. Fast Fourier Transform (FFT) of the temporal response to determine the fre-
quency components of the measured motion
The FFT analysis allows a direct comparison of the measured frequencies to the
expected frequencies, based on the BPM of the input sine wave.
Figure 4.8: The pixel closest to 50% of the maximum response is chosen for
temporal analysis. This pixel corresponds to the maximum and minumum of the
derivative of the profile, i.e the turning points. This pixel will show the most
interplay between the moving phantom and MLC leaves.
4.4.2.1 Quality Factor for Tracking System
FFT analysis can be used to derive a quality factor for each motion modality. Peaks
in the frequency spectrum are characteristic of the motion experienced. The FFT
of the no motion modality represents noise in the system and slow moving MLC
leaves in the case of a modulated treatment. There are no discernible peaks in the
FFT spectrum of the no motion modality, typically only a decaying DC component
of the temporal response at very low frequencies. Figure 4.9a shows a typical FFT
spectrum for the no motion modality.
To remove the DC component and noise from subsequent spectrums, the FFT mag-
nitude response of the no motion modality is subtracted from the other motion
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(a) (b)
Figure 4.9: (a) FFT of the no motion delivery. There are no discernable peaks
or characteristic frequency when no motion is present, only a fast decaying DC
component at low frequencies. (b) FFT of motion spectrum with and without
subtraction of the no motion FFT response.
modalities. This normalisation results in a spectrum such as figure 4.9b.
The spectra for the motion modalities feature a prominent peak at the resonant
frequency of the applied motion. The peaks can be described in terms of area and
height. Peak area has bounds defined by the FWHM and height is the maximum
value in the peak. An example of this analysis is shown in figure 4.10, where the
integral area and peak height are extracted from a spectrum.
The integral area of the spectral peaks, a, and the height of the peaks, h, is pro-
portional to the amount of dose delivered due to the motion. The FWHM was used
to define the bounds of integration. The height of each peak is taken as the max-
imum magnitude response value in the peak. A ’quality’ factor is defined which is
inversely proportional to the product of the integral area, a, and height, h, of the




The quality factor can be used to determine the effectiveness of a tracking com-
pensation algorithm to track a specific breathing pattern of a patient. The height
and width of peaks of a spectrum will be the largest for the motion with no track-
ing, which leads to the lowest quality factor for that combination of algorithm and
breathing pattern. In the FFT spectrum corresponding to the no motion case, there
is no discernible peak, the area and height in this case approach zero. The quality
factor for the no motion case then approaches infinity as limx→0 1x → ∞. The area
and height of the peaks from the tracking cases fall within these two extremes, hence
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Figure 4.10: FFT spectrum for the 10 BPM Sine wave. The peak height and
integral area are automatically detected and extracted. Yellow highlighted area
shows the integral region defined by the FWHM of the peak.
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(a) (b)
Figure 4.11: Hampel outlier detection is used to filter the raw time resolved
data. The original shape of the curve is preserved. (a) shows entire treatment
delivery, (b) shows zoomed region.
the relative effectiveness of each algorithm can be determined.
FFT spectra and quality factors were produced for all three Sine wave motions and
the prostate motion pattern.
4.4.3 Results and Discussion
In order to aid visual inspection of the motion traces reconstructed from the detector,
a Hampel filter (parametric low pass filter) is applied to the data in MATLAB (The
MathWorks, Inc). This allows the detection and elimination of outliers in a data
set while preserving the original shape of the curve. An example of this is shown in
figure 4.11.
When no motion is present the expected response of each pixel is constant through-
out the delivery, as shown in 4.12. The leading beam on edge can be observed after
a few seconds, then a flat constant response (besides noise in the system) and then
the trailing beam off edge after the delivery is complete.
With the 10 BPM sine wave motion activated, the dose response take the expected
shape as in figure 4.13. It is immediately apparent that the predictive tracking
modality has a large baseline drift compared to the other modalities. This is at-
tributed to the phantom moving position on the HexaMotion platform due to not
being secured correctly. The significance of this baseline drift is discussed further in
4.4.3.1.
For clarity, a second plot excluding the predictive modality is produced in 4.14a.
The time bases of each motion modality were manually aligned such that the leading
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Figure 4.12: Single pixel response as a function of time when no motion is
present. The response is constant through the entire beam on.
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beam on edge was simultaneous. All the wave forms have the expected number of 10
cycles per 60 seconds. Upon closer inspection of the zoomed in response in 4.14b, the
efforts of the tracking system in restoring the dose response to the no motion case
can be observed. For the motion modality the detector pixel is displaced into open
beam, then returns to be shielded under the MLC leaf. This repeats throughout the
motion trace creating the sinusoidal signal. With passive tracking activated there
is a lag between motion detection and MLC movement, therefore initially the pixel
moves into open beam increasing the signal as before, then the MLC starts to follow
and hence reduces the signal as the pixel to MLC distance decreases. This pattern
maintains during the cycles, the tracking signal is lower in magnitude as it decreases
the pixel to MLC distance present with no tracking.
Figure 4.13: Temporal response of a DUO pixel with the 10 BPM Sine wave
motion applied. There is a baseline drift apparent in the predictive modality.
This is due to the phantom moving on the HexaMotions plaform from not being
secured correctly.
The 15 BPM sine wave was also applied to the phantom and the measurements
repeated. The temporal response is shown in figure 4.15. There is a similar behaviour
to the 10 BPM motion when the passive tracking is activated. Predictive tracking is
also used for this motion trace, and the benefit can immediately be seen. After an
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(a) (b)
Figure 4.14: Temporal response of a DUO pixel with the 10 BPM Sine wave
motion applied. The pattern can be seen in the dose pattern. Passive tracking
reduces the amplitude of the response. (a) shows the entire treatment delivery
and (b) shows a zoomed region.
initial ’learning’ time frame of a few cycles of the motion, the predictive algorithm is
able to reduce the amplitude of the response by more than half compared to passive
tracking. The average of the predictive tracking response after learning is within
8% of the no motion response.
The results from the 20 BPM sine wave are similar to that of the 15 BPM sine wave,
the number of cycles reconstructed is as expected; 10 in 30 seconds. The figure is
in appendix A.1.2.
Finally, the prostate motion pattern was applied to HexaMotion for each motion
modality. The temporal response is shown in figure 4.16. Passive tracking exhibits
the same or better response as the motion case, with the majority of the time bring-
ing the amplitude closer to the no motion response. After 10 seconds or so the
predictive algorithm is able to perform much better than passive tracking. How-
ever just before the 30 second mark the amplitude of the predictive tracking signal
increases dramatically, greater than that of the passive algorithm. This is due to
a large displacement of the prostate at the same point in time as shown in figure
4.2(c). Several more large diaplacements follow throughout the rest of the treat-
ment delivery, the predictive algorithm is not able to ’re-learn’ any periodicity in
the motion so its performance is on par with passive tracking.
4.4.3.1 Fast Fourier Transform
Visually the detector appears to be reconstructing the time resolved dose distribu-
tions as expected, however a FFT of each of the time series gives a quantitative
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Figure 4.15: Temporal response of a DUO pixel with the 15 BPM Sine wave
motion applied. When predictive tracking is applied there is a clear benefit after
an initial ’learning’ time.
CHAPTER 4. STATIC GANTRY ADAPTIVE RADIOTHERAPY 81
Figure 4.16: Temporal response of a DUO pixel with the prostate motion ap-
plied. Predictive tracking shows superior performance until a large irregular peak
in the motion pattern at around 30 seconds.
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measure of performance. The magnitude response of the FFT of each of the Sine
motions was calculated and the frequency peaks are shown in figure 4.17. The peaks
correspond to the expected frequencies of 0.17, 0.25 and 0.33 Hz from the 10, 15
and 20 BPM Sine waves, respectively. This proves quantitatively that:
1. The HexaMotion platform is able to accurately reproduce the required motion
patterns
2. The temporal response of the detector system is able to reconstruct the mo-
tion patterns and correctly recover the expected frequency components of the
motion
Figure 4.17: Magnitude response of the FFT of the three Sine wave motions.
Peaks occur at the expected frequencies of 0.17, 0.25 and 0.33 Hz, corresponding
to the 10, 15 and 20 BPM motions, respectively.
The FFT analysis of the detector temporal response can be used to assess the efficacy
of the MLC tracking. Two methods are used to achieve this:
1. Visual inspection of the FFT spectra for each motion modality
2. Calculation of the quality factor for each motion modality
The spectra for the Sine 10 BPM motion are shown in 4.18. It can be seen that
passive tracking reduces the height of the characteristic spectrum compared to the
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motion case. Predictive tracking reduces this even further, however there is a large
DC component in this spectrum which has not beed eliminated after subtracting
the no motion spectrum. This is due to the large baseline drift that occurred for
the predictive tracking modality as seen in figure 4.13. The baseline drift is not
apparent in the no motion case, so the DC component for each of the modalities
differs. In addition to the large characteristic peak, the signal is also comprised of
secondary resonant peaks (0.34 Hz, 0.51 Hz and 0.68 Hz) and also noise.
Figure 4.18: FFT spectra for each motion modality for the 10 BPM Sine wave.
Similar spectra are produced when the same analysis is performed on the 15 and
20 BPM Sine motions, as shown in figures 4.19 and 4.20. There was no baseline
drift during any of the modalities for the 15 and 20 BPM motions, so the DC
component is eliminated in each of these acquisitions by subtracting the no motion
spectrum.
The peak height and integral area for the peaks in each of the spectra are shown
in tables 4.3, 4.4 and 4.5 for the 10, 15 and 20 BPM Sine wave motions, respec-
tively.
A similar analysis can be performed on the time response obtained when the prostate
motion trace was applied (figure 4.16). The FFT was computed for the temporal
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Figure 4.19: FFT spectra for each motion modality for the 15 BPM Sine wave.
Modality Integral Area Peak Height Quality Factor
Motion 0.0423 2.10 11
Passive Tracking 0.0157 1.04 61
Predictive Tracking 0.0142 0.25 279
Table 4.3: FFT peak integral area and height for the 10 BPM Sine wave motion.
These metrics are used to calculate the quality factor.
Modality Integral Area Peak Height Quality Factor
Motion 0.0436 1.53 15
Passive Tracking 0.0321 1.13 28
Predictive Tracking 0.0051 0.37 524
Table 4.4: FFT peak integral area and height for the 15 BPM Sine wave motion.
These metrics are used to calculate the quality factor.
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Figure 4.20: FFT spectra for each motion modality for the 20 BPM Sine wave.
Modality Integral Area Peak Height Quality Factor
Motion 0.049 2.13 10
Passive Tracking 0.0316 1.48 21
Predictive Tracking 0.0126 0.37 214
Table 4.5: FFT peak integral area and height for the 20 BPM Sine wave motion.
These metrics are used to calculate the quality factor.
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response from each of the tracking modalities. The DC component from the no
motion FFT was subtracted from each of the other FFT spectra, shown in figure
4.21.
Figure 4.21: FFT spectra for each motion modality for the prostate motion
pattern
The integral area and peak height for each of the motion modalities was calculated
and is shown in table 4.6.
Modality Integral Area Peak Height Quality Factor
Motion 0.069 1.672 9
Passive Tracking 0.0453 1.261 18
Predictive Tracking 0.0392 0.6091 42
Table 4.6: FFT peak integral area and height for the prostate motion. These
metrics are used to calculate the quality factor.
Quality factors are plotted as a function of modality in figure 4.22. Higher quality
factors indicate the treatment delivery is closer to the no motion case. This means
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the delivered treatment will more closely match the planned dose from the TPS. Low
quality factors indicate potentially large deviations from the planned dose which has
impacts on dose tracking and healthy tissue tolerance.
There is a clear trend for each of the sine motion patterns. Passive tracking is
better than no tracking, however predictive tracking is far superior. The large
difference between the tracking modalities can be attributed to the cyclic nature of
the motion patterns. After the initial learning window the predictive algorithm is
able to correctly predict the trajectory and amplitude of the Sine waves.
The prostate motion does benefit from tracking; the quality factor increases for each
tracking modality. However, the extent of the improvement with predictive tracking
is much lower compared to the cyclic sine waves. As discussed previously this is
due to a large displacement of the prostate during the delivery that is not cyclic in
nature. In this case the predictive algorithm cannot ’learn’ the motion as easily and
consequently is not as effective compared to when used with cyclic motion. In this
instance predictive tracking would not be recommended.
The temporal resolution offered by the detector system is able to accurately recon-
struct the motion patterns provided by HexaMotion. The calculated frequencies
of the Sine waves match the expected values and the quality factor can assist in
evaluating tracking performance.
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Figure 4.22: Quality factors for each of the motion patterns. Tracking provides
a clear benefit for all motion patterns. Predictive tracking is best for cyclic motion
patterns.
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4.5 Experiment 3 - Effect of phantom density on
tracking performance
4.5.1 Measurements
This experiment used both phantoms described in section 4.2.2: a homogenous solid
water phantom and a phantom composed of lower density timber combined with
solid water. The aim was to investigate the effect of a low density material within
a higher density material on the resulting dose distribution when MLC tracking is
used. This was designed to mimic the scenario of a lung (timber) and chest wall
(solid water).
The DUO detector was placed in each phantom for all measurements, details of the
detector configuration and geometry are described in section 3.1.
As per section 4.2.1, the phantoms were setup on the HexaMotion platform and
the detector plane aligned to isocentre. Two ’patients’ were used for this experi-
ment:
1. Patient 1 - corresponds to the ’Lung 1’ motion trace in figure 4.2(a)
2. Patient 2 - corresponds to the ’Lung 2’ motion trace in figure 4.2(b)
Both the 3D conformal and IMRT treatment plans (section 4.2.3) were delivered
for each patient. Four measurements were taken per patient, corresponding to the
motion modalities listed in section 4.2.1, i.e:
1. No motion - detector phantom is static throughout the treatment
2. Motion with no tracking - detector phantom follows supplied motion trace and
no MLC tracking is applied
3. Motion with passive tracking - detector phantom follows supplied motion trace
and passive MLC tracking algorithm is applied
4. Motion with predictive tracking - detector phantom follows supplied motion
trace and predictive MLC tracking algorithm is applied
The detector sampled the delivered dose for each linac pulse throughout the entire
treatment delivery.
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4.5.2 Analysis Procedure
High resolution dose profiles were reconstructed along the Sup-Inf (in-plane) and
Med-Lat (cross-plane) directions, according to each linear array of pixels on the
DUO detector.
In this experiment a mechanical fault (one edge of the aluminium shielding box
was not connected properly) of the shielding of one of the detector readout boards
generated a very noisy response of a section of the detector readout by that board.
The noise is induced by the RF generated by Calypso. This was due to the original
design of the shielding box which allowed the RF to reflect inside and onto two
AFE readout chips (see section 3.1.1.3 for details). As a result, some of the DUO
channels (pixels) were noisy. The pattern corresponded to every second pixel for a
portion of the array, due to the way the pixels are connected to each of the eight
AFE chips.
To overcome this issue a mask was generated that removed the noisy pixels from
the dataset. Each removed data point was replaced with a value interpolated using
a Piecewise Cubic Hermite Interpolating Polynomial. This was achieved with the
PCHIP function in MATLAB (The Mathworks Inc.). The resolution of the DUO
linear arrays is 200 µm, so the interpolation is not expected to influence the data in
any clinically significant manner. An example of a profile reconstructed from DUO
before and after the channel masking is shown in figure 4.23.
Figure 4.23: RF interference from Calypso affected the response of some of the
detector pixels. A noise reduction technique was adopted to recover the profile.
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Dose profiles were plotted for each motion modality, phantom material and treat-
ment delivery. Profiles were normalised to the maximum response of the respective
’no motion’ profile. The uncertainty associated with the measurements is ±1%
[3, 90, 104]. This is represented by the size of the markers in the profiles presented
in this section.
Percentage error was calculated and plotted as a function of distance across the
profile. This is simply the point-to-point difference between the response of each
motion modality using the ’no motion’ case as a reference.
An integral error was calculated by summing the percentage error across the entire




Where ∆r is the percentage error for a particular point along the profile and dx
implies the integration is carried out along the whole length of the profile.
To quantify the effect of MLC tracking, a ’percentage improvement’ metric was
calculated. This is basically a percentage difference of the integral error for a track-






Where Etracking corresponds to the integral error of either of the MLC tracking
modalities and Emotion is the integral error of the motion with no tracking modal-
ity.
The percentage improvement is used to compare the effect of tracking for different
phantom materials, tracking modalities and treatment plans. Integral error and
percentage improvement values are tabulated for all measurements.
A gamma analysis was performed on the dose profiles using the ’no motion’ profile
as a reference. Acceptance criteria of 3%/3mm, 2%/2mm and 1%/1mm were used.
Gamma pass rates are plotted as a function of tracking modality.
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4.5.3 Results and Discussion
4.5.3.1 Dose Profiles
The reconstructed dose profiles with percentage error plots are grouped according
to treatment delivery for each patient. The x axis of the plots represent distance
across the detector. The zero position for the Med-Lat direction corresponds to the
left side of the detector. The zero position for the Sup-Inf direction corresponds to
the inferior aspect of the detector.
Subfigures show the profiles for each phantom material and direction. Figures 4.24,
4.25, 4.26, 4.27 correspond to patient 1 3DCRT, patient 2 3DCRT, patient 1 IMRT
and patient 2 IMRT, respectively.
For patient 1 3DCRT there is a maximum dose error of 67% in solid water in the
sup-inf direction, as seen in figure 4.24, when motion is applied. Interestingly this
error is reduced to 57% with the same delivery in the timber phantom. A large
offset and distortion of the dose is also apparent. Tracking is able to reduce this
dose error to <20% in solid water and <10% in timber. The profiles also match
closely to the no motion case when tracking is enabled.
In the lateral direction there is very little effect of motion with the solid water
phantom. In the timber phantom the dose is perturbed with motion. This difference
is due to the larger range of secondary electrons in timber than in solid water. This
can be seen in the general shape of the profiles; in timber the penumbra are wider
and in solid water the penumbra are sharper.
Patient 2 motion during the 3DCRT delivery creates a triangular shaped dose profile
as seen in figure 4.25. The dose is not offset like it was for patient 1 due to this
motion trace being centred around zero, i.e no baseline offset (see figure 4.2). Dose
errors in both directions are reduced from 30% to under 20% with tracking in solid
water. Tracking appears to be slightly less effective in timber as the dose errors are
not particularly reduced in either direction. The lateral motion has a worse effect in
the solid water phantom for this patient, the effect of density depends on the motion
experienced.
The effect of phantom density on the dose profiles is really highlighted in the IMRT
delivery. For both patient motion in figures 4.26 and 4.27 the profiles in timber are
smoothed over in the central region compared to in solid water. The small peaks
created by MLC modulation on the solid water profiles are not present at all in the
timber profiles.
For patient 1 IMRT there is good tracking performance in the sup-inf direction for
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(a) Solid Water - Sup-Inf (b) Solid Water - Med-Lat
(c) Timber - Sup-Inf (d) Timber - Med-Lat
Figure 4.24: Dose profiles for Patient 1 with the 3DCRT treatment plan. Un-
certainty is estimated as ±1% and is represented by the size of the markers. Full
size figures are in appendix A.1.3.
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(a) Solid Water - Sup-Inf (b) Solid Water - Med-Lat
(c) Timber - Sup-Inf (d) Timber - Med-Lat
Figure 4.25: Dose profiles for Patient 2 with the 3DCRT treatment plan. Un-
certainty is estimated as ±1% and is represented by the size of the markers. Full
size figures are in appendix A.1.3.
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(a) Solid Water - Sup-Inf (b) Solid Water - Med-Lat
(c) Timber - Sup-Inf (d) Timber - Med-Lat
Figure 4.26: Dose profiles for Patient 1 with the IMRT treatment plan. Uncer-
tainty is estimated as ±1% and is represented by the size of the markers. Full
size figures are in appendix A.1.3.
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(a) Solid Water - Sup-Inf (b) Solid Water - Med-Lat
(c) Timber - Sup-Inf (d) Timber - Med-Lat
Figure 4.27: Dose profiles for Patient 2 with the IMRT treatment plan. Uncer-
tainty is estimated as ±1% and is represented by the size of the markers. Full
size figures are in appendix A.1.3.
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both phantom materials in figure 4.26. However in the med-lat direction, MLC
tracking actually produces worse results than motion with no tracking. A similar
effect occurs for patient 2 IMRT in figure 4.27. In the timber phantom sup-inf
direction the tracking modalities appear to be over correcting the profile compared
to the no motion case. This is another effect of the lower density and ’blurring’ of
the profiles in timber compared to solid water.
4.5.3.2 Integral error and percentage improvement using tracking
Patient 1
Integral Error (%)
Solid Water Phantom Timber Phantom
Sup-Inf Med-Lat Combined Sup-Inf Med-Lat Combined
No Tracking 5272 796 6068 4914 3619 8532
Passive 637 771 1408 476 905 1381
Predictive 497 797 1294 372 912 1283
Patient 2
Integral Error (%)
Solid Water Phantom Timber Phantom
Sup-Inf Med-Lat Combined Sup-Inf Med-Lat Combined
No Tracking 3219 2340 5559 2739 2166 4906
Passive 1447 1278 2726 1401 1432 2833
Predictive 704 812 1517 854 1563 2417
Table 4.7: Integral error values (%) for both patient motion traces using the
3DCRT delivery. The integral is obtained by summing percentage error values
along each dimension of the detector
The integral error for each patient is tabulated for the 3DCRT delivery in table 4.7
and for the IMRT delivery in table 4.8. The integral error is calculated in each
direction and then summed to give the ’combined’ integral error for the overall
treatment.
Improvement of the treatment using tracking is quantified with the percentage im-
provement metric. The percentage improvement for both patients using the 3DCRT
delivery is listed in table 4.9 and for the IMRT delivery in table 4.10. The percent-
age improvement is calculated for each direction (sup-inf and med-lat) separately
to highlight the tracking performance for each direction independently. It is also
calculated from the combined integral error to give an overall improvement when
tracking is used, taking the contribution from each direction into account.
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Patient 1
Integral Error (%)
Solid Water Phantom Timber Phantom
Sup-Inf Med-Lat Combined Sup-Inf Med-Lat Combined
No Tracking 4927 1053 5980 5085 1167 6252
Passive 642 1787 2429 1014 1573 2587
Predictive 637 1765 2402 633 1819 2452
Patient 2
Integral Error (%)
Solid Water Phantom Timber Phantom
Sup-Inf Med-Lat Combined Sup-Inf Med-Lat Combined
No Tracking 2429 656 3086 2180 714 2894
Passive 1213 1482 2696 1832 1299 3131
Predictive 797 1527 2324 999 1457 2456
Table 4.8: Integral error values (%) for both patient motion traces using the
IMRT delivery. The integral is obtained by summing percentage error values
along each dimension of the detector
Patient 1
Percentage Improvement (%)
Solid Water Phantom Timber Phantom
Sup-Inf Med-Lat Combined Sup-Inf Med-Lat Combined
Passive 87.9 3.1 76.8 90.3 75.0 83.8
Predictive 90.6 -0.1 78.7 92.4 74.8 85.0
Patient 2
Percentage Improvement (%)
Solid Water Phantom Timber Phantom
Sup-Inf Med-Lat Combined Sup-Inf Med-Lat Combined
Passive 55.0 45.4 51.0 48.8 33.9 42.2
Predictive 78.1 65.3 72.7 68.8 27.9 50.7
Table 4.9: Percentage improvement (%) for both patient motion traces using
the 3DCRT delivery. Percentage improvement is the calculated as the percentage
difference of the integral error values between each tracking modality and the no
tracking modality.
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Patient 1
Percentage Improvement (%)
Solid Water Phantom Timber Phantom
Sup-Inf Med-Lat Combined Sup-Inf Med-Lat Combined
Passive 87.0 -69.8 59.4 80.1 -34.8 58.6
Predictive 87.1 -67.7 59.8 87.6 -55.9 60.8
Patient 2
Percentage Improvement (%)
Solid Water Phantom Timber Phantom
Sup-Inf Med-Lat Combined Sup-Inf Med-Lat Combined
Passive 50.0 -125.8 12.6 16.0 -82.0 -8.2
Predictive 67.2 -132.7 24.7 54.2 -104.2 15.1
Table 4.10: Percentage improvement (%) for both patient motion traces using
the IMRT delivery. Percentage improvement is the calculated as the percentage
difference of the integral error values between each tracking modality and the no
tracking modality.
There could be a case where tracking performs extremely well in the sup-inf direction
but poorly in the med-lat direction. The overall percentage improvement may be
good, however it would be important to consider the organs at risk close by in each
direction. In lung for example, if there is poor tracking performance in the med-lat
direction then the heart could be getting excess dose. If only the overall tracking
performance was considered then this may not be immediately apparent.
For the 3DCRT delivery (table 4.9) there is relatively large improvement in the
sup-inf direction; the lowest and highest percentage improvement values were 48.8%
and 92%, respectively. Patient 1 had better tracking performance in the sup-inf
direction and overall than patient 2. In the med-lat direction in solid water for
patient 1, it appears the tracking performed poorly, considering the improvement
values of 3.1% and -0.1% for passive and predictive tracking, respectively. This is
due to the minimal impact motion had in this direction in solid water; the profiles
for all motion modalities are very similar. In fact the integral error from each (table
4.7) is essentially the same. This highlights the complex nature of MLC tracking and
the need to evaluate tracking performance using multiple metrics (eg a combination
of profiles, percentage improvement and gamma analysis).
Tracking performance is better in the sup-inf direction than med-lat direction, this
agrees with the profiles in figures 4.24 and 4.25. The reason for this trend is dis-
cussed below. Overall, tracking was beneficial for both patients with the 3DCRT
delivery; minimum overall improvement was 50.7% and maximum was 85%. Overall
performance in each phantom was dependent on the patient motion, there was no
clear better performer.
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The tracking performance with the IMRT delivery (table 4.10) in the sup-inf di-
rection is comparable to the 3DCRT delivery. Both patients saw a benefit using
tracking; the minimum improvement was 16% and maximum 87%. Tracking perfor-
mance in this direction was better in solid water than in timber. However, tracking
performance in the med-lat direction was worse than using no tracking. Tracking
introduced a larger dose error than the uncorrected motion for both patients. Track-
ing performance ranges from 35% to 133% worse than no tracking. However, despite
this, the overall percentage improvement is favourable in solid water for both pa-
tients and in timber for patient 1. For patient 2 in timber only the predictive tracking
was favourable. This again highlights the need to evaluate the performance in each
direction independently, in addition to considering the overall performance. Organs
at risk sitting laterally to the target in this case would have gotten a much larger
dose than predicted in the TPS.
4.5.3.3 Gamma Analysis
Percentage improvement is a decent metric to evaluate tracking performance, as-
suming that the uncorrected motion is equally detrimental for each patient motion
and phantom. This was not the case for patient 1 3DCRT in solid water for the med-
lat direction (figure 4.24b), for this case the motion had minimal effect on the dose
distribution and so the percentage improvement with tracking appeared poor.
A gamma analysis can overcome this issue by providing a measure of performance
for the uncorrected motion case as well as the tracking modalities. Profiles were
compared in each direction, for each treatment modality, patient motion trace and
phantom material. Pass rates are plotted for various acceptance criteria; figure 4.28
uses 3%/3 mm, figure 4.29 uses 2%/2mm and figure 4.30 uses 1%/1mm. Generally
for patient specific QA a minimum of 2%/2 mm would be used, especially for small
field treatments, however 3%/3 mm is also included as this has been a criteria used
in the past.
For the 3DCRT delivery there was an observable improvement with tracking in
both directions; pass rates are increasing from no tracking to passive tracking to
predictive tracking. For patient 1 in the med-lat direction (figure 4.30b) the benefit
of tracking can be seen, recall that this was not immediately evident using the
percentage improvement method above.
In figure 4.28, a criteria of 3%/3 mm was not sensitive enough to resolve the differ-
ence in performance between passive and predictive tracking; both modalities report
essentially 100% pass rate. Using 2%/2 mm (figure 4.29) the advantage of predic-
tive tracking can begin to be seen, and using 1%/1 mm (figure 4.30) confirms this.
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(a) 3DCRT sup-inf direction (b) 3DCRT lateral direction
(c) IMRT sup-inf direction (d) IMRT lateral direction
Figure 4.28: Gamma pass rates for profiles using a 3%/3 mm acceptance criteria.
Profiles are compared to the no motion case.
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(a) 3DCRT sup-inf direction (b) 3DCRT lateral direction
(c) IMRT sup-inf direction (d) IMRT lateral direction
Figure 4.29: Gamma pass rates for profiles using a 2%/2 mm acceptance criteria.
Profiles are compared to the no motion case.
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(a) 3DCRT sup-inf direction (b) 3DCRT lateral direction
(c) IMRT sup-inf direction (d) IMRT lateral direction
Figure 4.30: Gamma pass rates for profiles using a 1%1/ mm acceptance criteria.
Profiles are compared to the no motion case.
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However predictive tracking is not always better than passive tracking, as it was
shown in section 4.4.3, it depends on the motion experienced. In this case there was
slightly worse performance using the predictive algorithm for patient 1 3DCRT in
the med-lat direction (figure 4.30b). This is most likely due to the fact that this di-
rection experienced very little negative impact with uncorrected motion, as is shown
by the high pass rate (approximately 70%) for the no tracking modality.
When the IMRT delivery is used, the results are similar to the 3DCRT delivery in
the sup-inf direction; i.e tracking is beneficial. However it is quite the opposite in
the med-lat direction. Pass rates get worse when tracking is activated. This was also
seen in the dose profiles and percentage improvement metric discussed earlier. The
reason for this large discrepancy is the orientation of the MLC leaves with respect
to the target motion. Figure 4.31a shows the configuration used in this experiment
when the MLC are positioned for a 3DCRT delivery technique. Note the collimator
was rotated to 85 degrees for the treatments delivered here (as per local protocol at
Northern Sydney Cancer Centre), however the orientation in the figure corresponds
to a collimator angle of 90 degrees for clarity, this will be the assumed orientation
for this discussion.
The major motion axes for each patient was the sup-inf direction (see figure 4.2), so
by orienting the collimator at 90 degrees, the direction of travel of the MLC leaves
was parallel (actually very close to it with the collimator at 85 degrees) to the patient
sup-inf direction. This allowed for the larger of the two motion components to be
compensated for easily by the MLC leaves. Motion parallel to the MLC direction of
travel is compensated for by either extending or retracting a leaf/leaves. Motion as
small as the MLC motor step resolution and as large as the MLC maximum velocity
can be accounted for in this direction.
In the direction perpendicular to leaf travel (i.e patient med-lat in this case), to
compensate for motion an entire MLC leaf has to either move out of or in to position.
The magnitude of the MLC leaf shift depends on the treatment target size. It is
slower to compensate motion in this direction as the time to move a leaf in or out
is limited by the maximum leaf velocity. In figure 4.31a, if the target (blue) was to
move medially, the two leaves positioned above the target would have to open and
the two leaves below the target would have to close.
In addition to the MLC velocity, the tracking in med-lat direction is also limited
by the thickness of each MLC leaf. For Varian linacs using the Millennium 120
leaf MLC, the width of the central 60 leaves is 5 mm. The MLC tracking settings
are such that motion has to be greater than the leaf thickness before the leaf is
commanded to move. This means motion in the med-lat direction would have to
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(a) Example 3DCRT MLC aperture
(b) Example IMRT MLC aperture
Figure 4.31: Example MLC apertures for (a) 3D conformal and (b) IMRT
treatments. In this case the collimator is rotated 90 degrees such that target
motion in the sup-inf direction is parallel to the direction of travel of the MLC
leaves.
CHAPTER 4. STATIC GANTRY ADAPTIVE RADIOTHERAPY 106
exceed 5 mm before a leaf is instructed to retract to compensate. These two effects
combined limit the tracking performance for motion perpendicular to the MLC travel
direction, even for the 3DCRT treatment.
For 3DCRT deliveries there is no motion of the MLC leaves for a static target, it is
simply an open aperture designed to conform to the target shape as seen from the
beams-eye-view. When MLC tracking is implemented the entire aperture is moved
to compensate for the target motion. The leaf configuration for a typical IMRT
delivery is shown in figure 4.31b, for a single point in time (control point). Under
static conditions (no motion of the treatment target) the MLC leaves are sweeping
across the field to generate the many small beamlets required for the delivery. When
MLC tracking is introduced there is an additional layer of potential motion. The
MLC are now receiving positional instructions from two sources: the control point
positions as described by the treatment plan and additionally the tracking system.
It is possible to get a conflict of information here such that the tracking system
instructs a leaf to open at a certain point during treatment but the treatment plan
says to close. For cases like this the leaf will have to decelerate, stop and then
accelerate again in the opposite direction. Depending on the patient motion this
effect could average out or not be apparent at all.
In addition to the competing modulation and tracking movements, the MLC leaves
are moving relative to the treatment target for an IMRT delivery. This so called ’in-
terplay effect’ has been discussed extensively [105–109]. IMRT deliveries are planned
on a CT dataset (3D or 4D) that represents patient motion at a specific point in
time. When the treatment is delivered the motion may be the same amplitude but
differ in phase. Motion may place the target under closed MLCs for some of the
treatment meaning the target could be under-dosed. The amplitude and phase of
tumour motion has to be the same at the time of the planning CT and the time of
beam on for treatment to achieve the dose coverage as described by the treatment
plan.
The effects described above all play a role in limiting the effectiveness of tracking,
especially in the direction perpendicular to MLC travel. The interplay effect can
be somewhat overcome by using 3DCRT techniques on targets experiencing large
motion, such as lung tumours.
Real-time measurement tools such as DUO can be used to determine the benefit of
tracking on a patient-by-patient basis based on each motion pattern and treatment
plan.
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4.6 Conclusion
The performance of the MP512 and DUO detector systems has been benchmarked
under MLC tracking conditions. The detectors were able to accurately reconstruct
dose profiles when the target was undergoing motion.
The effect of motion on the delivered dose can easily be seen and measured quan-
titatively by considering the profile FWHM and penumbral width when motion is
present. These metrics were compared when MLC tracking was activated; tracking
was able mitigate a large portion of the FWHM and penumbral width increase due
to motion.
The temporal performance of the system was investigated by using a set of basic
Sine wave motion patterns. The response of individual detector pixels was examined
as a function of time throughout the treatment delivery. The detector is able to
reconstruct the correct periodicity and number of peaks based on the breaths per
minute of the input Sine wave. A fast Fourier transform was used to recover the
harmonic frequencies of the reconstructed motion trace. The peaks in the resulting
frequency response spectrum matched within 3% to the expected frequencies of the
Sine waves.
High resolution dose profiles were obtained using DUO for all tracking modalities.
The effect of a low density material within a high density surrounding was inves-
tigated. A clear distortion of the dose profiles in lower density timber was seen
compared to the sharper, more well defined profiles in higher density solid water.
This is due to the larger range of secondary electrons in the timber phantom. The
tracking performance was quantified with a percentage improvement metric that
was derived from the point-to-point dose error for each motion modality. Addi-
tionally a gamma analysis was also performed with various acceptance criteria. It
was shown that for the IMRT treatment delivery, tracking induced a larger error
than the uncorrected motion. This was attributed to a combination of the interplay
effect and limitation to compensate motion in the direction perpendicular to MLC
leaf travel.
The treatment plans delivered for the experiments in this chapter were simple ge-
ometries delivered from gantry angle zero. Now that the detector performance has
been proven, the next step is to apply the same methodology to a more typical
clinical patient case. Chapter 5 describes the measurement and analysis of this next




5.1 MP512 for Rotating Gantry Adaptive Radio-
therapy Conditions
MP512 (discussed in chapter 3) has been used for dosimetry of VMAT arc treatment
deliveries with dynamic MLC tracking of a moving target. This section covers the
experimental setup, analysis procedure and results for this experiment. The work
detailed in this chapter has been published in a peer reviewed journal [3]:
M. Duncan, M. K. Newall, V. Caillet, J. T. Booth, P. J. Keall, M. Lerch, V. Pere-
vertaylo, A. B. Rosenfeld, and M. Petasecca, Real-time high spatial resolution dose
verification in stereotactic motion adaptive arc radiotherapy, J. Appl. Clin. Med.
Phys., vol. 19, no. 4, pp. 173184, 2018.
5.2 Angular Dependence Correction
Silicon detectors are known to exhibit an angular dependence of their response.
MP512 is a monolithic silicon detector which has an intrinsic asymmetric structure
which contributes to an angular dependence. A procedure has been developed to
measure the angular dependence of MP512 and derive a set of correction factors as
a function of gantry angle [110].
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5.2.1 Measurement of Correction Factors
MP512 was placed inside a cylindrical PMMA phantom of diameter 30 cm and
length 40 cm. The central pixel of the detector was aligned to the isocentre of a
Varian Clinac iX linear accelerator. The detector was oriented in a vertical position
to avoid any couch interference, as shown in figure 5.1. As such the 0 degree rotation
point is defined at a gantry angle of 270◦ and all other angles are referenced to this
zero.
Figure 5.1: MP512 placed inside cylindrical PMMA phantom. The detector
is oriented vertically to avoid the treatment couch and the detector surface is
perpindicular to the beam direction [110].
The gantry was rotated from 0◦ to 180◦ in 15◦ increments, as per figure 5.1. This
corresponds to a physical gantry position of 270◦ to 90◦. At each angle 100 MU was
delivered at 600 MU/min at energies of 6 MV and 10 MV. A 10× 10 cm2 field size
was used. This was repeated five times for each gantry angle. A finer resolution
of 1◦ increments was used between 85◦ and 95◦ which is the expected maximum
variation from 0◦.
EBT3 film was used as a reference dosimeter to correct the MP512 angular mea-
surements. EBT3 has been designed to be angular independent, the film pieces were
placed in the PMMA phantom in the same location of MP512. The films were irra-
diated for angles 0◦, 45◦, 90◦, 135◦ and 180◦. An interpolation was used to obtain
values at every degree for both EBT3 and MP512. A set of calibration films was
used to convert film response to dose (cGy) in imageJ (National Institute of Health,
USA) and MATLAB (Mathworks, USA).
5.2.2 Application of Correction Factors
A calibration factor aij expressed in counts/cGy was defined as the ratio MP512
response to EBT3 film response at each gantry angle and for each detector pixel
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i, j (equation 5.1). Here i represents the row index (perpendicular to phantom






An angular response calibration tensor, MP (Ci,j(θ)) was calculated by dividing the
calibration factor at an arbitrary gantry angle θ by the calibration factor obtained





The response of MP512 was then corrected by dividing the raw response MP ′ij(θ)





Before angular correction was applied the MP512 response varied by nearly 20%
compared to the response at zero degrees. Figure 5.2 shows the detector response
as a function of gantry angle for a 10×10 cm2 field size and 6 MV and 10 MV beam
energies.
After the angular correction factors were applied, MP512 response agreed to EBT3
response within 2%. Dose profiles were reconstructed from EBT3 and from MP512




Motion tracking was implemented in a similar manner to that of the previous ex-
periments in chapter 4. The same tracking modalities were used for this experi-
ment:
1. No motion - detector phantom is static throughout the treatment
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Figure 5.2: Average angular response of the four central pixels of the MP512
detector array as a function of gantry angle for an open field size of 10× 10 cm2
for 6 MV and 10 MV photons [110].
2. Motion with no tracking - detector phantom follows supplied motion trace
(section 4.2.1) and no MLC tracking is applied
3. Motion with passive tracking - detector phantom follows supplied motion trace
and passive MLC tracking algorithm is applied
4. Motion with predictive tracking - detector phantom follows supplied motion
trace and predictive MLC tracking algorithm is applied
A treatment delivery (section 5.3.4) was made for each motion modality.
5.3.2 Detector Phantom
The same phantom construction used in chapter 4 and shown in figure 4.3 is em-
ployed here. Additional details are provided around the aluminium shielding.
MP512 was encased in a PMMA phantom holder as discussed in chapter 3 and
shown in figure 3.2. An aluminium shielding box was designed to attenuate the
RF signal coming from Calypso. The alternating RF field induced a current in the
copper detector wiring and analogue front end electronics which contributed to a
large baseline fluctuation.
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Figure 5.3: Comparison of dose profiles from EBT3 film and MP512 with and
without angular correction for a 1×1 cm2 open field for 10 MV photons for gantry
angles; (a) 0◦, (b) 45◦, (c) 90◦ and (d) 135◦[110].
The thickness of the aluminium shield was designed such that the transmitted power
of the incident RF field was less than 0.1%. This was calculated by considering the
”skin effect” produced by conduction materials and approximating the RF signal as
a plane electromagnetic wave. Table 5.1 summarises the electromagnetic parameters
required to calculate the skin depth, which is given by equation 5.4.
Parameter Description Typical Value Units
0 Permittivity of free space 8.854× 10−12 F/m
µ0 Permeability of vacuum 4pi × 10−7 H/m
µr Relative permeability 1 For aluminium
ω Angular frequency 2pif Hz
σ Conductivity 1.54× 105 (Ωcm)−1 for aluminium
Table 5.1: Electromagnetic parameters used for aluminium shield thickness
calculations






For an incident wave intensity of ψ0, thickness of aluminium z and attenuation of






= 0.001→ z ≈ 2mm (5.5)
Hence the thickness of the aluminium shielding was determined to be 2 mm. The
effect of the shielding in terms of dose perturbation was investigated with Geant4
simulations [104]. The simulation geometry was a 30× 30× 30 cm3 water phantom.
A phase space file was used to simulate 6 MV x-rays coming from a Varian 2100C
linac for beam sizes 1×1 cm2, 2×2 cm2 and 3×3 cm2. The beam model, geometry
and simulation physics were validated experimentally previously [111]. The Geant4
electromagnetic physics package was used which includes all the physics processes
associated with megavoltage photons such as Compton scattering, photoelectric ef-
fect, ionisation and Bremsstrahlung. A dose scoring grid of 1 mm3 was used.
A comparison is made between the homogenous water phantom and a water phantom
with the first 2 mm replaced with aluminium. Figure 5.4 (a) shows the percentage
depth dose (PDD) response of the simulations. The aluminium has a higher density
than water (approx. 2.7 g/cm3) which creates an increased electron fluence compared
to the same thickness of water. As a result there is a slight increase in dose within
the buildup region of the PDD with the shielding in place. There is then a consistent
1% low response after the depth of maximum dose which is within the uncertainty
of the simulation. Figure 5.4 (b) confirms the negligible effect of the shielding on
dosimetry, the cross plane profiles show no appreciable difference with or without
the shielding. Uncertainty here is also 1% and is represented by the size of the
markers.
A second test was conducted to evaluate the effectiveness of the shielding to attenu-
ate the RF signal from Calypso. The baseline of the detector system (dark current)
was acquired under three conditions (a) detector unshielded and Calypso off, (b)
detector unshielded and Calypso on, (c) detector shielded and Calypso on. Each
acquisition was 120 seconds and at a sampling rate of 360 Hz (the same as used
in experimental measurements). The dark current from each detector pixel was
averaged and standard deviation was calculated. Figure 5.5 shows the frequency
distribution of the standard deviation. It can be seen that the unshielded detector
measures baseline fluctuation of up to 9% when Calypso is activated (black bars).
This signal becomes summed into the true detector response and contributes to a
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large error of the measurement. The aluminium shielding is able to remove these
fluctuations (red bars) bringing the response close to that of the no RF case (red
bars).
Figure 5.4: (a) Geant4 simulation of percentage depth dose and (b) dose profiles
for 1× 1 cm2, 2× 2 cm2 and 3× 3 cm2 field sizes [104]
The aluminium shielding was designed to allow 5 mm of solid water to be placed
between it and the PMMA detector holder below. This puts the sensitive volumes
of the detector at a water equivalent depth of approx 15 mm which corresponds to
the depth of maximum dose, dmax, for a 6 MV photon beam. Table 5.2 summarises
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Figure 5.5: Baseline fluctuation of the detector signal for three conditions:
Calypso on, detector shielded (red), Calypso on, detector unshielded (black) and
Calypso off, detecter unshielded (green) [104]
the thickness and density of each of the materials used to make up the phantom
scattering conditions. Equation 5.6 shows the calculation used to determine the
water equivalent depth of the detector.
Material Thickness (τi) Density (ρi)
PMMA 4 mm 1.18 g/cm3
Solid Water 5 mm 1.03 g/cm3
Aluminium 2 mm 2.7 g/cm3





τi × ρi = 15.27mm (5.6)
Figure 5.6 shows the final phantom cross section used including RF shielding and
solid water backscatter. Note this is the same detector construction used used in
chapter 4 and shown in figure 4.3.
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Figure 5.6: Cross section of scattering conditions of the solid water phantom.
Units are mm. Detector surface is at an approximate water equivalent depth
of 15 mm and the PMMA phantom is encapsulated by aluminium to minimise
induced noise from RF field of Calypso. Coordinate system is marked with the
Y direction coming out of the page
5.3.3 Reproducing Organ Motion
The movable platform HexaMotion by Scandidos (Upsalla, Sweeden) was used to
mimic patient organ motion. The detail of this implementation was discussed pre-
viously in 4.2.1.
HexaMotion provided simultaneous motion in each of the x (lateral), y (sup-inf) and
z (ant-post) directions.
Patient motion patterns were extracted from 4DCT lung traces from patients at
Northern Sydney Cancer Centre (Royal North Shore Hospital, St Leonards NSW).
A sampling rate of 25 ms was used. Three distinct lung motion patterns were chosen
to represent a wide variety of breathing types:
1. Patient 1 - lung trace with approximately 8 mm sup-inf offset (baseline shift)
2. Patient 2 - lung trace centred around zero
3. Patient 3 - lung motion with a predominant component in the lateral direction
Figure 5.7 shows motion traces as a function of time for each patient in x, y and z
directions.
5.3.4 Treatment Planning and Delivery
The detector phantom was CT scanned at Northern Sydney Cancer Centre with 1
mm slice thickness. Figure 5.8 shows the setup at CT, the detector surface was set
to the laser isocentre so that setup could be replicated at treatment. A third party
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Figure 5.7: Three dimensional lung motion traces corresponding to (a) patient
1, (b) patient 2 and (c) patient 3. Data is from 4DCT sampled every 25 ms.
X component corresponds to motion in left-right direction, Y component corre-
sponds to motion in sup-inf direction and Z corresponds to motion in ant-pos
direction
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DICOM viewer was used to visualise the CT dataset at a later date. Figure 5.9
shows a transverse slice of the CT dataset used for treatment planning.
Figure 5.8: MP512 phantom aligned to isocentre lasers at CT
A VMAT treatment plan was generated in Eclipse treatment planning system (Var-
ian Medical System, USA) consisting of two opposing arcs. The first arc started at
gantry angle 150 degrees, rotated counter-clockwise and stopped at gantry angle 340
degrees. The second arc started at 340 degrees and rotated clockwise back to 150
degrees. Arc 1 delivered 496 monitor units (MU) and arc 2 delivered 508 MU on a
Varian Clinac iX, nominal beam energy and dose rate was 6 MV and 600 MU/min,
respectively. The beam arrangement allowed sufficient target coverage while largely
avoiding irradiating through the treatment couch.
A GTV was contoured manually as a rough spherical volume of diameter 2 cm placed
at the centre of the detector. A PTV expansion of 3 mm was used to replicate
a clinically relevant lung plan but also to keep the contours within the phantom
geometry. A dose prescription of 5 Gy in a single fraction was applied and optimised
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Figure 5.9: A transverse slice of the CT scan of the detector phantom. The
GTV (blue) and PTV (red) used for treatment planning are marked.
on a 2 mm dose grid.
DICOM dose maps were exported from Eclipse and overlaid on the CT data set as
visualised in the third party DICOM viewer. This is shown in figure 5.10.
Figure 5.10: Left: Beams eye view of the detector (coronal plane) with TPS
dose map overlaid on CT data set. Right: The DICOM dose map exported from
Eclipse. Detector sensitive area marked in boxes.
The same treatment plan was used for all motion modalities, there was no ITV based
plan used for the no motion case. The aim of this experiment was to characterise
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MP512 for use in adaptive arc radiotherapy using MLC tracking, so for ease of
comparison the same plan was used for all motion modalities.
5.4 Measurements
For this experiment the response of MP512 was expressed in terms of absorbed dose,
in order to compare with EBT3 and TPS. MP512 exhibits a linear response with
accumulated dose, so to calibrate the detector, dose was delivered in the range 50
cGy to 1000 cGy. The detector was placed at dmax under a 10 x 10 cm
2 field of 6 MV
photons. The detector charge (pC) was plotted against dose (cGy) and the slope of
the linear relationship was used as a conversion factor for future measurements.
EBT3 film was used to verify the response of MP512 under the arc conditions.
Gamma analysis was performed on the 2D dose distribution from each dosimeter.
Film pieces were cut to fit precisely in the detector cut out of the PMMA phantom,
in this way the dose maps from each dosimeter were intrinsically co-registered. The
films were scanned six times in a flatbed scanner and the last three scans were
averaged to obtain the optical density. A set of calibration films was used to convert
the optical density to dose in Matlab (Mathworks inc). The film handling and
processing procedure is described in a previous study [90].
Gamma pass rates are reported for 2%/2 mm and 3%/3 mm dose difference and
distance to agreement criteria. Dose maps were extracted from Eclipse TPS with
2 mm resolution. To co-register the dose maps to MP512 geometry, the data was
cropped according to the square overlay regions seen in figure 5.10. The same gamma
pass rates are reported to quantify TPS agreement with MP512.
To characterise the effect of the motion tracking, dose maps from MP512 were
compared between modalities. The baseline data set was the no motion case, the
other modalities were compared to this baseline using the same gamma analysis.
This allowed an investigation into the efficacy of the tracking modalities for different
patient motions.
Dose profiles were extracted from the 2D distribution of MP512 and EBT3 for
patient 1 motion in both the sup-inf and left-right directions (X and Y directions
in figure 5.10). The dose profiles were aligned to the left 50% response and plotted
on the same axes. The baseline fluctuation of the MP512 response was observed to
be around ±1% and the uncertainty in the film dose was calculated to be approx.
±2% [90]. Dose profiles from MP512 for each motion modality were plotted on the
same axes for comparison. The point-to-point dose difference was also plotted to
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highlight areas of under and over dose, with respect to the no motion baseline. This
was repeated for each patient motion.
5.5 Results
The linear dose response of MP512 is shown in figure 5.11 for the range 50 cGy to
1000 cGy. The MP512 measured charged is converted to dose using the calibration
factor in table 5.3.
Figure 5.11: Linear dose response exhibited by MP512 for cumulative dose
delivery. The slope of the linear fit is used to convert measured detector charge
(nC) to absorbed dose (cGy). Error bars indicate measured baseline fluctuation
of ±1%.
Value Units
Slope 0.2325 ±1.4e-4 nC/cGy
Table 5.3: Dose calibration factor derived from the linear relationship between
measured detector charge and absorbed dose.
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5.5.1 Reconstructed Dose Profiles
The dose profiles for patient 1 motion from EBT3 and MP512 are shown in figure
5.12 for the sup-inf direction and in figure 5.13 for the lateral direction. The uncer-
tainty in both data sets are shown. An analysis was carried out the determine the
full width at half maximum (FWHM) and penumbral width of each of the profiles,
defined as the distance between the 20% and 80% response. This was compared for
each motion modality for patient 1 and shown in table 5.4.
MP512 profiles agree with EBT3 film within 5 mm for penumbral width and 1 mm
for FWHM. The shape of the dose distribution is clearly effected in the motion case
which increased the left side penumbral width by 1.6 mm compared to no motion.
Passive tracking is able to recover the shape of the dose profile and reduce the
penumbra distortion to 0.6 mm larger than the no motion case, this corresponds to
a reduction of 60%. Predictive tracking decreases this discrepancy further to only
0.3 mm which is a reduction of 80%.
Dose profiles are also reconstructed from MP512 for each motion modality and
overlaid on a single set of axes to show the efficacy of both tracking methods. Point-
to-point difference is also plotted in terms of absolute dose difference and percentage
difference to highlight areas of under and over dose. Patient 1 motion causes a sub-
stantial shift in dose towards the right of the profile, figure 5.14. This results in an
under dose around the left penumbra of 280 cGy (corresponding to 45% of the max-
imum dose) and an over dose around the right penumbra of 200 cGy (corresponding
to 35% of the maximum dose), in a single fraction. When tracking is applied these
discrepancies are reduced to around 30 cGy (4.5% of maximum dose). This cor-
responds to an error reduction of approximately 90% for the right penumbra and
85% for the left penumbra. The motion trace for patient 1 has a relatively small
displacement in the lateral direction (figure 5.7) of approximately 1.5 mm. This is
less than the width of a MLC leaf (5 mm) and hence the leaves are not triggered
for tracking in this direction. The resulting dose distribution is largely unaffected
in the lateral direction for this reason.
The profiles corresponding to patient 2 motion are shown in figure 5.15. The motion
profile is highly distorted and triangular in shape. The distortion causes under and
over dose of up to ±200 cGy around the penumbrae, representing an error of 20% of
maximum dose. The error is halved to approximately 10% when tracking is applied.
This motion trace also has a small lateral component and this is shown in the profiles
in this direction.
Patient 3 had a predominately lateral component to their breathing trace which can
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be seen in figure 5.16. This meant that the dose profiles in the sup-inf direction are
relatively unaffected however there was still a measurable over dose of 8% on the
central axis when tracking is applied. The error was reduced to 6% with tracking.
A shift of the dose is evident in the lateral profile however the MP512 sensitive area
is not large enough to fully reconstruct the profile in this direction.
(a) No Motion (b) Motion
(c) Passive (d) Predictive
Figure 5.12: MP512 vs EBT3 dose Profiles for various motion modalities with
patient 1 motion applied. Profiles reconstruced in the sup-inf direction. Un-
certainty is estimated as ±1% for MP512 ±1% for EBT3. Full size figures in
appendix A.2.1.
5.5.2 Reconstructed Dose Maps
The 2D dose maps used for gamma analysis are shown in figure 5.17. Angular
corrections were applied frame by frame for each gantry angle before summing the
dose. Qualitatively there is good agreement between the three dose maps. Due
to the manufacturing process of implanting and wire bonding 512 individual silicon
diodes, there were some dead pixels in the MP512 matrix. Dose values for these dead
pixels have been interpolated from neighbouring pixels in the same row. This process
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(a) No Motion (b) Motion
(c) Passive (d) Predictive
Figure 5.13: MP512 vs EBT3 dose Profiles for various motion modalities with
patient 1 motion applied. Profiles reconstructed in the lateral direction. Un-
certainty is estimated as ±1% for MP512 ±1% for EBT3. Full size figures in
appendix A.2.1.
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Modality Data Source FWHM (mm) LHS (mm) RHS (mm)
No Motion
EBT3 23.9 3.7 4.2
MP512 24.5 4.1 4.7
TPS 23.7 4.1 4.7
Motion
EBT3 24.0 5.3 5.4
MP512 24.6 5.7 5.9
Difference 0.6 0.3 0.5
Passive Tracking
EBT3 23.8 4.7 5.3
MP512 24.6 4.7 5.3
Difference 0.8 0 0
Predictive Tracking
EBT3 23.8 4.3 5.3
MP512 24.7 4.4 5.4
Difference 0.9 0.1 0.1
Table 5.4: Summary of the FWHM and left/right penumbral width between
MP512 and EBT3 for dose profiles in the sup-inf direction. Uncertainty is
±0.3mm
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(a) Sup-Inf (b) Lateral
Figure 5.14: Dose profiles measured with MP512 when Patient 1 motion was
applied for each motion modality. Point-to-point dose difference is expressed in
terms of dose and percentage. Uncertainty is estimated as ±1% and is represented
by the size of the markers. Full size figures in appendix A.2.2
is not able to fully recover dose information for every single dead pixel, especially
when two or more adjacent pixels are dead. This effect is seen in the bottom and
top right corners of the MP512 dose map, however in general the interpolation is a
robust solution.
The benchmarking of MP512 to EBT3 film and TPS was quantified through the
gamma pass rates shown in table 5.5. The effect of motion and tracking on the
measured dose distribution is shown in the gamma pass rates in table 5.6 as measured
by MP512.
Tracking Modality Comparison 2%/2mm (%) 3%/3mm (%)
No Motion
TPS to MP512 98.44 100
EBT3 to MP512 95.31 99.31
Table 5.5: Gamma pass rates for MP512 compared to TPS and EBT3 film for
the no motion case.
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(a) Sup-Inf (b) Lateral
Figure 5.15: Dose profiles measured with MP512 when Patient 2 motion was
applied for each motion modality. Point-to-point dose difference is expressed in
terms of dose and percentage. Uncertainty is estimated as ±1% and is represented
by the size of the markers. Full size figures in appendix A.2.2
Motion Trace Tracking Modality 2%/2mm (%) 3%/3mm (%)
Patient 1








No Tracking 79.69 91.32
Passive 95.66 98.61
Predictive 93.23 96.35
Table 5.6: Gamma pass rates for MP512 vs MP512 response with respect to the
no motion case for each motion modality.
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(a) Sup-Inf (b) Lateral
Figure 5.16: Dose profiles measured with MP512 when Patient 3 motion was
applied for each motion modality. Point-to-point dose difference is expressed in
terms of dose and percentage. Uncertainty is estimated as ±1% and is represented
by the size of the markers. Full size figures in appendix A.2.2
5.5.3 Temporal Analysis
As discussed in chapter 3, MP512 can be synchronised with the linac electron gun
pulse so that a full temporal reconstruction of the delivered dose is possible. A
single pixels’ temporal response can be examined which allows investigation of the
dose delivered at that specific point within the phantom. The dose delivered to
the target depends on both the phantom motion and MLC leaf motion, and more
importantly on the interplay of these two independent motion axes. It is possible
to characterise the interplay effect by examining the temporal response of the pixels
which experience the most interplay. These pixels are generally around the 50%
dose response point of the integral dose profiles. See section 4.4.2 for details.
An example of the temporal response of one of these pixels is shown in figure 5.18, for
each motion modality. Black points show the response when no motion is applied,
this response is due to MLC modulation only. The no motion case is taken as the
reference value. When motion is applied the interplay between the phantom motion
and MLC leaf motion creates a distortion of the pixel response, this is shown by the
red points on figure 5.18. Passive tracking is able to compensate for the majority
of motion shown as blue points on figure 5.18. The response follows the no motion
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(a) EBT3 (b) MP512
(c) TPS
Figure 5.17: Dose maps reconstructed from (a) EBT3 film, (b) MP512 and (c)
Eclipse TPS
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reference with a small delay associated with the lag of the passive algorithm. The
delay is approximately 0.5 seconds and can be seen at the 23rd second in figure 5.18.
The green points represent the response for the predictive tracking modality, this
algorithm is also able to restore the dose almost completely to the reference case
and the delay of the tracking system has been reduced. The predictive algorithm
performs best for relatively slow motion, such as between 3 to 8 seconds and 12 to 20
seconds in figure 5.18. When the motion is abrupt or aperiodic the passive algorithm
shows superior performance, due to the difficulty in predicting such a signal. This
effect is particularly evident in the large troughs at 2 seconds and 9 seconds of figure
5.18.
Figure 5.18: Response of a single pixel as a function of time for each motion
modality. Black represents the dose response when no motion is applied, this is
the best case scenario. Red shows the effect of applying lung motion with no
tracking. Blue represents the response when passive MLC tracking is applied and
green shows the response of predictive MLC tracking. This highlights the errors
that patient motion introduces to the local dose at specific points in time and
how the tracking is able to correct for the majority of these errors.
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5.6 Discussion
Gamma analysis of the 2D dose maps from MP512 showed a very close match to
the 2D dose measured from EBT3 film and dose extracted from Eclipse TPS. Using
a 2%/2 mm acceptance criteria the response of MP512 matched that of EBT3 for
95% of points and TPS for 98% of points. When a 3%/3 mm acceptance criteria
was used the agreement was 99% and 100% for EBT3 and TPS respectively. This
confirms the accuracy of MP512 as a 2D dosimetry system even under complex
clinical conditions. MP512 can reconstruct the dose delivered during realistic patient
breathing with real-time MLC tracking and full arc delivery. As a result, MP512
can be used as a tool to quantify the efficacy of a particular tracking regime, and
in patient specific pre-treatment QA. Gamma analysis was also performed on the
MP512 measured dose maps to inter-compare each motion modality, this gives some
insight into the effect of MLC tracking.
Patient 1 motion (with no tracking) resulted in a pass rate of 78% (2%/2mm)
however the two tracking modalities brought the pass rate to 95% or above for both
3%/3 mm and 2%/2 mm acceptance criteria. Patient 2 uncorrected motion had a
pass rate of 55% (2%/2 mm) and patient 3 had 80% pass rate (2%/2 mm) with
motion. When tracking was applied pass rates of above 93% were observed for both
patient 2 and patient 3 for both criteria.
Gamma pass rates above 95% for 3%/3mm agreement are commonly accepted as
sufficient to proceed with treatment [112]. In our case when the Patient 1 motion
pattern was introduced there was a large drop in the 2%/2 mm pass rate when
no tracking is applied, however the 3%/3 mm criteria was relatively unchanged at
98%. If a gamma analysis using 3%/3 mm acceptance criteria was the only form
of pre-treatment QA for this plan, it appears to be clinically acceptable. However,
it is somewhat unlikely as this plan was designed to be used in conjunction with
MLC tracking and would not be used clinically when no tracking is to be applied,
rather an ITV based plan would be created. This result still highlights the need
to use caution when depending solely on gamma analysis (especially with a rather
loose acceptance criterion) as a form of pre-treatment QA. A similar conclusion was
reached in previous studies [113, 114] which showed that gamma analysis pass rates
for 3%/3 mm and 2%/2 mm acceptance criteria for particular 2D dose planes had
very little correlation to errors in clinically relevant patient DVH metrics and even
a 1%/1 mm acceptance criteria only showed moderate correlation. MP512 monitors
the beam in real time, for every linac pulse. As a result, the data are available
immediately after the measurement. This information can be used to give insight
into the efficacy of a particular tracking regime. For example, the results from the
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gamma analysis show the predictive tracking algorithm did not always lead to a
higher pass rate when compared to passive tracking, in this case it was particularly
dependent on the type of motion being experienced by the target volume.
In our study, for periodic motion patterns, the predictive algorithm had superior
performance and gave better target tracking; however, for motion patterns that are
aperiodic and erratic the passive tracking gave better results. We hypothesise this
is due to the difficulty in accurately predicting an irregular signal and depends on
the type and duration of the learning process adopted in the predictive algorithm
[115]. Some algorithms use an initial learning window before treatment where the
program learns the breathing trace over a few respiratory cycles and others employ
a dynamic type of learning which can adapt faster to irregularities in the motion
[116].
Dose profiles from MP512 and EBT3 film undergoing patient 1 motion were plot-
ted on a single axis and compared (figures 5.12 and 5.13). It was found that in
the sup-inf direction (major axis of organ motion due to the breathing cycle) the
penumbral width of both profiles were within 0.5 mm and FWHM agrees within 1
mm for all deliveries. The agreement of data between MP512 and EBT3 film over
multiple datasets further proves the accuracy of MP512 for use in adaptive therapy
treatments.
MP512 measured dose profiles from each motion modality were plotted on a single
axis, this allowed a qualitative overview of the effect of patient motion and MLC
tracking on the dose delivered. The effect of Patient 1 (figure 5.14) motion on the
dose distribution can clearly be identified through the spread of the profile and loss
of the dose distribution shape presented in the no motion case. The discrepancy
is quantified by an increase in left penumbral width of 1.62 mm compared to the
no motion case. Passive tracking was able to reduce the penumbral width by 60%.
The predictive algorithm showed a reduction of 79%, an agreement within 0.34 mm
of the no motion case. The motion trace for Patient 1 is primarily in the vertical
direction with a maximum lateral displacement of approximately 1.5 mm (Figure
2a); because the lateral shift is smaller than the MLC leaf width, it produces very
little change in the profiles along the horizontal direction and the tracking is not
able to compensate for it.
Point-to-point dose difference plots were included to highlight the dose error (in cGy
and %) as a function of distance across the profile. This allowed for a quantitative
measure of dose errors and their locations, introduced by patient motion, and shows
the effectiveness of the tracking system in reducing areas of under and over dose.
When motion was applied there were under dose and over dose regions of up to 280
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cGy (45% of max dose) and 200 cGy (35% of max dose) measured respectively, for
a single fraction. The predictive tracking algorithm allowed the MLC to effectively
compensate for the motion, the dose discrepancies were reduced to just 30 cGy which
is 4.5% of the maximum dose. This represents a reduction in dose error of up to
90% when tracking is applied compared to the no motion case.
The effect of Patient 2 motion on the dose distribution is plotted in figure 5.15. The
motion profile is highly distorted with a triangular shape and large areas of under
and over dose, up to 200 cGy. These dose errors are halved from 20% of maximum
dose to around 10% when tracking is applied. There is not much effect from the
motion along the horizontal component due to the small contribution of the motion
in this direction. Figure 5.15 shows the dose profile when Patient 3 motion trace was
applied. Due to the predominantly left-right component of this breathing pattern,
the vertical profile is not largely affected however there is an overdose of 8% on the
central axis in this direction when no tracking is applied which is reduced slightly
to around 6% when tracking is activated. The shift of the dose in the horizontal
direction is evident in this case due to the large lateral component of the motion
trace. Although the MP512 sensitive area is not large enough to reconstruct the full
dose profile in this direction, the effect of motion causing distortion of the profile
exemplifies the benefits of tracking.
At the present time, MP512 is restricted to small field measurements only due to
its small sensitive area. MP512 is a proof-of-concept detector, future work would
involve fabrication of similar detectors with larger sensitive area. This would be
applicable to a broader range of radiotherapy treatments.
5.7 Conclusion
CMRP has developed MP512, a 2D silicon diode array for use in small field dosime-
try. It consists of 512 individual ion implanted diodes of size 0.5x0.5 mm2 with 2 mm
centre-to-centre distance. In this study a two arc VMAT treatment was delivered
to the phantom and MP512s angular dependence was corrected frame-by-frame.
MP512 response was comparable to EBT3 film and the calculated TPS dose. These
results provide confidence that detector based pre-treatment dosimetry is clinically
feasible despite fast real-time MLC reconfigurations.
Chapter 6
Microbeam Radiation Therapy
The study presented in this chapter was carried out at the European Synchrotron
Radiation Facility in Grenoble, France. The study has been published in peer re-
viewed journal Medical Physics [4]:
M. Duncan et al., First experimental measurement of the effect of cardio-synchronous
brain motion on the dose distribution during microbeam radiation therapy, Med.
Phys., vol. 47, no. 1, pp. 213222, 2020.
The results of this study were presented at the IEEE Nuclear Science Symposium
and Medical Imaging Conference (IEEE NSS-MIC), 2019 in Manchester, United
Kingdom.
6.1 Motion during Microbeam Radiation Ther-
apy
Organ motion has long been an issue in all radiation therapy modalities, MRT is no
exception. The brain is known to exhibit motion that is synchronous to the cardiac
rhythm [117–119]. This occurs when an arterial pulse travels into the cerebrovas-
cular system leading to expansion and contraction of the cerebrospinal fluid. The
amplitude of this motion is of the order of 100 to 200 µm and 2 to 3 Hz in frequency
(figure 6.1) [120, 121] so it does not pose an issue for conventional radiotherapy
modalities where field sizes of the order of cm in diameter are generally adopted.
However, for MRT the motion amplitude is of the same order of magnitude as the
beam width and spacing, resulting in a potential dose blurring through overlap of
microbeams. This can result in a reduced PVDR which can potentially compromise
the radiobiological effectiveness of the treatment.
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Figure 6.1: Amplitude of cardio synchronous brain motion as reported by
Soellinger [120] (left) and Zhong [121] (right).
The effect of cardio synchronous brain motion on the dose distribution in MRT
has recently been studied using Monte Carlo techniques [122]. The study found
that PVDR decreases and FWHM of the peaks increases as a function of brain
motion amplitude. There are some aspects of MRT that Monte Carlo simulations
do not consider, namely beam divergence and vibration/wobbling artefacts gener-
ated by the goniometer stage and other mechanical components used to move the
target across the beam. This work presents the first experimental measurement of
microbeam profiles under simulated brain motion conditions using a silicon single
strip detector and Gafchromic films. Experimental data are compared to a dataset
calculated using Monte Carlo Geant4.
6.2 Materials and Methods
The measurements in this work have been carried out at the biomedical beamline
(ID17) at the European Synchrotron Radiation Facility (ESRF) in Grenoble, France.
Highly brilliant collinear x-rays are generated using a wiggler insertion device. The
geometry of the ID17 beamline [123, 124] and beam conditions for MRT [125] have
been described in detail and published previously. The homogenous incoming beam
of size 0.5 mm x 24 mm was segmented into microbeams of width 50 µm and centre-
to-centre peak distance of 400 µm using a multi slit collimator (MSC).
In contrast to conventional radiotherapy, the synchrotron x-ray source cannot be
moved. The reference field size for MRT is 2 x 2 cm2. This is obtained by scanning
the beam (0.5 mm height) through the volume of interest at a constant speed.
This is achieved using a highly precise goniometer stage. A fast shutter system is
synchronised with the vertical position of the goniometer to mitigate uncertainties
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in the dose distribution generated by the acceleration and deceleration of the motor
stage [126]. This method has been shown to deliver a dose distribution equivalent





Equation 6.1 shows the relationship between dose and scan speed. D is the dose
(Gy), D˙ is the dose rate (Gy/s), h is the beam height (mm) and s is the scan
speed (mm/s). Note the synchrotron storage ring current is slowly decaying during
normal operation, which leads to a decreasing dose rate over a long period. This is
accounted for by scaling the dose rate with the storage ring current at the time of
measurement [128].
The x-ray energy spectrum is in the range of 50 to 350 keV with mean energy
approximately 100 keV [83]. This provides microbeams with very sharp penumbrae
compared to megavoltage radiotherapy, due to the limited range of the lower energy
secondary electrons.
The Centre for Medical Radiation Physics (CMRP) at the University of Wollongong
has developed a real time dosimetry system for MRT based on a silicon single strip
detector (SSSD) [96, 100], as discussed in section 3.2. The detector is a single
microstrip diode with a sensitive area of 10 × 900 µm2. A guard ring surrounds
the sensitive volume with a 5 µm margin. The strip is fabricated on a 50 µm thick
epitaxial substrate with total chip dimensions of 1.5 mm × 1.0 mm. With the
detector arranged in edge on -straight configuration [97] (figure 6.2) the effective
sensitive volume is controlled by the applied bias voltage. A value of -30 V gives a
sensitive volume of approximately 5 to 7 µm.
A custom data acquisition system was used to readout the detector and consists of
a preamplifier, high voltage bias control and central system unit which is controlled
by a Field Programmable Gate Array [96]. The sampling rate is up to 1 Mhz which
is suitable for the high dose rates encountered in MRT.
The detector was mounted at 2 cm depth in a 15 x 15 x 15 cm3 solid water phantom
[129] approximately 1.3 m downstream from the MSC. A reference dose measurement
was performed using a PTW PinPoint ionisation chamber with traceability to a
primary standard of absorbed dose. The reference conditions employed for MRT
dosimetry are 2 cm depth in the solid water phantom, a 2c m x 2 cm field size
(broadbeam i.e no MSC in the beam) and a beam height of 0.5 mm [128]. These
conditions were used for both the PinPoint and SSSD. The dose measured by the
PinPoint was used to calculate the calibration factor (pC/Gy) to convert the charge
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Figure 6.2: SSSD orientation options. In edge on mode the sensitive volume is
a function of applied bias voltage
(pC) measured by the SSSD into dose (Gy).
Brain motion was modelled using the data from Soellinger et al. [120] for both the
Monte Carlo simulations and experimental measurements, and is shown in figure
6.3.
The brain motion was realised by a stepper motor which forms part of the sample
stage positioning system, mounted orthogonally above the goniometer stage. The
geometry of the goniometer and stepper motor relative to the incoming beam is
shown in figure 6.4 and figure 6.5. The goniometer scans vertically in the Z direction
and the stepper motor applies brain motion laterally in the Y direction. Figure 6.4
shows the phantom from a beams-eye-view and figure 6.5 shows the beam incoming
from the X direction towards the phantom. The motion shown in figure 6.3 is
in the patient superior-inferior direction. For MRT treatment the patient can be
positioned laying supine and orthogonal to the beam axis, hence brain motion is
applied along the Y direction. Motion in this direction will also have the largest
effect on the PVDR and FHWM of the microbeams. The stepper motor was reset
to the same initial position at each scan and synchronised with the vertical motion
of the goniometer stage such that the motion was reproducible between scans.
The goniometer is capable of variable vertical scan speeds; 5 mm/s, 10 mm/s and
20 mm/s were chosen. At each scan speed we took measurements with and without
brain motion. In addition to this, we chose three vertical positions (lines) within the
field to sample the dose; the centre of the field , -800 µm from the centre and +500
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Figure 6.3: Brain motion trace used for the measurements. Data are based on
those from Soellinger et al [120].
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Figure 6.4: Beams-eye view of the experimental setup. The goniometer scans
vertically through the beam in the Z direction. The brain motion is applied
laterally by the stepper motor (Y direction) and the beam is incoming from the
X direction
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Figure 6.5: Side on view of the experimental setup. The broad beam is incident
along the X direction where it intercepts the multi-slit collimator before hitting
the phantom.
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µm from the centre, see figures 6.7 and 6.8. The effect of the motion on the dose
distribution is expected to vary depending on the specific position within the field
due to the interplay between the motion directions of the goniometer (Z direction)
and brain motion (Y direction). In order to reconstruct the microbeam profiles, the
detector was stepped laterally (Y direction) through the field at intervals of 10µm
in the valley and 5 µm in the peaks. At each step the detector was scanned through
the beam (moved along Z direction). The sum of the counts corresponding to the
integral dose at each position was used in combination with the known step distance
to reconstruct the dose profiles. PDVR and FWHM was calculated for the profiles
obtained with different scan speed, with and without lateral brain motion.
Gafchromic HD-V2 film was used under the same conditions as the SSSD. Film
samples were sized to cover the entire field in one irradiation, so all the lines were
acquired simultaneously. The same scan speeds were used with and without brain
motion. An optical microscope was used to readout the films, this allows a resolution
of 2 µm [130]. Profiles were reconstructed for two microbeams in the centre of the
field corresponding to the same vertical positions of the SSSD. The PVDR and
FWHM was calculated for each of the profiles.
Monto Carlo simulations were performed using the Geant4 toolkit [131–133]. The
incoming photon spectrum was modelled using the X-ray Oriented Programs (XOP)
[134], a collection of codes for calculating characteristics of x-ray sources such as
wigglers and their interaction with matter. Dose was scored in a 1 mm thick layer
centred at 2 cm depth in a 15 cm x 15 cm x 15 cm homogenous water phantom. A
scoring grid of 5 µm x 5 µm was used, and secondary particles were cut after 1 µm.
Motion is realised in the simulation by a displacement of the beam relative to the
scoring grid. The displacement is varied based on the brain motion wave form. The
resulting energy deposition simulates the effect of brain motion, see figure 6.6.
Dose profiles were extracted for the same vertical positions corresponding to the
nominal positions of the SSSD and PVDR and FWHM was calculated.
6.3 Results
Figure 6.7 illustrates the position of each of the measurement lines within the ra-
diation field with no brain motion applied, figure 6.8 shows the same with brain
motion. The lines in the figures are superimposed over the Geant4 simulation data
set. These positions will be referred to as line 1 for the central line, line 2 for the
lower line and line 3 for the upper line.
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Figure 6.6: Energy deposition in the Geant4 simulation is offset according to
the phase of the brain motion.
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Dose profiles were reconstructed from the SSSD for each scan speed and at each
line. The dose delivered is proportional to irradiation time and hence inversely
proportional to the scan speed, see Equation 1. This can be seen in figure 6.9 where
the dose profiles obtained in line 2 are shown. The FWHM of the normalised profiles
are also presented in table 6.1.
Figure 6.7: Position of each of the ’lines’ on the simulation dose distribution
with no brain motion at 20 mm/sec scan speed. Line 1 corresponds to the central
line, line 2 to the lower line and line 3 to the upper line. The effect of the
motion depends on the spatial position within the field. Zoomed area on right
corresponds to region of interest on left.
Figure 6.8: Position of each of the ’lines’ on the simulation dose distribution
with brain motion at 20 mm/sec scan speed. Line 1 corresponds to the central
line, line 2 to the lower line and line 3 to the upper line. The effect of the
motion depends on the spatial position within the field. Zoomed area on right
corresponds to region of interest on left.
Brain motion introduces large perturbations in the dose profiles, particularly at low
scan speed. Figure 6.9b shows the effect of brain motion for each scan speed on the
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(a) No Motion (b) Motion
Figure 6.9: Dose profiles reconstructed from the SSSD for each scan speed for
line 2. (a) is with no motion and (b) is with brain motion. Total dose delivered
is inversely proportional to the scan speed
FWHM (µm) 5 mm/sec 10 mm/sec 20mm/sec Max Variation (%)
MC Simulations 52.8 53.7 52.7 1.9%
SSSD 59.4 59.4 61.4 3.4%
Film 61.0 55.9 52.8 15.5%
Table 6.1: FWHM for dose profiles as a function of scan speed for line 2 with
no brain motion.
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dose distribution, this is in comparison with figure 6.9a where no brain motion was
applied. Figure 6.10 shows the dose distribution for 5 mm/sec scan speed with and
without brain motion at line 2.
Figure 6.10: Effect of brain motion on dose profiles for 5 mm/sec scan speed.
Dose profiles are significantly offset and wider with brain motion for line 2.
Dose maps were reconstructed from simulation and film data. The effect of brain
motion is shown in figure 6.11 for simulation data and figure 6.12 for film data.
Profiles are extracted along the vertical and horizontal directions according to the
black line overlay on the dose maps, which corresponds to line 1 for the lateral
profiles.
In order to quantify the effect of brain motion on the delivered dose distribution, the
FWHM and PVDR was calculated for dose profiles reconstructed from the SSSD,
MC data and film. The FWHM and PVDR values were normalised to the no motion
case such that a value >1 indicates an increase in the parameter and a value < 1
indicates a decrease in the parameter, when motion is applied. This analysis was
repeated for all lines and scan speeds. Figures 6.13, 6.14 and 6.15 show the results of
the analysis for the single strip detector, simulation data and film data, respectively.
The uncertainties for SSSD and film measurements are estimated as 2.5% and 5.2%,
respectively. Table 6.2 shows a breakdown of the uncertainties for both detectors.
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(a) No Motion (b) Motion
Figure 6.11: Dose map reconstructed from simulation data for (a) no motion and
(b) with brain motion. Vertical and horizontal profiles are extracted according to
the black lines. Scan speed is 20 mm/sec. Lateral profile (horizontal line on dose
map) corresponds to line 1.
(a) No Motion (b) Motion
Figure 6.12: Dose map reconstructed from film data for (a) no motion and (b)
with brain motion. Vertical and horizontal profiles are extracted according to the
black lines. Scan speed is 20 mm/sec. Lateral profile (horizontal line on dose
map) corresponds to line 1.
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The uncertainty in the simulation data is estimated as 2% based on the statistics of
the number of primary photons generated. Due to the small field size, the number
of photons that participate in dose deposition is low.
SSSD Relative standard uncertainty (%)
Positioning reproducibility 2
SSSD calibration against PinPoint chamber 1.5
PinPoint calibration at primary standards lab 0.5





Microscope readout noise [130] 3.5
Combined standard uncertainty (%) 5.2
Table 6.2: Uncertainty budget for measurements with SSSD and film
(a) SSSD FWHM (b) SSSD PVDR
Figure 6.13: Effect of brain motion on FWHM (left) and PVDR (right) of dose
profiles reconstructed from the single strip detector, for each scan speed and ’line’.
Error bars represent the estimated uncertainty of 2.5%
6.4 Discussion
To validate the performance of the SSSD, the FWHM of profiles from the SSSD,
simulation data and film were compared as a function of scan speed. Changing scan
speed should have no appreciable effect on the FWHM of dose profiles, when no
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(a) Simulation FWHM (b) Simulation PVDR
Figure 6.14: Effect of brain motion on FWHM (left) and PVDR (right) of dose
profiles reconstructed from the simulation data, for each scan speed and ’line’.
Error bars represent the estimated uncertainty of 2%
(a) Film FWHM (b) Film PVDR
Figure 6.15: Effect of brain motion on FWHM (left) and PVDR (right) of dose
profiles reconstructed from the film data, for each scan speed and ’line’. Error
bars represent the estimated uncertainty of 5.2%
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brain motion is present. Table 6.1 summarises the calculated FWHMs for line 2.
The SSSD and simulation profiles vary less than 3.5% between scan speeds, however
film exhibits up to 15% variation. The high discrepancy obtained for film with
respect to MC simulations at lower speeds is due to the impossibility to deliver the
dose to the film without a strong effect of the saturation of the dose at the peaks
for such low speeds and high dose rate. This effect has the natural consequence to
over-estimate the dose recorded by the film and, by extension, the FWHM of the
peaks. Different speeds should be used to better match the delivered dose on the
films within the defined calibration curve. In addition, the limited dynamic range of
the film read-out protocol makes it difficult to accurately measure dose in the peak
and valley simultaneously. The uncertainty associated with the microscope readout
is higher compared to the SSSD measurements.
The FWHM of the profiles as measured by the SSSD are wider (6˜0 µm) than the
nominal 50 µm microbeams. This is due to the finite size of the silicon sensitive
volume which is approximately 7 µm at -30V of bias. The effect of beam divergence
is also responsible for the over-estimation of the microbeam width from the SSSD
measurement. The goniometer (and detector phantom) is around 1.3 metres from
the MSC which leads to widening of the microbeam profiles downstream due to the
small beam divergence. This can also be seen in the film FWHM measurements.
In addition, there is some uncertainty associated with wobbling and vibrations of
the goniometer as it scans through the beam. This can be seen in the film dose
map and lateral profile in figure 6.12. These effects increase the apparent size of the
microbeams and are neglected in the simulations.
Brain motion during MRT irradiation can significantly impact the resulting dose
distribution. Comparing figure 6.9a and figure 6.9b for 5mm/sec and 10 mm/sec
scan speeds there is a decrease in total dose delivered (to that specific line) and the
distribution is distorted and broadened. This means for that particular volume the
delivered dose is not the same as the planned dose. For the 20 mm/sec scan speed
the dose delivered appears to be the same however the profile is offset by around
120 µm. Although a small number in magnitude, it is a significant shift considering
the peak to peak spacing of the microbeams is 400 µm.
The offset of microbeams has implications for MRT treatment planning, specifi-
cally if multiple entrance ports are used. Port angles and placement of interlaced
microbeams is optimised to reduce dose to healthy tissue and increase the PVDR.
Misalignment of microbeams at treatment delivery will result in a reduced PVDR
and irradiation of additional healthy tissue within the valley region. The radiobi-
ological effectiveness of MRT can be compromised in such situations. The SSSD
shows a two-fold increase in FWHM of dose profiles and a 50% reduction of the
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PVDR with brain motion (figure 6.13). The simulation data corroborate this result
with an increase of FWHM of around 1.8 times and a decrease in PVDR of about
40% with brain motion (figure 6.14).
Both the simulation and film data can give 2D dose map information, as shown
in figure 6.11 and figure 6.12. The vertical profiles along the field length of each
dose map shows the displacement of dose when brain motion is present. Simulation
and film dose maps qualitatively agree in this regard. However, film is not able to
reproduce accurately the trend and the values of FWHM and PVDR in respect to
simulation at the lines analysed in figure 6.15. The effect of brain motion on FWHM
and PVDR from the SSSD and simulation shows the same trend for each line and
scan speed (figure 6.13 and 6.14). For lines 1 and 2, FWHM decreases with faster
scan speed and is relatively unchanged for line 3. The film data does not follow
this trend. In addition, the SSSD and simulation data generally show an increase in
PVDR with faster scan speed. The film data is relatively insensitive to scan speed
for PVDR. This is explained by recalling the limitation of the dynamic range of the
film in resolving the peak and valley dose simultaneously.
6.5 Conclusion
The effect of brain motion on the dose distribution during MRT has been measured
experimentally with a novel silicon detector. The SSSD response during MRT was
validated with a Geant4 simulation for various scan speeds. Variability of FWHM
between scans was < 3.5% for the SSSD and around 1.5% for simulation. Brain
motion was applied to both the experimental measurements and simulation. The
SSSD was able to reconstruct dose profiles under motion conditions and predict
similar effects on FWHM and PVDR as calculated by the simulation. It was shown
there is a 150-200% increase in FWHM and 40 to 50% decrease in PVDR when
brain motion is present during MRT. Higher scan speeds mitigate the effect to
some extent however a lateral offset of the dose was apparent even for the fastest
scan speed of 20mm/sec. This has implications for MRT treatment planning when
multiple ports are used. The SSSD detector proposed in this work represents a
viable technological solution for accurate microbeam dosimetry in MRT not only
for reference dosimetry but also for patient specific QA when motion of the organs
or uncertainty generated by the mechanical setup (goniometer wobbling) must be
taken into account to maximise the treatment outcome.
Chapter 7
Conclusions and Future Work
The aim of this thesis was to determine the feasibility of using high spatial reso-
lution silicon detectors for quality assurance in radiotherapy where the treatment
target is undergoing motion. MP512 and DUO were used for dose measurements
during real-time adaptive radiotherapy (RTAT) with real-time MLC tracking. The
detectors were able to reconstruct the time resolved and integral dose distribution
from the modulated beam. The agreement between the detectors, EBT3 film and
the treatment planning system was found to be better than 95% at 2%/2 mm. The
detector system is suitable for quality assurance of RTAT which involves also the
use of small field photon beams.
Intra-fraction motion is also an issue in microbeam radiation therapy. The X-treme
dosimetry system using a single silicon strip detector was used for the first exper-
imental measurement of the effect of brain motion on the dose distribution during
MRT.
The use of silicon detectors during adaptive radiotherapy
In conventional radiotherapy, intra-fraction organ motion leads to expanded treat-
ment margins and irradiation of an increased volume of healthy tissue. RTAT such
as MLC tracking enables a reduction in margins but introduces a treated dose distri-
bution that could differ from the treatment plan. There can be uncertainty in dose
reporting to the tumour and healthy tissue in this case. Real-time high spatial and
temporal resolution detectors are required for quality assurance of real-time RTAT
treatments. MP512 and DUO are 2D pixelated monolithic silicon detectors de-
signed for dose measurement in small field radiotherapy. The detectors were tested
for use with MLC tracking and were able to accurately reconstruct the delivered
dose distribution.
The high temporal resolution of the data acquisition system was tested and it was
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found that the entire time-resolved dose distribution could be reconstructed pulse
by pulse. Inspecting the dose to a specific pixel as a function of time time aids
in identifying whether a certain tracking algorithm is beneficial for a particular
patients motion. The Fast Fourier transform was used to quantify the performance
of various tracking algorithms based on a calculated quality factor. It was found
that predictive tracking is only beneficial for cyclic motion such as patient breathing
but not for random motions such as prostate drift displacements.
MP512 was used to reconstruct the delivered dose from a two arc VMAT treatment
undergoing lung motion. The agreement found between the measured dose distri-
bution and the treatment planning system was better than 95% at 2%/2 mm. The
settings used for the tracking algorithm were appropriate for this specific tumour
motion. The detector system and quality factor can be used to optimise the tracking
settings before the first fraction, leading to more individualised treatment for the
patient.
Quantifying the effect of brain motion in MRT
Cardio-synchronous brain motion (±200µm) is of the same order of magnitude as
the beam width and spacing in MRT (50 µm beam width and 400 µm beam spacing).
This motion has the potential to reduce the peak to valley dose ratio, which would
affect one of the fundamental parameters used to assess the radiobiological advantage
of MRT. Experimental dosimetry in MRT is challenging due to small field sizes
and high dose rates. A single silicon strip detector system has been designed to
overcome the limitations of commercially available dosimetry systems. In this work
the detector was used for the first experimental measurement of the effect of brain
motion on the MRT dose distribution. The microbeams measured by the single strip
detector were also measured with film and compared to Monte-Carlo simulations.
The agreement between the silicon strip detector and simulations has been assessed
by measuring the PVDR and beam width, verifying experimentally that the effect
of motion is reduced using a faster treatment time (increasing the scan speed during
the exposure of the target to the beam). The detector would be suitable for pre-
treatment dose measurement to assess the effect of brain motion on a particular
patients treatment or eventually for use of MRT in organs which are affected by
heart beating or breathing related motions.
Future work
The detector systems presented here are viable tools for pre-treatment quality as-
surance of small field RTAT treatments. There are a few improvements that can be
made to future versions of the system that would make it more clinically appeal-
ing:
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• Incorporation of angular correction and dead pixel interpolation within the
acquisition software, currently this is carried out by post processing
• Development of a new model of detector with larger sensitive area to be used
for a broader range of radiotherapy treatments
• Addition of tools to aid in analysis of the time resolved dose distribution
from various motion modalities within the acquisition software. For example
calcuation of the Fourier spectrum from a partiular delivery and comparison
of the frequency peaks for each tracking algorithm
• Online calculation of Fourier spectrum during the treatment delivery to give a
prediction of the effectiveness of the tracking before the full treatment has been
delivered. A tool such as this could reduce the time required for pre-treatment
measurements
• Automating the comparison of measured dose vs planned dose. This would
involve re-calculating the patient treatment plan on a CT scan of the detector
(embedded into a phantom). The DICOM dose distribution overlay would
then be imported into the acquisition software. After the measurement the
software would extract the dose from the DICOM for the appropriate plane
and compare to measured using gamma analysis and profiles
• Improvement to detector packaging. This would include rigidly mounting the
detector in a suitable box with minimal cable connections e.g just power and
USB and development of a suitable phantom to house the detector
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A.1 Supplementary Data for Chapter 4
A.1.1 Experiment 1
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Figure A.1: 3DCRT - Lateral Direction
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Figure A.2: 3DCRT - Sup-Inf direction
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Figure A.3: 3DCRT - Lateral Direction
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Figure A.4: 3DCRT - Sup-Inf direction
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A.1.2 Experiment 2
Figure A.5: Temporal response of a DUO pixel with the 20 BPM Sine wave
motion applied. When predictive tracking is applied there is a clear benefit after
an initial ’learning’ time.
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A.1.3 Experiment 3
A.1.3.1 Patient 1 3DCRT
Figure A.6: Solid Water - Sup-Inf
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Figure A.7: Solid Water - Med-Lat
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Figure A.8: Timber - Sup-Inf
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Figure A.9: Timber - Med-Lat
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A.1.3.2 Patient 2 3DCRT
Figure A.10: Solid Water - Sup-Inf
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Figure A.11: Solid Water - Med-Lat
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Figure A.12: Timber - Sup-Inf
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Figure A.13: Timber - Med-Lat
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A.1.3.3 Patient 1 IMRT
Figure A.14: Solid Water - Sup-Inf
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Figure A.15: Solid Water - Med-Lat
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Figure A.16: Timber - Sup-Inf
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Figure A.17: Timber - Med-Lat
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A.1.3.4 Patient 2 IMRT
Figure A.18: Solid Water - Sup-Inf
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Figure A.19: Solid Water - Med-Lat
APPENDIX A. SUPPLEMENTARY DATA 191
Figure A.20: Timber - Sup-Inf
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Figure A.21: Timber - Med-Lat
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A.2 Supplementary Data for Chapter 5
A.2.1 EBT3 Film vs MP512
A.2.1.1 Vertical Profiles
Figure A.22: No Motion
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Figure A.23: Motion
A.2.1.2 Horizontal Profiles
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Figure A.24: Passive
A.2.2 MP512 Dose Profiles
A.2.2.1 Patient 1
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Figure A.25: Predictive
A.2.2.2 Patient 2
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Figure A.26: No Motion
A.2.2.3 Patient 3
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Figure A.27: Motion
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Figure A.28: Passive
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Figure A.29: Predictive
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Figure A.30: Sup-Inf
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Figure A.31: Lateral
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Figure A.32: Sup-Inf
APPENDIX A. SUPPLEMENTARY DATA 204
Figure A.33: Lateral
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Figure A.34: Sup-Inf




This appendix contains Matlab functions and scripts that were used as part of data




Written by Matthew Newall.
This function is called from several other functions. It is used to find the FWHM
or 80-20 points of a dose profile.
1 function [X] = findX v2(InputArray, Yvalue)
2 % findX - this function determines the x-axis location of a ...
single y-axis
3 % normalised value along a gaussian distribution (i.e. beam ...
profile) via
4 % interpolation; using the 'piecewise cubic hermite interpolation
5 % polynomial ('pchipinterp').
6 %
7 % A is a two column array; the first column consists of the x-axis
8 % coordinates, the second column contains the y-axis coordinates.
9 %
10 % Yvalue is the y-axis value (whose location is of interest) ...
as a
11 % percentage of the maximum value in the profile, expressed as ...
a decimal
12 % e.g. 0.5 to find the "exact" location of the Half Maximums.
207
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13 %
14 % Returns an array, X, containing the x-axis locations of the ...
y-axis
15 % values for the Left Hand Side (LHS) and Right Hand Side ...
(RHS) of the
16 % distribution (about the central maximum).
17 %




21 MaximumOfInput = max(InputArray(:,2));
22
23 SizeOfInput = size(InputArray);
24
25 IndexOfMaximumInput = find(InputArray(:,2)==MaximumOfInput);
26
27 CentreOfProfile = InputArray(IndexOfMaximumInput,1);
28
29 FitModelOfInput = ...
fit(InputArray(:,1),InputArray(:,2),'pchipinterp');
30
31 %plot(FitModelOfInput); %Visualises the fit model.
32
33 objective = @(i) FitModelOfInput(i) - (Yvalue*MaximumOfInput);
34
35 X(1,1) = fzero(objective,[InputArray(1,1) CentreOfProfile]); ...
%LHS





Written by Nathanael C. Yoder.
This function is used to find peaks within a noisy signal. It is freely available
at https://au.mathworks.com/matlabcentral/fileexchange/25500-peakfinder-x0-sel-
thresh-extrema-includeendpoints-interpolate
1 function varargout = peakfinder(x0, sel, thresh, extrema, ...
includeEndpoints, interpolate)
2 %PEAKFINDER Noise tolerant fast peak finding algorithm
3 % INPUTS:
4 % x0 - A real vector from the maxima will be found (required)
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5 % sel - The amount above surrounding data for a peak to be,
6 % identified (default = (max(x0)-min(x0))/4). Larger ...
values mean
7 % the algorithm is more selective in finding peaks.
8 % thresh - A threshold value which peaks must be larger ...
than to be
9 % maxima or smaller than to be minima.
10 % extrema - 1 if maxima are desired, -1 if minima are desired
11 % (default = maxima, 1)
12 % includeEndpoints - If true the endpoints will be ...
included as
13 % possible extrema otherwise they will not be included
14 % (default = true)
15 % interpolate - If true quadratic interpolation will be ...
performed
16 % around each extrema to estimate the magnitude and the
17 % position of the peak in terms of fractional ...
indicies. Note that
18 % unlike the rest of this function interpolation ...
assumes the
19 % input is equally spaced. To recover the x values of ...
the input
20 % rather than the fractional indicies you can do:
21 % peakX = x0 + (peakLoc - 1) * dx
22 % where x0 is the first x value and dx is the spacing ...
of the
23 % vector. Output peakMag to recover interpolated ...
magnitudes.
24 % See example 2 for more information.
25 % (default = false)
26 %
27 % OUTPUTS:
28 % peakLoc - The indicies of the identified peaks in x0
29 % peakMag - The magnitude of the identified peaks
30 %
31 % [peakLoc] = peakfinder(x0) returns the indicies of local ...
maxima that
32 % are at least 1/4 the range of the data above surrounding ...
data.
33 %
34 % [peakLoc] = peakfinder(x0,sel) returns the indicies of local ...
maxima
35 % that are at least sel above surrounding data.
36 %
37 % [peakLoc] = peakfinder(x0,sel,thresh) returns the indicies ...
of local
38 % maxima that are at least sel above surrounding data and ...
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larger
39 % (smaller) than thresh if you are finding maxima (minima).
40 %
41 % [peakLoc] = peakfinder(x0,sel,thresh,extrema) returns the ...
maxima of the
42 % data if extrema > 0 and the minima of the data if ...
extrema < 0
43 %
44 % [peakLoc] = peakfinder(x0,sel,thresh,extrema, includeEndpoints)
45 % returns the endpoints as possible extrema if ...
includeEndpoints is
46 % considered true in a boolean sense
47 %
48 % [peakLoc, peakMag] = ...
peakfinder(x0,sel,thresh,extrema,interpolate)
49 % returns the results of results of quadratic interpolate ...
around each
50 % extrema if interpolate is considered to be true in a ...
boolean sense
51 %
52 % [peakLoc, peakMag] = peakfinder(x0,...) returns the indicies ...
of the
53 % local maxima as well as the magnitudes of those maxima
54 %
55 % If called with no output the identified maxima will be ...
plotted along
56 % with the input data.
57 %
58 % Note: If repeated values are found the first is identified ...
as the peak
59 %
60 % Example 1:
61 % t = 0:.0001:10;
62 % x = 12*sin(10*2*pi*t)-3*sin(.1*2*pi*t)+randn(1,numel(t));
63 % x(1250:1255) = max(x);
64 % peakfinder(x)
65 %
66 % Example 2:
67 % ds = 100; % Downsample factor
68 % dt = .001; % Time step
69 % ds dt = ds*dt; % Time ∆ after downsampling
70 % t0 = 1;
71 % t = t0:dt:5 + t0;
72 % x = ...
0.2-sin(0.01*2*pi*t)+3*cos(7/13*2*pi*t+.1)-2*cos((1+pi/10)*2*pi*t+0.2)-0.2*t;
73 % x(end) = min(x);
74 % x ds = x(1:ds:end); % Downsample to test interpolation
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75 % [minLoc, minMag] = peakfinder(x ds, .8, 0, -1, false, true);
76 % minT = t0 + (minLoc - 1) * ds dt; % Take into account 1 based ...
indexing
77 % p = plot(t,x,'-',t(1:ds:end),x ds,'o',minT,minMag,'rv');
78 % set(p(2:end), 'linewidth', 2); % Show the markers more clearly
79 % legend('Actual Data', 'Input Data', 'Estimated Peaks');
80 % Copyright Nathanael C. Yoder 2015 (nyoder@gmail.com)
81




86 s = size(x0);
87 flipData = s(1) < s(2);
88 len0 = numel(x0);
89 if len0 6= s(1) && len0 6= s(2)
90 error('PEAKFINDER:Input','The input data must be a vector')
91 elseif isempty(x0)




96 warning('PEAKFINDER:NotReal','Absolute value of data will be ...
used')
97 x0 = abs(x0);
98 end
99
100 if nargin < 2 | | isempty(sel)
101 sel = (max(x0)-min(x0))/4;
102 elseif ¬isnumeric(sel) | | ¬isreal(sel)
103 sel = (max(x0)-min(x0))/4;
104 warning('PEAKFINDER:InvalidSel',...
105 'The selectivity must be a real scalar. A selectivity ...
of %.4g will be used',sel)
106 elseif numel(sel) > 1
107 warning('PEAKFINDER:InvalidSel',...
108 'The selectivity must be a scalar. The first ...
selectivity value in the vector will be used.')
109 sel = sel(1);
110 end
111
112 if nargin < 3 | | isempty(thresh)
113 thresh = [];
114 elseif ¬isnumeric(thresh) | | ¬isreal(thresh)
115 thresh = [];
116 warning('PEAKFINDER:InvalidThreshold',...
117 'The threshold must be a real scalar. No threshold will ...
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be used.')
118 elseif numel(thresh) > 1
119 thresh = thresh(1);
120 warning('PEAKFINDER:InvalidThreshold',...
121 'The threshold must be a scalar. The first threshold ...
value in the vector will be used.')
122 end
123
124 if nargin < 4 | | isempty(extrema)
125 extrema = 1;
126 else
127 extrema = sign(extrema(1)); % Should only be 1 or -1 but ...
make sure
128 if extrema == 0
129 error('PEAKFINDER:ZeroMaxima','Either 1 (for maxima) or ...




133 if nargin < 5 | | isempty(includeEndpoints)
134 includeEndpoints = true;
135 else
136 includeEndpoints = boolean(includeEndpoints);
137 end
138
139 if nargin < 6 | | isempty(interpolate)
140 interpolate = false;
141 else
142 interpolate = boolean(interpolate);
143 end
144
145 x0 = extrema*x0(:); % Make it so we are finding maxima regardless
146 thresh = thresh*extrema; % Adjust threshold according to extrema.
147 dx0 = diff(x0); % Find derivative
148 dx0(dx0 == 0) = -eps; % This is so we find the first of repeated ...
values
149 ind = find(dx0(1:end-1).*dx0(2:end) < 0)+1; % Find where the ...
derivative changes sign
150
151 % Include endpoints in potential peaks and valleys as desired
152 if includeEndpoints
153 x = [x0(1);x0(ind);x0(end)];
154 ind = [1;ind;len0];
155 minMag = min(x);
156 leftMin = minMag;
157 else
158 x = x0(ind);
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159 minMag = min(x);
160 leftMin = min(x(1), x0(1));
161 end
162
163 % x only has the peaks, valleys, and possibly endpoints
164 len = numel(x);
165
166 if len > 2 % Function with peaks and valleys
167 % Set initial parameters for loop
168 tempMag = minMag;
169 foundPeak = false;
170
171 if includeEndpoints
172 % Deal with first point a little differently since ...
tacked it on
173 % Calculate the sign of the derivative since we tacked ...
the first
174 % point on it does not neccessarily alternate like the ...
rest.
175 signDx = sign(diff(x(1:3)));
176 if signDx(1) ≤ 0 % The first point is larger or equal to ...
the second
177 if signDx(1) == signDx(2) % Want alternating signs
178 x(2) = [];
179 ind(2) = [];
180 len = len-1;
181 end
182 else % First point is smaller than the second
183 if signDx(1) == signDx(2) % Want alternating signs
184 x(1) = [];
185 ind(1) = [];





191 % Skip the first point if it is smaller so we always start ...
on a
192 % maxima
193 if x(1) ≥ x(2)
194 ii = 0;
195 else
196 ii = 1;
197 end
198
199 % Preallocate max number of maxima
200 maxPeaks = ceil(len/2);
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201 peakLoc = zeros(maxPeaks,1);
202 peakMag = zeros(maxPeaks,1);
203 cInd = 1;
204 % Loop through extrema which should be peaks and then valleys
205 while ii < len
206 ii = ii+1; % This is a peak
207 % Reset peak finding if we had a peak and the next peak ...
is bigger
208 % than the last or the left min was small enough to reset.
209 if foundPeak
210 tempMag = minMag;
211 foundPeak = false;
212 end
213
214 % Found new peak that was lager than temp mag and ...
selectivity larger
215 % than the minimum to its left.
216 if x(ii) > tempMag && x(ii) > leftMin + sel
217 tempLoc = ii;
218 tempMag = x(ii);
219 end
220
221 % Make sure we don't iterate past the length of our vector
222 if ii == len




226 ii = ii+1; % Move onto the valley
227 % Come down at least sel from peak
228 if ¬foundPeak && tempMag > sel + x(ii)
229 foundPeak = true; % We have found a peak
230 leftMin = x(ii);
231 peakLoc(cInd) = tempLoc; % Add peak to index
232 peakMag(cInd) = tempMag;
233 cInd = cInd+1;
234 elseif x(ii) < leftMin % New left minima




239 % Check end point
240 if includeEndpoints
241 if x(end) > tempMag && x(end) > leftMin + sel
242 peakLoc(cInd) = len;
243 peakMag(cInd) = x(end);
244 cInd = cInd + 1;
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245 elseif ¬foundPeak && tempMag > minMag % Check if we ...
still need to add the last point
246 peakLoc(cInd) = tempLoc;
247 peakMag(cInd) = tempMag;
248 cInd = cInd + 1;
249 end
250 elseif ¬foundPeak
251 if x(end) > tempMag && x(end) > leftMin + sel
252 peakLoc(cInd) = len;
253 peakMag(cInd) = x(end);
254 cInd = cInd + 1;
255 elseif tempMag > min(x0(end), x(end)) + sel
256 peakLoc(cInd) = tempLoc;
257 peakMag(cInd) = tempMag;




262 % Create output
263 if cInd > 1
264 peakInds = ind(peakLoc(1:cInd-1));
265 peakMags = peakMag(1:cInd-1);
266 else
267 peakInds = [];
268 peakMags = [];
269 end
270 else % This is a monotone function where an endpoint is the only ...
peak
271 [peakMags,xInd] = max(x);
272 if includeEndpoints && peakMags > minMag + sel
273 peakInds = ind(xInd);
274 else
275 peakMags = [];




280 % Apply threshold value. Since always finding maxima it will ...
always be
281 % larger than the thresh.
282 if ¬isempty(thresh)
283 m = peakMags>thresh;
284 peakInds = peakInds(m);
285 peakMags = peakMags(m);
286 end
287
288 if interpolate && ¬isempty(peakMags)
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289 middleMask = (peakInds > 1) & (peakInds < len0);
290 noEnds = peakInds(middleMask);
291
292 magDiff = x0(noEnds + 1) - x0(noEnds - 1);
293 magSum = x0(noEnds - 1) + x0(noEnds + 1) - 2 * x0(noEnds);
294 magRatio = magDiff ./ magSum;
295
296 peakInds(middleMask) = peakInds(middleMask) - magRatio/2;




300 % Rotate data if needed
301 if flipData
302 peakMags = peakMags.';
303 peakInds = peakInds.';
304 end
305
306 % Change sign of data if was finding minima
307 if extrema < 0
308 peakMags = -peakMags;
309 x0 = -x0;
310 end
311
312 % Plot if no output desired
313 if nargout == 0
314 if isempty(peakInds)






321 varargout = {peakInds,peakMags};
322 end
B.2 Code for Chapter 4
FFTAnalysis
This function takes time series data for each motion modality and calculates the
fast fourier transform.
1 function[] = FFTAnalysis(motion,passive,predictive)
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2 % Time specifications:
3 Fs = input('Sampling Frequency: '); % samples per second
4 numberofpeaks = input('Number of peaks to find: ');
5 dt = 1/Fs; % seconds per sample
6 x = motion;
7 y = passive;
8 z = predictive;
9
10 useBinWidth = 0;
11 if useBinWidth == 1
12 binWidth = 0.001; %Hz
13 numberOfPoints = Fs/binWidth;
14 else
15 numberOfPoints = length(motion);
16 end
17
18 y exists = 1;
19 z exists = 1;
20
21 if length(y) == 1
22 y exists = 0;
23 end
24 if length(z) == 1
25 z exists = 0;
26 end
27
28 max size = max(length(x),length(y));
29 max size = max(max size,length(z));
30
31 x pad = abs(max size-length(x));
32 x = padarray(x,x pad,0,'post');
33
34 y pad = abs(max size-length(y));
35 y = padarray(y,y pad,0,'post');
36
37 z pad = abs(max size-length(z));




42 freq = [];
43
44 columnsX = size(x);
45 if(columnsX(:,2)>1)
46 for i = 1:columnsX(:,2);
47 tempfft(:,i) = fft(x(:,i)-mean(x(:,i)));
48 end
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49 X = sum(tempfft,2);
50 else
51 % Fourier Transform;
52 X = fft(x-mean(x),numberOfPoints);
53 Y = fft(y-mean(y),numberOfPoints);
54 Z = fft(z - mean(z),numberOfPoints);
55 end
56
57 N = 0;
58 if useBinWidth == 1
59 N = numberOfPoints;
60 else
61 N = length(x);
62 end
63
64 % Frequency specifications:
65 df=1/(N*dt);
66 dF = Fs/N; % hertz
67 f = 0:dF:Fs-dF; % hertz
68 s = strcat('frequency ',num2str(Fs),'Hz sampling');
69 assignin('base',s,f');
70 % Output the main frequency component
71 [maxValue,indexMax] = max(abs(fft(x)));
72 [pks,locsX,h] = findpeaks(abs(X));
73
74 frequencyX = locsX(1:numberofpeaks) * dF-dF
75
76 % Plot the MOTION spectrum:
77 hold all;
78 trunc = abs(X)/N;
79 plot1 = plot(f(1:numberOfPoints),trunc(1:numberOfPoints),'r');
80 %save the fft data to a workspace variable
81 q = abs(X)/N;
82 s = inputname(1);
83 s = strcat(s,' fft');
84 assignin('base',s,q);
85 %setup the plot
86 xlabel('Frequency (in hertz)');
87 title('Magnitude Response');
88 ymax = max(abs(X));
89 xmax = max(frequencyX)+2*max(frequencyX);
90 xlim([0 50]);
91 colors = 'grbkmcrgkgrbkmcrgk';
92 for i = 1:length(frequencyX)
93 txt = num2str(frequencyX(i));
94 % string = strcat('\downarrow',' ',txt,' Hz');
95 % ...
APPENDIX B. MATLAB CODE 219
text(frequency(i),pks(i)+0.1*pks(i),string,'HorizontalAlignment','center');
96 %scat(i) = scatter(frequencyX(i),pks(i)/N,[],colors(i));
97 scat(i) = scatter(frequencyX(i),pks(i)/N);
98 end
99 freqX = num2str(frequencyX);
100
101 for i=1:length(frequencyX)
102 freq = [freq frequencyX(i)];
103 end
104 % freqX = num2str(frequencyX);
105 % l = legend(scat,freqX);
106 % t = get(l,'title');
107 % set(t,'string','Frequencies - Motion');
108
109 % Plot the Passive spectrum:
110 if y exists == 1
111
112 [pks, locsY] = findpeaks(abs(fft(y-mean(y))));
113 frequencyY = locsY(1:numberofpeaks) * dF-dF
114 trunc = abs(Y)/N;
115 plot2 = plot(f(1:numberOfPoints),trunc(1:numberOfPoints),'g');
116 u = abs(Y)/N;
117 s = inputname(2);
118 s = strcat(s,' fft');
119 assignin('base',s,u);
120 xlabel('Frequency (in hertz)');
121 title('Magnitude Response');
122 ymax = max(abs(Y));
123 xmax = max(frequencyY)+2*max(frequencyY);
124 xlim([0 50]);
125 colors = 'grbkmcrgk';
126 for i = 1:length(frequencyY)
127 txt = num2str(frequencyY(i));




130 scat2(i) = scatter(frequencyY(i),pks(i)/N,'x');
131 end
132 freqY = num2str(frequencyY);
133 % freqY = num2str(frequencyY);
134 % l = legend([scat,scat2],freqY);
135 % t = get(l,'title');
136 % set(t,'string','Frequencies - Passive');
137 for i=1:length(frequencyY)
138 freq = [freq frequencyY(i)];
139 end





144 % Plot the Predictive spectrum:
145 if z exists == 1;
146
147 [pks, locsZ] = findpeaks(abs(fft(z - mean(z))));
148 frequencyZ = locsZ(1:numberofpeaks) * dF-dF
149 trunc = abs(Z)/N;
150 plot3 = plot(f(1:numberOfPoints),trunc(1:numberOfPoints),'b');
151 v = abs(Z)/N;
152 s = inputname(3);
153 s = strcat(s,' fft');
154 assignin('base',s,v);
155 xlabel('Frequency (in hertz)');
156 title('Magnitude Response');
157 ymax = max(abs(Z));
158 xmax = max(frequencyZ)+2*max(frequencyZ);
159 xlim([0 50]);
160 colors = 'grbkmcrgk';
161 for i = 1:length(frequencyZ)
162 txt = num2str(frequencyZ(i));




165 %scat3(i) = ...
gscatter(frequencyZ(i),pks(i)/N,[],colors(i),'ˆ');
166 scat3(i) = scatter(frequencyZ(i),pks(i)/N,'ˆ');
167 end
168 freqZ = num2str(frequencyZ);
169 % freqZ = num2str(frequencyZ);
170 % l = legend([scat,scat2,scat3]);
171 % t = get(l,'title');
172 % set(t,'string','Frequencies - Predictive');
173 for i=1:length(frequencyZ)





179 freq = num2str(freq);
180 freq = strsplit(freq,' ');
181
182 freq1 = ['Motion' freq];
183 l = legend([plot1,scat],freq1);
APPENDIX B. MATLAB CODE 221
184
185
186 if y exists == 1
187 freq2 = ['Motion' 'Passive' freq];
188 l = legend([plot1,plot2,scat,scat2],freq2);
189
190 end
191 if z exists == 1
192 freq3 = ['Motion' 'Passive' 'Predictive' freq];
193 l = legend([plot1,plot2,plot3,scat,scat2,scat3],freq3);
194 end
filterFFT
This function is used to find the integral, peak location and peak height of frequency
peaks within the FFT magnitude response of the detector signal.
1 function [ output args ] = filterFFT(x,y,freqCutoff)
2
3
4 xStart = 5;
5 indexOfcutoff = find(x>freqCutoff); % find the index of the ...
cutoff value, to select only data between xstart and cutoff
6 x = x(xStart:indexOfcutoff(1));
7 y = y(xStart:indexOfcutoff(1));
8
9 derivative = diff(y);
10
11 Filtered Data = hampel(derivative,5,0.5);
12 x = x(1:size(Filtered Data));
13 derivative = derivative(1:size(Filtered Data));
14 y = y(1:size(Filtered Data));
15
16 subtract = derivative-Filtered Data;
17 for i = 1:size(subtract)
18 if subtract(i) > 0
19 subtract(i) = 0;
20 end
21 end
22 subtract = abs(subtract);
23 newData = y.*subtract;
24 trapz(x,newData)
25
26 [peakLoc] = peakfinder(newData,(max(newData)-min(newData))/2)
27
28 figure





33 legend('Original','Potential Peaks','Peaks to Find')
34 hold off
35
36 for i = 1:size(peakLoc)
37 if peakLoc(i) ≥ 5
38 rangeLower = peakLoc(i)-2;
39 rangeUpper = peakLoc(i)+2;
40 potentialPeakx = x(rangeLower:rangeUpper);
41 potentialPeaky = y(rangeLower:rangeUpper);
42
43 x max = max(potentialPeakx);
44
45 InputArray = [potentialPeakx potentialPeaky];
46
47 [X] = findX v2(InputArray,0.5);
48 leftX = X(1,1)
49 rightX = X(1,2)
50
51 % interpolate the data so that the integral is more ...
'accurate'
52
53 % set increment of the x vector (e.g frequency)
54 ∆x = x(2)-x(1);
55 interp amount = 1000; % set how many times more data ...
you want
56 xi = potentialPeakx(1):∆x/interp amount:x max; % ...
create the new x vector
57 yi = interp1(x,y,xi,'pchip'); %interpolate the data
58
59
60 leftY = yi(find(abs(xi-leftX)<0.00001)); %find ...
the Y value corresponding to the leftX (the left ...
0.5 value)
61 rightY = yi(find(abs(xi-rightX)<0.00001));
62 leftY = leftY(1)
63 rightY = rightY(1)
64
65 leftXBound = [leftX leftX leftX];
66 leftYBound = [0 leftY max(yi)];
67 rightXBound = [rightX rightX rightX];
68 rightYBound = [0 rightY max(yi)];
69 leftFWHM = [leftX rightX];
70 rightFWHM = [leftY rightY];
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71
72
73 peakY = max(yi)
74 peakYindex = find(abs(yi-peakY)<0.00000001);





80 plot1 = plot(leftXBound,leftYBound);
81 plot2 = plot(rightXBound,rightYBound);
82 plot3 = plot(leftFWHM,rightFWHM);
83 plot4 = plot(x,y);
84 plot5 = scatter(peakX,peakY);
85 %plot6 = plot(xi,baselineY);
86
87 % find the total integral
88
89 leftYindex = find(abs(yi-leftY)<0.00001)




94 xInt = leftX:xi(2)-xi(1):rightX;





100 yInt = yInt(1:length(xInt));
101 elseif(length(yInt)<length(xInt));




106 int = trapz(xInt,yInt)
107
108 %find the baseline integral
109
110 % baseline intY = baselineY(leftYindex:rightYindex);
111
112 % if(length(xInt)<length(baseline intY))
113 % baseline intY = baseline intY(1:length(xInt));
114 % elseif(length(baseline intY)<length(xInt))
115 % xInt = xInt(1:length(baseline intY));
116 % end
117
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118 %baseline int = trapz(xInt,baseline intY)
119
120 %total int = int - baseline int
121
122 plot6 = area(xInt,yInt,'FaceColor',[1 1 0.1]);
123 %hatchfill2(plot6);
124 legend([plot1 plot2 plot3 plot4 plot5 plot6], 'Left ...
50%','Right 50%','Half Height','FFT ...
Spectrum',num2str(peakX),strcat('Integral:',num2str(int)));









B.3 Code for Chapter 5
VMATAnalysis
This function is used to generate dose maps from MP512 for VMAT deliveries. It
takes the raw decoded data files and uses the mp512 map to arrange the data in
the same geometry as the detector. Angular correction factors are applied for every
1 degree of gantry rotation, as defined in the anglesfile. A mask is applied that





3 %path = '/Volumes/Mitch SSD/RNSH 11:12:16/VMAT Plan';
4
5 path = '/Users/Mitch/OneDrive/PhD/Experiments/RNSH 20161211/VMAT ...
Plan - Data/';
6
7 % data files (usual motion pattern)
8 % file{1} = ...
fullfile(path,'11-12-16 14-43-51 AcqLength-70s IntTime-78us Range-7 Freq-360Hz Decoded.txt'); ...
% no motion arc1
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9 % file{2} = ...
fullfile(path,'11-12-16 14-45-19 AcqLength-70s IntTime-78us Range-7 Freq-360Hz Decoded.txt'); ...
% no motion arc2
10 % file{3} = ...
fullfile(path,'11-12-16 14-58-58 AcqLength-70s IntTime-78us Range-7 Freq-360Hz Decoded.txt'); ...
% motion arc1
11 % file{4} = ...
fullfile(path,'11-12-16 15-00-49 AcqLength-70s IntTime-78us Range-7 Freq-360Hz Decoded.txt'); ...
% motion arc2
12 % file{5} = ...
fullfile(path,'11-12-16 15-15-15 AcqLength-70s IntTime-78us Range-7 Freq-360Hz Decoded.txt'); ...
% passive tracking arc1
13 % file{6} = ...
fullfile(path,'11-12-16 15-18-25 AcqLength-70s IntTime-78us Range-7 Freq-360Hz Decoded.txt'); ...
% passive tracking arc2
14 % file{7} = ...
fullfile(path,'11-12-16 15-08-52 AcqLength-70s IntTime-78us Range-7 Freq-360Hz Decoded.txt'); ...
% predictive tracking arc1
15 % file{8} = ...
fullfile(path,'11-12-16 15-12-13 AcqLength-70s IntTime-78us Range-7 Freq-360Hz Decoded.txt'); ...
% predictive tracking arc2
16
17 % data files (patient 2)
18 %file{1} = ...
fullfile(path,'11-12-16 14-43-51 AcqLength-70s IntTime-78us Range-7 Freq-360Hz Decoded.txt'); ...
% no motion arc1
19 %file{2} = ...
fullfile(path,'11-12-16 14-45-19 AcqLength-70s IntTime-78us Range-7 Freq-360Hz Decoded.txt'); ...
% no motion arc2
20 %file{3} = ...
fullfile(path,'11-12-16 16-45-41 AcqLength-70s IntTime-78us Range-7 Freq-360Hz Decoded.txt'); ...
% motion arc1
21 %file{4} = ...
fullfile(path,'11-12-16 16-50-54 AcqLength-70s IntTime-78us Range-7 Freq-360Hz Decoded.txt'); ...
% motion arc2
22 %file{5} = ...
fullfile(path,'11-12-16 16-40-06 AcqLength-70s IntTime-78us Range-7 Freq-360Hz Decoded.txt'); ...
% passive tracking arc1
23 %file{6} = ...
fullfile(path,'11-12-16 16-42-24 AcqLength-70s IntTime-78us Range-7 Freq-360Hz Decoded.txt'); ...
% passive tracking arc2
24 %file{7} = ...
fullfile(path,'11-12-16 16-54-01 AcqLength-70s IntTime-78us Range-7 Freq-360Hz Decoded.txt'); ...
% predictive tracking arc1
25 %file{8} = ...
fullfile(path,'11-12-16 16-57-28 AcqLength-70s IntTime-78us Range-7 Freq-360Hz Decoded.txt'); ...
% predictive tracking arc2
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26
27 % data files (predominantly left right)
28
29 file{1} = ...
fullfile(path,'11-12-16 14-43-51 AcqLength-70s IntTime-78us Range-7 Freq-360Hz Decoded.txt'); ...
% no motion arc1
30 file{2} = ...
fullfile(path,'11-12-16 14-45-19 AcqLength-70s IntTime-78us Range-7 Freq-360Hz Decoded.txt'); ...
% no motion arc2
31 file{3} = ...
fullfile(path,'11-12-16 17-08-35 AcqLength-70s IntTime-78us Range-7 Freq-360Hz Decoded.txt'); ...
% motion arc1
32 file{4} = ...
fullfile(path,'11-12-16 17-10-18 AcqLength-70s IntTime-78us Range-7 Freq-360Hz Decoded.txt'); ...
% motion arc2
33 file{5} = ...
fullfile(path,'11-12-16 17-20-44 AcqLength-70s IntTime-78us Range-7 Freq-360Hz Decoded.txt'); ...
% passive tracking arc1
34 file{6} = ...
fullfile(path,'11-12-16 17-23-18 AcqLength-70s IntTime-78us Range-7 Freq-360Hz Decoded.txt'); ...
% passive tracking arc2
35 file{7} = ...
fullfile(path,'11-12-16 17-13-22 AcqLength-70s IntTime-78us Range-7 Freq-360Hz Decoded.txt'); ...
% predictive tracking arc1
36 file{8} = ...
fullfile(path,'11-12-16 17-17-20 AcqLength-70s IntTime-78us Range-7 Freq-360Hz Decoded.txt'); ...
% predictive tracking arc2
37
38 %%
39 %angles files (ususal motion pattern)
40 % anglesfile{1} = ...
fullfile(path,'11-12-16 14-43-51 AcqLength-70s IntTime-78us Range-7 Freq-360Hz angles.aux'); ...
% no motion arc1
41 % anglesfile{2} = ...
fullfile(path,'11-12-16 14-45-19 AcqLength-70s IntTime-78us Range-7 Freq-360Hz angles.aux'); ...
% no motion arc2
42 % anglesfile{3} = ...
fullfile(path,'11-12-16 14-58-58 AcqLength-70s IntTime-78us Range-7 Freq-360Hz angles.aux'); ...
% motion arc1
43 % anglesfile{4} = ...
fullfile(path,'11-12-16 15-00-49 AcqLength-70s IntTime-78us Range-7 Freq-360Hz angles.aux'); ...
% motion arc2
44 % anglesfile{5} = ...
fullfile(path,'11-12-16 15-15-15 AcqLength-70s IntTime-78us Range-7 Freq-360Hz angles.aux'); ...
% passive tracking arc1
45 % anglesfile{6} = ...
fullfile(path,'11-12-16 15-18-25 AcqLength-70s IntTime-78us Range-7 Freq-360Hz angles.aux'); ...
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% passive tracking arc2
46 % anglesfile{7} = ...
fullfile(path,'11-12-16 15-08-52 AcqLength-70s IntTime-78us Range-7 Freq-360Hz angles.aux'); ...
% predictive tracking arc1
47 % anglesfile{8} = ...
fullfile(path,'11-12-16 15-12-13 AcqLength-70s IntTime-78us Range-7 Freq-360Hz angles.aux'); ...
% predictive tracking arc2
48
49 %angles files (patient 2)
50 %anglesfile{1} = ...
fullfile(path,'11-12-16 14-43-51 AcqLength-70s IntTime-78us Range-7 Freq-360Hz angles.aux'); ...
% no motion arc1
51 %anglesfile{2} = ...
fullfile(path,'11-12-16 14-45-19 AcqLength-70s IntTime-78us Range-7 Freq-360Hz angles.aux'); ...
% no motion arc2
52 %anglesfile{3} = ...
fullfile(path,'11-12-16 16-45-41 AcqLength-70s IntTime-78us Range-7 Freq-360Hz angles.aux'); ...
% motion arc1
53 %anglesfile{4} = ...
fullfile(path,'11-12-16 16-50-54 AcqLength-70s IntTime-78us Range-7 Freq-360Hz angles.aux'); ...
% motion arc2
54 %anglesfile{5} = ...
fullfile(path,'11-12-16 16-40-06 AcqLength-70s IntTime-78us Range-7 Freq-360Hz angles.aux'); ...
% passive tracking arc1
55 %anglesfile{6} = ...
fullfile(path,'11-12-16 16-42-24 AcqLength-70s IntTime-78us Range-7 Freq-360Hz angles.aux'); ...
% passive tracking arc2
56 %anglesfile{7} = ...
fullfile(path,'11-12-16 16-54-01 AcqLength-70s IntTime-78us Range-7 Freq-360Hz angles.aux'); ...
% predictive tracking arc1
57 %anglesfile{8} = ...
fullfile(path,'11-12-16 16-57-28 AcqLength-70s IntTime-78us Range-7 Freq-360Hz angles.aux'); ...
% predictive tracking arc2
58
59 %angles files (predominantly left right)
60 anglesfile{1} = ...
fullfile(path,'11-12-16 14-43-51 AcqLength-70s IntTime-78us Range-7 Freq-360Hz angles.aux'); ...
% no motion arc1
61 anglesfile{2} = ...
fullfile(path,'11-12-16 14-45-19 AcqLength-70s IntTime-78us Range-7 Freq-360Hz angles.aux'); ...
% no motion arc2
62 anglesfile{3} = ...
fullfile(path,'11-12-16 17-08-35 AcqLength-70s IntTime-78us Range-7 Freq-360Hz angles.aux'); ...
% motion arc1
63 anglesfile{4} = ...
fullfile(path,'11-12-16 17-10-18 AcqLength-70s IntTime-78us Range-7 Freq-360Hz angles.aux'); ...
% motion arc2
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64 anglesfile{5} = ...
fullfile(path,'11-12-16 17-20-44 AcqLength-70s IntTime-78us Range-7 Freq-360Hz angles.aux'); ...
% passive tracking arc1
65 anglesfile{6} = ...
fullfile(path,'11-12-16 17-23-18 AcqLength-70s IntTime-78us Range-7 Freq-360Hz angles.aux'); ...
% passive tracking arc2
66 anglesfile{7} = ...
fullfile(path,'11-12-16 17-13-22 AcqLength-70s IntTime-78us Range-7 Freq-360Hz angles.aux'); ...
% predictive tracking arc1
67 anglesfile{8} = ...
fullfile(path,'11-12-16 17-17-20 AcqLength-70s IntTime-78us Range-7 Freq-360Hz angles.aux'); ...
% predictive tracking arc2
68
69
70 % import data and angles files
71 for i=1:8
72 data{i} = importdata(file{i},'\t');
73 angles{i} = importdata(anglesfile{i},'\t');
74 end
75
76 %check first entry of angles file makes sense
77 for i=1:8
78 difference = abs(angles{i}(1)-angles{i}(2));
79 if difference > 5




84 % round angles to nearest 1 degrees to match correction factors
85 for i=1:8
86 angles{i} = round(angles{i},0);
87 vector = angles{i};
88 for j = 1:length(vector)
89 if vector(j,:) < 0
90 vector(j,:) = 360+vector(j,:);
91 end
92 end




97 %map the equalisation file
98 mapEqual = rearrange(equalisationVector,mp512Map);
99
100
101 % iterate through all data files and angles
102 for i=1:8
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103 for angle = 0:359
104 currentAngle = angle;
105 indexs = find(angles{i} == currentAngle); % find the ...
index of all frames corresponding to the current angle
106 correction = angularCorrection{angle+1}; % look up the ...
angular correction map for the current angle
107 for j = 1:length(indexs)
108 currentIndex = indexs(j); % loop through each index ...
one by one
109 currentData = data{i};
110 if currentIndex ≤ length(currentData)
111 dataVector = currentData(currentIndex,:); % ...
isolate the data frame (row) corresponding ...
to current index
112 mapped{currentIndex} = ...
rearrange(dataVector,mp512Map); % map the ...
current data frame to 2d mp512 layout
113 mapped{currentIndex} = ...






118 datasum = 0;
119 for l = 1:length(mapped)
120 datasum = datasum + mapped{l}; % add each mapped frame ...
together to get the final integral value
121 %datasum = sum(mapped{l});
122 end
123
124 correctedData{i} = datasum;
125 originalData{i} = sum(data{i});
126 originalData{i} = rearrange(originalData{i},mp512Map);
127
128 correctedData{i} = correctedData{i}.*mapEqual;
129 originalData{i} = originalData{i}.*mapEqual;
130
131 % convert from counts to counts/cGy
132 correctedData{i} = correctedData{i}./65535; % divide by ...
AFE RANGE to get number of times capacitor was filled
133 correctedData{i} = correctedData{i}.*100;
134 correctedData{i} = correctedData{i}.*0.000412852041785; % ...
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137
138 %find dead channels (=0) and interpolate using neighbouring ...
columns
139 [row col] = find(correctedData{i} == 0);
140 for j = 1:length(row)
141 if col(j) ≥ 4 && col(j) ≤ 21
142 x = [1 2 4 5];
143 xq = 3;
144 v1 = correctedData{i}(row(j),col(j)-2);
145 v2 = correctedData{i}(row(j),col(j)-1);
146 v3 = correctedData{i}(row(j),col(j)+1);
147 v4 = correctedData{i}(row(j),col(j)+2);
148 v = [v1 v2 v3 v4];
149 elseif col(j) == 3
150 x = [1 3 4 5];
151 xq = 2;
152 v1 = correctedData{i}(row(j),col(j)-1);
153 v2 = correctedData{i}(row(j),col(j)+1);
154 v3 = correctedData{i}(row(j),col(j)+2);
155 v4 = correctedData{i}(row(j),col(j)+3);
156 v = [v1 v2 v3 v4];
157 elseif col(j) == 22
158 x = [1 2 3 5];
159 xq = 4;
160 v1 = correctedData{i}(row(j),col(j)+1);
161 v2 = correctedData{i}(row(j),col(j)-1);
162 v3 = correctedData{i}(row(j),col(j)-2);
163 v4 = correctedData{i}(row(j),col(j)-3);
164 v = [v1 v2 v3 v4];
165 elseif col(j) == 2
166 x = [2 3 4 5];
167 xq = 1;
168 v1 = correctedData{i}(row(j),col(j)+1);
169 v2 = correctedData{i}(row(j),col(j)+2);
170 v3 = correctedData{i}(row(j),col(j)+3);
171 v4 = correctedData{i}(row(j),col(j)+4);
172 v = [v1 v2 v3 v4];
173 elseif col(j) == 23
174 x = [1 2 3 4];
175 xq = 5;
176 v1 = correctedData{i}(row(j),col(j)-1);
177 v2 = correctedData{i}(row(j),col(j)-2);
178 v3 = correctedData{i}(row(j),col(j)-3);
179 v4 = correctedData{i}(row(j),col(j)-4);
180 v = [v1 v2 v3 v4];
181 end
182 newData = interp1(x,v,xq,'pchip');
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183 correctedData{i}(row(j),col(j)) = newData;
184
185 %set non-pixels back to -1, mask should be a mp512 map ...
file with a 0
186 %for non-pixels and a 1 for real pixels
187 correctedData{i} = correctedData{i}.*mask;
188 mask2 = mask==0;
189 mask2 = mask2.*-1;
190 correctedData{i} = correctedData{i}+mask2;
191
192
193 % if col(i)>4 && col(i)<21
194 % x = [1 2 4 5];
195 % v1 = correctedData{i}(row(i),col(i)-2);
196 % v2 = correctedData{i}(row(i),col(i)-1);
197 % v4 = correctedData{i}(row(i),col(i)+1);
198 % v5 = correctedData{i}(row(i),col(i)+2);
199 % v = [v1 v2 v4 v5]
200 % elseif col(i)>3 && col(i)<20
201 % x = [1 2];
202 % v1 = correctedData{i}(row(i),col(i)-1);
203 % v2 = correctedData{i}(row(i),col(i)+1);






210 originalDataFilt = hampel(originalData{1},3,0.5);
211 correctedDataFilt = hampel(correctedData{1},3,0.5);
212
213 difference = abs(correctedData{1} - originalData{1});
214
215 noMotion = correctedData{1}+correctedData{2};
216 motion = correctedData{3} + correctedData{4};
217 passive = correctedData{5} + correctedData{6};
218 predictive = correctedData{7} + correctedData{8};
219




224 assignin('base', 'angles', angles);
225
226 assignin('base', 'noMotionArc1', correctedData{1});
227 assignin('base','motionArc1',correctedData{3});
228 assignin('base','passiveArc1',correctedData{5});
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229 assignin('base','predictiveArc1',correctedData{7});







237 % az = 0;
238 % el = 90;
239 % figure(1);
240 % fig1 = surf(noMotion,'EdgeColor','none');
241 % title('No Motion');
242 % view(az,el)
243 % figure(2);
244 % fig2 = surf(motion,'EdgeColor','none');
245 % title('Motion');
246 % view(az,el)
247 % % figure(3);
248 % % displayDICOM;
249 % % title('TPS Dose Map');
250 % % view(az,el)
251 % figure(4);












264 assignin('base', 'angles', angles);
265 %assignin('base','convertedData',convertedData);
266
267 integral = sum(data{1});
268 integral = rearrange(integral,mp512Map);
269 integral = integral.*0.000412848;
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This functions allows the user to crop a large film dose map (scanned image) to
match the dimensions of another detector.
1 function croppedDoseMap = cropDoseMap(targetDoseMap)
2 % This function is used to crop a dose map to the size of ...
another detector (i,e MP512 or DUO). Input should be a dose map
3 % corresponding to an entire film. User inputs are amount to ...
offset the crop in the vertical and horizontal directions.
4 % Output is saved as croppedDoseMap
5
6 disp('Use top left corner of each object as reference point, e.g ...
top top left corner of film relative to bottom left corner ...
of detector');
7 prompt = {'Horizontal offset (mm)','Vertical offset (mm)'};
8
9 str = inputdlg(prompt)
10




14 rectXpos = str2num(str{1,1});
15 rectYpos = str2num(str{2,1});
16
17 %define the height and width of the area to be cropped in mm
18 height = 47;
19 width = 47;
20
21 %distance in mm need to be converted to number of pixels. The film
22 %resolution is 72 DPI or 72 pixels/inch. There are 25.4mm in an ...
inch so we
23 %have 72/25.4 = 2.834645669 pixels/mm
24
25 mm2pixleConversion = 72/25.4;
26
27 rectHeightInPixels = height*mm2pixleConversion;
28 rectWidthInPixels = width*mm2pixleConversion;
29 rectXpos = rectXpos*mm2pixleConversion;
30 rectYpos = rectYpos*mm2pixleConversion;
31
32 rect = [rectXpos rectYpos rectWidthInPixels rectHeightInPixels];
33
34 % define the dose map that will be cropped
35 %targetDoseMap = filmNoMotion; % change as needed
36 im = uint8(targetDoseMap);
37 RGB = insertShape(im,'rectangle',rect);
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38 imshow(RGB);
39
40 % Construct a questdlg with three options
41 choice = questdlg('Does the area selected look correct?', ...
42 'How Did It Go?', ...
43 'Yes','No','Yes');
44 % Handle response
45 switch choice
46 case 'Yes'






53 % az = 0;




B.4 Code for Chapter 6
MRTAnalysis
This function calculates the FWHM and penumbral width of two microbeam peaks
1 function [peak1,peak2] = MRTAnalysis(dataVector,mode)
2 % dataVector should be a two column vector with column 1 ...
corresponding to position data
3 % and column 2 corresponsding to dose data




7 position = dataVector(:,1); % column 1
8 dose = dataVector(:,2); % column 2
9
10 % split data in half to fit two peaks seperately
11 bound1 = (length(position)-1)/2;
12 bound2 = length(position);
13 position1 = position(1:bound1);
14 position2 = position(bound1+1:bound2);
15 dose1 = dose(1:bound1);
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16 dose2 = dose(bound1+1:bound2);
17
18 % create a higher sampled x vector
19 xi1 = position1(1):0.001:position1(end);
20 xi1 = xi1';
21 gaussfit = fit(position1,dose1,mode);
22 fittedData1 = gaussfit(xi1); % use the fit on new x vector
23
24 array1 = horzcat(xi1,fittedData1); % put the two vectors together
25 peak1 = array1;
26
27 % repeat for second peak
28 xi2 = position2(1):0.001:position2(end);
29 xi2 = xi2';
30 gaussfit = fit(position2,dose2,mode);
31 fittedData2 = gaussfit(xi2);
32
33 array2 = horzcat(xi2,fittedData2);
34 peak2 = array2;
35
36 makeFigures = 0; % 0 for no, 1 for yes
37
38 if makeFigures == 1
39 fig1 = figure(1);
40 hold on;
41 scatter(position,dose);







48 % find FWHM and penumbra information
49 x1 = findX v2(array1,0.5);
50 x2 = findX v2(array2,0.5);
51 FWHM1 = (x1(2)-x1(1))*1000 %convert from mm to micron
52 FWHM2 = (x2(2)-x2(1))*1000 %convert from mm to micron
53 x1 20 = findX v2(array1,0.2);
54 x1 80 = findX v2(array1,0.8);
55 x2 20 = findX v2(array2,0.2);
56 x2 80 = findX v2(array2,0.8);
57
58
59 leftPenumbra1 = abs(x1 80(1) - x1 20(1))*1000 % *1000 to convert ...
from mm to micron
60 rightPenumbra1 = abs(x1 80(2) - x1 20(2))*1000
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61 leftPenumbra2 = abs(x2 80(1) - x2 20(1))*1000
62 rightPenumbra2 = abs(x2 80(2) - x2 20(2))*1000
63
64 % norm = array1(:,2)/(max(array1(:,2)));
65 %
66 % peak1 80 = find(abs(norm-0.8)<0.01);
67 % peak1 20 = find(abs(norm-0.2)<0.01);
68 %
69 % peak1Pen = array1(peak1 80(1),1)-array1(peak1 20(1),1)
70 end
CompareMRTPlots
This script enables the comparison of experimental data with simulation data. Mi-
crobeam profiles for measured data are overlaid on the simulation distribution.
1
2 dataset = filmDataMotion 10 1;
3 %backgroundDataset = static5mmSimData;
4
5 expData = Motion 10 1;
6
7 scaling = 0.88;
8
9 newSpacing = expData(:,1)*scaling;
10 newExpData = expData;
11 newExpData(:,1) = newSpacing;
12
13 % newSpacing = peak1(:,1)*scaling;
14 % newPeak1 = peak1;
15 % newPeak1(:,1) = newSpacing;
16 % newSpacing = peak2(:,1)*scaling;
17 % newPeak2 = peak2;
18 % newPeak2(:,1) = newSpacing;
19
20
21 expData = newExpData;
22
23
24 f = figure;
25 ax = axes('Parent',f,'position',[0.13 0.39 0.77 0.54]);
26 row = 1;
27 centre = size(dataset(row,:),2)/2
28 range = 0;
29 dx = 22/size(dataset(:,:),1);
30 x = (0:dx:22-dx);
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31 mapHeight = 22;
32 mapdx = mapHeight/size(dataset,2);
33 mapX = (0:mapdx:mapHeight-mapdx);
34
35 numberPhotons = 1e11;
36 dataset = dataset.*numberPhotons*100;
37
38 % normalisation
39 normalise = 1;
40 size(expData)
41 if normalise == 1
42 for i = 1:size(dataset,1)
43 singleRow = dataset(i,:);
44 singleRowMax = max(singleRow);
45 singleRow = singleRow/singleRowMax*100;
46 dataset(i,:) = singleRow;
47 end
48 for i = 1:size(backgroundDataset,1)
49 singleRow = backgroundDataset(i,:);
50 singleRowMax = max(singleRow);
51 singleRow = singleRow/singleRowMax*100;
52 backgroundDataset(i,:) = singleRow;
53 end
54
55 maxval = max(expData(:,2));




60 h = ...
plot(x(centre-range:centre+range),dataset(row,centre-range:centre+range));
61 %j = ...
plot(x(centre-range:centre+range),backgroundDataset(row,centre-range:centre+range));
62 k = plot(expData(:,1),expData(:,2));
63
64 b = ...
uicontrol('Parent',f,'Style','slider','Position',[81,54,419,23],...
65 'value',row, 'min',0, 'max',size(dataset(:,:),1));
66 bgcolor = f.Color;
67 bl1 = ...
uicontrol('Parent',f,'Style','text','Position',[50,54,23,23],...
68 'String','0','BackgroundColor',bgcolor);
69 bl2 = ...
uicontrol('Parent',f,'Style','text','Position',[500,54,23,23],...
70 'String',num2str(size(dataset(:,:),1)),'BackgroundColor',bgcolor);
71 bl3 = ...
uicontrol('Parent',f,'Style','text','Position',[240,25,100,23],...




75 maxSliderValue = get(b, 'Max');
76 minSliderValue = get(b, 'Min');
77 theRange = maxSliderValue - minSliderValue;
78
79 stepResolution = 0.1 %mm
80 numSteps = stepResolution/mapdx;
81
82 steps = [1/theRange*numSteps, 10/theRange*numSteps];
83 set(b, 'SliderStep', steps);
84
85 b.Callback = @(es,ed) ...
sliderCallback(h,j,x,mapX,dataset,backgroundDataset,es.Value)
86
87 % second slider
88
89 c = ...
uicontrol('Parent',f,'Style','slider','Position',[81,74,419,23],...
90 'value',row, 'min',0, 'max',2000);
91 cgcolor = f.Color;
92 cl1 = ...
uicontrol('Parent',f,'Style','text','Position',[50,54,23,23],...
93 'String','0','BackgroundColor',bgcolor);
94 cl2 = ...
uicontrol('Parent',f,'Style','text','Position',[500,54,23,23],...
95 'String',num2str(size(dataset(:,:),1)),'BackgroundColor',bgcolor);





100 maxSliderValue = get(c, 'Max');
101 minSliderValue = get(c, 'Min');
102 theRange = maxSliderValue - minSliderValue;
103
104 numSteps = 2000;
105 steps = [1/theRange*numSteps, 10/theRange*numSteps];
106 set(c, 'SliderStep', [1/numSteps,10/numSteps]);
107
108 c.Callback = @(es,ed) sliderCallback2(k,expData,es.Value)
109
110 function sliderCallback(h,j,x,mapX,dataset,backgroundDataset,value)
111 row = value
112 rowHeight = mapX(value)
113 centre = size(dataset(row,:),2)/2;
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119 baseOffSet = 10;
120 offSet = value*0.01
121 newData = expData(:,1);
122 newData = newData + offSet + baseOffSet;
123 multiplier = 1;%0.115;
124 for i = 2:size(newData)
125 dx = newData(i)-newData(i-1);
126 dx = dx*multiplier;






133 % function makeplot(hObject,event,hplot)





1 % this script will automate the analysis required for ESRF brain ...
motion
2 % data analysis
3
4 % first you need to run compareMRTplots seperately to find the ...
data you
5 % need
6 % Change 'dataset' to be the simulation data you want to use as the
7 % background
8 % Change expData to the be measured data you want to overlay and ...
move over
9 % the top of the sim data
10
11 % From there record the offset and row of the simulation data
12
13 % Now run getSimDataSet to extract the data you just viewed
14
15 row = 2201; % change to the correct row
16 range = 200; % how many data points you want either side of the ...
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central point
17 dataSet = motion10mmSimData; % the simulation data you want to ...
extract from
18 expData = NoMotion 5 2; % the expData you want to extract from
19 searchRadius = 50;
20
21 %simRow = getSimDataSet(dataSet,row,range); % if comparing to ...
monte carlo simulation
22 simRow = filmDataMotion 5 3; % if comparing to film profiles
23
24 % Now take note of which peaks you want to keep, these will need ...
to be
25 % separated for analysis
26
27 figg = plot(simRow);
28 ax = figg.Parent; % Important
29 set(ax, 'XTick', 0:100:size(simRow,2));
30 xtickangle(90);
31
32 prompt = {'Index before first peak'};
33 dlg title = 'Peak 1';
34 num lines = 1;
35 def = {'0'};
36 peak1Start = inputdlg(prompt,dlg title,num lines,def);
37 clear dlg title num lines def prompt
38
39 prompt = {'Index between first and second peak'};
40 dlg title = 'Peak 1';
41 num lines = 1;
42 def = {'0'};
43 peak1End = inputdlg(prompt,dlg title,num lines,def);
44 clear dlg title num lines def prompt
45
46 prompt = {'Index after second peak'};
47 dlg title = 'Peak 2';
48 num lines = 1;
49 def = {'0'};
50 peak2End = inputdlg(prompt,dlg title,num lines,def);
51 clear dlg title num lines def prompt
52
53
54 peak1Start = str2double(peak1Start{1}); % index before peak1 to keep
55 peak1End = str2double(peak1End{1}); % index between peak1 and ...
peak2 to keep
56 peak2Start = peak1End+1;
57 peak2End = str2double(peak2End{1}); % index after peak2 to keep
58
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59 maxFWHM = 0;
60 minPVDR = 1000;
61
62 for i = row-searchRadius:row+searchRadius
63
64 %simRow = getSimDataSet(dataSet,i,range); % only enable if using ...
sim data
65
66 peak1y = simRow(peak1Start:peak1End);







74 % Now convert the x-axis of the peaks into physical distance
75
76 mapHeight = 22;
77 mapdx = mapHeight/size(dataSet,2);
78 mapX = (0:mapdx:mapHeight-mapdx);
79 centre = size(dataSet,2)/2;
80
81 mapX = mapX(centre-range:centre+range);
82
83 %peak1x = mapX(peak1Start:peak1End); % if using monte carlo
84 %peak2x = mapX(peak2Start:peak2End); % if using monte carlo
85
86 filmResolution = 1.29/1000; % convert to mm
87 profileLength = size(simRow,2); % if using film
88 filmXVector = ...
0:filmResolution:(profileLength*filmResolution)-filmResolution; ...
% if using film
89
90 peak1x = filmXVector(peak1Start:peak1End); % if using film
91 peak2x = filmXVector(peak2Start:peak2End); % if using film
92
93 peak1 = vertcat(peak1x,peak1y)';
94 peak2 = vertcat(peak2x,peak2y)';
95






102 % Now find the FWHM of each peak seperately
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103 width1 = double(fwhm(peak1(:,1),peak1(:,2)));
104 width2 = double(fwhm(peak2(:,1),peak2(:,2)));
105
106 avgWidth = (width1+width2)/2;
107




112 peak1max = max(peak1(:,2));
113 peak1norm = peak1(:,2)./peak1max;
114 peak2max = max(peak2(:,2));




119 peak1AvgValley = mean(peak1norm(1:30))
120 peak2AvgValley = mean(peak2norm(1:30))
121
122
123 PVDRPeak1 = max(peak1norm)/peak1AvgValley;
124 PVDRPeak2 = max(peak2norm)/peak2AvgValley;
125
126 avgPVDR = (PVDRPeak1+PVDRPeak2)/2;
127
128 if avgWidth > maxFWHM
129 maxFWHM = avgWidth
130 end
131
132 if avgPVDR < minPVDR





138 % Now we want to find the width of the equivalent exp data
139
140 length = size(expData,1);
141 halfLength = length/2;
142 expDatax = expData(:,1);
143 expDatay = expData(:,2);
144 expPeak1x = expDatax(1:halfLength);
145 expPeak1y = expDatay(1:halfLength);
146 expPeak2x = expDatax(halfLength:length);
147 expPeak2y = expDatay(halfLength:length);
148
149 expPeak1 = horzcat(expPeak1x,expPeak1y);
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157 expwidth1 = double(fwhm(expPeak1(:,1),expPeak1(:,2)))
158 expwidth2 = double(fwhm(expPeak2(:,1),expPeak2(:,2)))
159
160 avgWidthExp = (expwidth1+expwidth2)/2
161
162 peak1max = max(expPeak1(:,2));
163 peak1norm = expPeak1(:,2)./peak1max;
164 peak2max = max(expPeak1(:,2));
165 peak2norm = expPeak1(:,2)./peak2max;
166
167 PVDRPeak1 = max(peak1norm)/min(peak1norm);
168 PVDRPeak2 = max(peak2norm)/min(peak2norm);
169
170 avgPVDRExp = (PVDRPeak1+PVDRPeak2)/2
171
172 minPVDR
173 maxFWHM
